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Introduction
For over 20 years, transplant professionals all over the world have been working 
with the FACT-JACIE Standards for haematopoietic stem cellular (HSC) therapy as 
a means to improve the care and services provided to their patients and donors and 
as a framework within which to pursue continuous improvement. The FACT1 and 
JACIE2 accreditation schemes stand out for the high take-up among centres not only 
in high-income countries but also the increasing interest in quality among transplant 
professionals in low- to medium-income countries.3 This success is testimony to the 
efforts of the community as a whole.
The ongoing evolution of the standards over the years demands that quality man-
agement systems can adapt to new needs and requirements, not just for accredita-
tion but also to meet changing regulations and best practice. This handbook aims to 
be a professional resource on how to approach those challenges faced by many 
transplant programmes worldwide. The intended readers are not only centres at the 
beginning of their quality journey but also those centres with the experience of sev-
eral accreditation cycles but with staff assuming new responsibilities for quality 
management.
The chapters offer different perspectives on approaches to common challenges 
and the reader is invited to reflect on how to best incorporate and adapt them to the 
realities of their own institutions. The topics include, among others, good documen-
tation practice, internal audits, validation and qualification, outcome analysis, 
personnel requirements, performance measurement, tracking and traceability, 
adverse events and CAPAs, maintaining the quality of management programme and 
risk management.
The authors are all professionals working in quality in cellular therapy with a 
combined wealth of practical experience.
1 www.factwebsite.org
2 www.ebmt.org/jacie-accreditation
3 datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups
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In the future, JACIE, as part of the EBMT, an international collaborative peer 
network of professionals working in centres and as individuals in the field of clinical 
bone marrow transplantation and cellular therapy, intends to issue revisions of this 
guide and to also assess how to exploit the contents as material for ongoing training 
and education as part of the EBMT’s wider education strategy.
JACIE (Joint Accreditation Committee – ISCT & EBMT) is the EBMT commit-
tee established for the purposes of assessment and accreditation in the field of hae-
matopoietic stem cell transplantation (HSCT). The Committee was founded in 1998 
by the then-European Group for Blood and Marrow Transplantation (EBMT) and 
European members of the International Society for Cellular Therapy (ISCT). JACIE 
largely modelled itself on the US-based Foundation for the Accreditation of Cellular 
Therapy (FACT), established in 1996 by the ISCT and the American Society for 
Blood and Marrow Transplantation (ASBMT). JACIE continues to actively collabo-
rate with FACT on maintaining standards for the provision of quality medical and 
laboratory practice in HSCT, and the two organisations jointly publish the FACT- 
JACIE international standards.
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Chapter 1
Quality and Standards for Haematopoietic 
Stem Cells Transplantation Programs
Eoin McGrath and Dunia Jawdat
 Quality
The word “quality” emerged in the fourteenth century from the Latin “qualis” and 
the French “qualitie” [1]. Quality in healthcare as we know it today can trace its 
origins back to the early twentieth century when a number of measures were taken 
to address great variations in medical education and care [2]. The WHO defines 
quality of health care as “the extent to which health care services provided to indi-
viduals and patient populations improve desired health outcomes”.1
Quality itself is not a static concept – in its dynamic form, it becomes continuous 
improvement [3]. Furthermore, quality assurance (QA), concerned with compli-
ance, should not be considered to be the same as quality improvement (QI), which 
is defined as the framework we use to systematically improve the ways care is 
delivered to patients [4]. Quality improvement has been further defined as “the com-
bined and unceasing efforts of everyone  – healthcare professionals, patients and 
their families, researchers, payers, planners and educators – to make the changes 
1 www.who.int/maternal_child_adolescent/topics/quality-of-care/definition/en/ consulted 11/06/2020.
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that will lead to better patient outcomes (health), better system performance (care) 
and better professional development” [5].
In 1966, Avedis Donabedian (1919–2000), one of the great pioneers of quality in 
healthcare, introduced the concepts of structure, process, and outcome as the basis 
to evaluate the quality of health care. “Structure” includes the settings, qualifica-
tions of providers and administrative systems through which care takes place; “pro-
cess” as the components of care delivered and “outcome” as recovery, restoration of 
function and survival [6]. These concepts will probably be familiar to readers today 
even if they are not aware of their origins. In HSCT, structure would include the 
physical facilities where care is delivered, the experience and qualification of the 
medical and laboratory teams, the overall support structure and regulatory and reim-
bursement frameworks. Process would be how the patient and the healthcare system 
interact, e.g. referral from primary healthcare provider to tertiary care and necessary 
testing. Outcome includes the effect of care on diseases and their prevention, such 
as the mortality rate, the error rate and the quality of life [7].
The concept of quality management (QM) has been known since the 1950s and 
applied by different sectors for many years. However, in the field of cellular therapy, 
it is relatively new in comparison to quality assurance and quality control. The 
implementation of a QM programme with its components including quality control, 
quality assurance, quality assessment and quality improvement advances the quality 
of service provided for patients and helps programs and stem cell banks to address 
external threats and internal weaknesses which could negatively impact services 
and products.
In HSCT, different stakeholders have been identified as holding an interest in 
ensuring that patients receive quality care: patients, referring physicians, payers, 
other community healthcare providers, and professional and patient organizations [8].
 Standards
A standard has been defined as “a desired and achievable level of performance 
against which actual performance is measured” [9]. Standard-setting organisations 
also consider themselves as facilitators of the above-mentioned evolution from 
compliance towards improvement [10].
In 1998, the European Society for Blood and Marrow Transplantation (EBMT) 
and the International Society for Cellular Therapy (ISCT) established the Joint 
Accreditation Committee – ISCT & EBMT (JACIE) – to develop international stan-
dards and offer an inspection-based accreditation process in the field of HSCT. JACIE 
is a committee of the EBMT, and its members are appointed by and are accountable 
to the EBMT Board and ISCT is represented through two members of the Committee. 
JACIE collaborates with the US-based Foundation for the Accreditation of Cellular 
Therapy (FACT), a non-profit corporation co-founded by ISCT and the American 
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Society of Transplantation and Cellular Therapy (ASTCT), which pioneered the 
standards and accreditation model starting in the mid-1990s in the USA. JACIE and 
FACT develop and maintain global standards for the provision of quality medical 
and laboratory practice in cellular therapy. The FACT-JACIE international standards 
stand out as an example of a profession-driven initiative to improve quality in trans-
plantation which have subsequently been incorporated by third parties to support 
healthcare reimbursement (health insurers, social security) and authorization of 
treatment (regulatory authorities) processes.2
In 1974, the first bone marrow registry was founded in the UK, and since then 
many registries have been established around the world. Hence, for more than four 
decades, bone marrow registries have been crucial in facilitating the search for hae-
matopoietic stem cells from adult donors or cord blood units for any patient around 
the world.
In 1988, three pioneers in the field of blood stem cell transplantation, John 
Goldman, E. Donnell Thomas and Jon J. van Rood, initiated the founding of the 
Cooperative Marrow Donor Programme, an international collaboration that was 
essential at that time and led to the official founding of the World Marrow Donor 
Association (WMDA) in 1994 in Leiden in the Netherlands to give all patients equal 
access to high-quality stem cells for clinical transplantation by providing interna-
tional standards and guidelines relating to best practices in every aspect of the reg-
istry’s operation promoting quality and donor safety. The WMDA established an 
accreditation programme for unrelated donor registries as an assurance to all orga-
nizations involved in HSCT.
Together with FACT accreditation of stand-alone cord blood banks, WMDA 
accreditation reassures transplant physicians in terms of the quality of product and 
services provided.
In 2007, EBMT, the Center for International Blood & Marrow Transplant 
Research (CIBMTR) and the Asian Pacific Blood and Marrow Transplantation 
Group (APBMT) together with WMDA among others founded the Worldwide 
Network for Blood and Marrow Transplantation (WBMT), a non-profit scientific 
organization aiming to promote excellence in stem cell transplantation, donation 
and cellular therapy.
Standards in cell therapy are offered through what are typically voluntary 
schemes such as AABB,3 JACIE,4 FACT,5 NetCord6 and Fundación CAT7 among 
others and serve to promote patient care and excellence in clinical and labora-
tory practice by standardizing procedures for the collection, analysis, banking 
2 https://www.ebmt.org/regulations-guidelines consulted 22/07/2020.
3 www.aabb.org/sa/standards/ consulted 11/06/2020.
4 www.ebmt.org/jacie consulted 11/06/2020.
5 www.factwebsite.org/ consulted 11/06/2020.
6 wmda.info/professionals/quality-and-accreditation/netcord-fact-standards/ consulted 11/06/2020.
7 www.catransfusion.es/.
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and administration of cells for transplantation [11]. As an example, the JACIE 
and FACT accreditation systems are based on the regular update of standards 
covering the entire transplantation process, from the selection of the donor/
patient to the follow- up, including collection, characterization, processing and 
storage of the graft. Considering the different competences included in the pro-
cess, the standards are articulated in 4 parts: Clinical Programme, Bone Marrow 
Collection, Apheresis Collection and Processing Facility. A QM section is 
embedded in each part, aimed to provide a tool for both the applicants to develop 
a comprehensive quality system and the inspectors to check the compliance of 
the transplant programme to the standards. Processing labs can apply indepen-
dently; however, the target of the accreditation is the programme, intended as the 
process in its entirety, thus requiring a full integration of units, laboratories, 
services and professionals. Each section focuses on the competence of person-
nel, listing the topics for which the evidence of specific training is required and 
also including the minimum requirements of experience for positions of respon-
sibility. Maintenance of competencies is also required for all professionals.
The standards are revised on a 3-yearly basis by a commission formed by experts 
appointed by FACT and JACIE, including specialists in HSCT administration, cell 
processing and storage, blood apheresis, transplant registries and QM. The stan-
dards are based on published evidence and, when this is not available, on expert 
consensus. A legal review and comparison with current regulations is carried out for 
each version. When the developmental phase is finalized, the standards are pub-
lished for public review and comment before being approved by FACT and 
JACIE. The standards incorporate sound principles of quality medical and labora-
tory practice in cellular therapy, but they do not cover the legal requirements which 
fall to the relevant competent authorities.
The standards cover the use of different sources of hematopoietic stem cells and 
nucleated cells from any hematopoietic tissue source administered in the context of 
the transplant process, such as donor lymphocyte infusion (DLI). The inclusion of 
the term “hematopoietic” in the title is to define the scope of these standards due to 
an increasing number of accredited facilities that also support non-hematopoietic 
cellular therapies. Since the release of edition 6.1  in 2018, the standards have 
included new items specifically developed for other cellular therapy products, with 
special reference to immune effector cells (IEC). This reflects the rapidly evolving 
field of cellular therapy through mainly, but not exclusively, genetically modified 
cells such as CAR-T cells. The standards do not cover manufacturing of such cells 
but include the chain of responsibilities where the product is provided by a third 
party, usually a pharmaceutical manufacturer, and ensure the competence of the 
personnel in the management of adverse events related to the infusion and subse-
quent care.
E. McGrath and D. Jawdat
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 Impact
What if any is the impact on clinical outcomes? – a crucial question given the effort 
and resources needed to establish and maintain the required standards in each trans-
plant centre and subject to much investigation across healthcare at large [12]. 
Evidence does exist for HSCT where studies using European HSCT registry data 
have correlated the different phases of preparation for and achievement of accredita-
tion at centre level with incremental improvements in patient survival and reduction 
in procedural mortality [13, 14]. Evidence relating clinical trials participation and 
FACT accreditation in the United States also indicated a positive impact, although 
with some mixed findings [15].
Implementing a quality management system and achieving accreditation in the 
field of cellular therapy by a transplant centre prove the level of commitment to 
high-quality measures and monitoring cellular therapy practice and downstream 
patient care. This provides reassurance to patients and their families, healthcare 
professionals, commercial suppliers, regulatory authorities and insurance payers.
Standards-setting organizations must be alert to the risk of overburdening their 
users with requirements, falling behind the pace of change or losing the focus on what 
actually matters to patients: health, safety and optimal experience [12, 16]. Braithwaite 
et al propose the need for a new generation of standards that do not just assess compli-
ance but also enable healthcare system transformation and sustainability [16].
 Conclusion
The international take-up of specialized standards in a complex field such as HSCT 
is due to a number of factors: the early championing by some HSCT leaders empha-
sizing the need for quality measures to better control a complex process; interna-
tional professional association support; the early observation at local level of the 
organisational impact and inclusion among national regulatory requirements. This 
widespread acceptance then provides a basis to present other aspects, such as stan-
dardised performance benchmarking of survival outcomes and minimal centre 
activity, as further means of quality improvement.
To help guard against overburdening users with unwieldy requirements, ulti-
mately, we must keep in mind why quality – and by extension, standards – is impor-
tant. Avedis Donabadian said in an interview not long before he died: “Ultimately 
the secret of quality is love. You have to love your patient, you have to love your 
profession, you have to love your God. If you have love, you can then work back-
ward to monitor and improve the system” [17]. This simple but powerful statement 
captures the real purpose of quality.
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Key Points
• Quality care is firmly established as a goal by healthcare professionals.
• Accreditation based on an internationally agreed standard system led by HSCT 
professionals is an effective tool to drive quality improvement in transplant 
programmes.
• Standards are regularly updated to reflect developments and innovation in 
practice.
• There is evidence that quality of care has been improved in HSCT by applying 
standards to clinical and laboratory practice.
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Chapter 2
Development of Organizational Quality 
Management System
Phuong Huynh and Renza Monteleone
FACT-JACIE accreditation is how a HSCT programme can demonstrate that it is 
performing to a required level of practice in accordance with agreed quality stan-
dards in haematopoietic cell therapy (HSCT). An essential component of accredita-
tion is that a centre must demonstrate that it operates an effective quality management 
system (QMS). Development of a comprehensive quality management system is 
often the most challenging and time-consuming exercise that the transplant pro-
gramme encounters when preparing for accreditation (Chap. 14).
The FACT-JACIE Standards define a quality management system as ‘an organi-
zation’s comprehensive system of quality assessment, assurance, control, and 
improvement’. A quality management system is designed to prevent, detect and 
correct deficiencies that may adversely affect the quality of the cellular therapy 
product or increase the risk of communicable disease introduction or transmission. 
It may also be referred to by other terms [1].
A quality management system (QMS) is a mechanism to ensure that procedures 
are being carried out in line with agreed standards with full participation by all staff 
members. In a cell transplant programme, this ensures that the clinical, collection 
and laboratory units are all working together to achieve excellent communication, 
effective common work practices and increased guarantees for patients. It is a means 
of rapidly identifying errors or accidents and resolving them so that the possibility 
of repetition is minimised. It assists in training and clearly identifies the roles and 
responsibilities of all staff. Once the required level of quality has been achieved, the 
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remaining challenge is to maintain this standard of practice. With a working quality 
management system in place and adequate resources, the fundamental elements 
necessary to sustain the program are continued staff commitment and vigilance.1
The QMS in the FACT-JACIE standards establishes a framework for everyday 
delivery of HSCT (clinical, collection, processing) in the centre. It also includes 
guidelines for purchasing, human resources and document control related to the 
cellular therapy product and patient and donor management. In addition, the QMS 
includes the preparation of the quality management plan (QMP, or quality manual) 
(see also Chap. 13), writing of the SOPs, describing necessary processes and their 
interactions, and the preparation of templates for different kinds of documents and 
records that will be used (see Chap. 3). These are subjected to very careful scru-
tiny by management reviews (see Chaps. 6, 9, and 12), internal audits (see Chap. 
4) and Corrective and Preventive Actions (CAPA) procedures to deal with and 
correct any non-conformities detected to keep the quality management system 
effective (see Chap. 11).
 1. Development of a comprehensive QMS is often the most challenging and time- 
consuming exercise for the haematopoietic cell transplant (HSCT) programme 
as, at least in the first instance, it often requires a cultural shift in working, espe-
cially for the clinical HSCT service. Given the challenges, there needs to be a 
clear justification when implementing the QMS to motivate the team in terms of 
benefits of quality improvement for the team, their working patterns and facili-
ties, and ultimately for patients. Professional pride and possible advantage rela-
tive to other treating centres from a successful accreditation or certification 
process may also be drivers for change in culture. The adoption of a QMS as part 
of the accreditation process also firms up collaboration between departments, 
services, registries and other ‘third parties’, e.g. national or regional blood ser-
vices, unrelated donor collection centres and registries. Use of the QMS may 
also help to meet legal and other regulatory requirements of social and private 
health insurance systems and clinical trials. The QMS is central to achieving 
JACIE accreditation, which is now used by many external regulators as an indi-
cator of quality for delivery of HSCT to patients.
 2. The QMS should be designed to fit the real organisation of the HSCT program 
and its broader institution. This should reflect not Work as Imagined (WAI) but 
Work as Done (WAD) [2], i.e. not how a team would like to work but how they 
are really working. The HSCT programme will need to discuss and agree inter-
nally the organisational structure of the QMS and assign clear roles. This will 
inform the quality management plan (see Chap. 7) and summarise the relation-
ships between each of the three services – clinical, collection and processing – 
e.g. how they are managed, where they are based, staffing and leadership, and 
whether external or third-party services provide services or components.
1 www.ebmt.org/accreditation-definitions
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 3. The QMS will need to show the lines of communication and responsibility across 
and throughout the entire HSCT program and should summarise staffing and 
describe what is expected of them.
 – All centres’ staff should have clearly defined roles and responsibilities and 
these should be shown on the organisational chart (Table 2.1). This could then 
be further explained in the QMP, especially the responsibilities, the Job 
Descriptions or the contact information. If staff are not directly employed by 
the same institution, honorary contracts may be necessary. An honorary con-
Table 2.1 List of the personnel who work within the transplant programme at the centre who 
could appear in the organigramme
Position
Note: not all positions listed here will be relevant to all programmes – centres should only 
reflect their real organisation, roles and structure
HSCT Clinical Programme Director
Clinical Adult Facility Medical Director, as applicable
Clinical Paediatric Facility Medical Director, as applicable
Adult Attending Physicians
Paediatric Attending Physicians
Junior Doctor
Physician in training
Bone Marrow Transplant Unit (BMTU) and Oncology Day Beds Unit (ODB) Senior Nurses and 
Education Sisters
Nursing Quality Management Lead
BMT Ward Manager
ODB Ward Manager
Clinical Risk lead
BMT Education Sister
Paediatric Haematology/Oncology Education Sister
BMTU Coordinators
Nurse Coordinator
BMT Medical Coordinator
Donor Coordinator Programme
BMT Pharmacist
Clinical Programme Quality Manager
Clinical Programme Data Manager
Clinical Programme Infection Control Lead
Apheresis Facility Medical Director
National Blood Service Quality Management
Quality Assurance Manager
Assistant Quality Assurance Manager
Processing Facility Medical Director
Laboratory Technician
2 Development of Organizational Quality Management System
12
tract gives individuals the right to work in more than their own institution and 
is good evidence of integration across different organisations.
 – The FACT-JACIE standards require that the QMS includes an organigramme 
or organisational chart (see Chap. 7), i.e. visual representation of the structure 
of all parts of the HSCT programme, and makes clear who is responsible for 
what aspects of which services (collection/clinical/processing). It should 
illustrate who reports to whom and who has responsibility for the different 
aspects of the transplant programme (Figs. 2.1, 2.2 and 2.3). The structure 
will enable both new/existing staff and external organisations to easily iden-
tify the make-up of the programme and lines of authority. Patients could also 
be provided with information about the team who are looking after them. The 
HSCT programme will need to show where the collection and processing take 
place and the individuals involved. Third-party collection and processing ser-
vices are likely to have their own QMS which is perfectly acceptable if there 
are service-level agreements (SLAs, Chap. 8) or contracts in place that define 
how the respective QMS interact.
Below is a list of roles that should be considered for inclusion in the programme 
organigramme and sample organisational charts showing differently structured 
programmes.
The Quality Assurance and Performance Improvement System is a coordinated, 
comprehensive and systematic plan for monitoring and continuously working to 
improve the services to support the care that patients receive. It will assist staff in 
Fig. 2.1 Example 1 of organisation chart template
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Fig. 2.2 Example 2 of organisation chart template
Fig. 2.3 Example 3 of organisation chart template
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meeting their individualized objectives and shall be managed by the quality man-
ager. Quality managers are responsible for the development, implementation and 
maintenance of the QMS, while the clinical program directors, in collaboration with 
the respective collection and processing directors, shall retain overall responsibility 
for quality.
Depending on how the HSCT programme is organised and its size, there may be 
a single quality manager or separate quality managers for each service, i.e. clinical, 
collection and processing.
Although the overall responsibility for the quality of the HSCT programme lies 
with the services directors, the quality manager has key roles including, but not 
limited to, the following:
 – Understand the entire HSCT process from start to finish.
 – Facilitate the development of documentation.
 – Facilitate improvements to standardise and enhance the overall service.
 – Support the HSCT programme director and facilities directors and educate the 
team in establishing and sustaining a quality management culture.
 – Coordinate the quality programme.
 – Report and communicate minutes of quality meetings between the clinical, col-
lection and processing facilities, and the quality management activities at a mini-
mum quarterly. A description of the process for annual performance review and 
provisions for continuing education (Chap. 17) also need to be included.
 – Communicate regularly with HSCT programme staff (e.g. collection, nursing, 
administrative, laboratory, consultants, junior doctors, data managers).
 – Be visible within the centre and motivate people with respect to quality 
improvement.
The quality manager must understand how the HSCT process works in various 
settings (allogeneic, autologous, etc.) and the steps patients and donors follow, for 
example:
• To understand the collection and processing part of the HSCT process, following 
a patient, donor and/or product through the process of stem cell collection and 
processing to understand the pathways for the patient/donor and the cellular 
therapy product.
• To understand the HSCT process from the patient’s perspective, asking the 
patients for their opinion. For instance, did they get all the information they 
needed? Was the procedure as they expected?
• To understand the HSCT process from the staff perspective, observing them 
while they see a few patients all undergoing the same procedure, then ask ques-
tions about how and why things are done in a particular way and if there is alter-
native way to do it.
The quality manager must also use standardised control documents, meetings 
with staff from each of the services, audits as well as methods for reporting, inves-
tigating and correcting adverse events whether the HSCT service is fully integrated 
or comprised of three separate facilities.
P. Huynh and R. Monteleone
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One of the key aims of the QMS should be to improve communication and 
understanding of roles and responsibilities across all the different staff groups 
within the HSCT program. Poor communication between groups of staff is cited as 
one of the biggest single causes of quality programme failure [3]. Joint Commission 
sentinel events analysis between 2004 and 2014 consistently showed poor commu-
nication as a contributor to failures or inefficiencies of processes [4].
A quality programme will only be successful if there is communication between 
all the staff involved. Regular group and team meetings should be set up to maintain 
and increase integration and ensure that different systems work together (Table 2.2). 
The QMS and QMP are central to improving communication between staff and 
departments and to ensure that everybody is clear about roles, responsibilities and 
processes for decision-making. Examples of template agendas and signing in sheets 
Table 2.2 Suggested quality groups/teams
Group Who What
Quality management group Quality manager, HSCT 
programme director(s), medical 
staff, senior nursing staff, 
pharmacists, data managers, 
collection facility staff, 
processing facility staff, 
laboratory staff and clinical trials 
staff
SOP development/review, 
audit timetable development, 
incident reporting, training/
educational programme 
development and service 
improvement
Clinical policy group
This group does not have to 
be separate from the Quality 
Management Group and 
could form part of the same 
meeting
Quality manager,
transplant physicians, nursing, 
pharmacy and support staff
Clinical policies
Multidisciplinary group Transplant physicians, nursing 
staff, collection/processing and 
other support service staff
Morbidity and mortality 
meetings : presentations of 
specific cases allow treatment 
pathways and outcomes to be 
discussed
Stem cell facility user group 
meetings –: in centres where 
a separate or third party 
collection and processing 
facility is used
Hosted by the third-party facility 
to discuss issues around the 
service provided
The agenda can include 
document development where 
documents are linked, i.e. 
delivery to the centre, 
incidents with product 
delivery, biological product 
deviations
Other management review 
meetings.
All directors, quality manager, 
nursing and medical staff
National or regional blood 
services, unrelated donor 
collection centres and registries
Look at the entire QMS in 
relation to other institutional 
organisations and HSCT 
referral base
Ward meetings, staff 
meetings, handovers, etc.
Quality manager, ward team, 
staff, etc.
To bring quality issues to the 
ward
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serve as evidence of meetings, joint decision-making and integration within the 
HSCT programme.
Below are suggestions of the types of groups that should be contributing to the 
maintenance of the QMS [5].
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Chapter 3
Document Development, Implementation, 
Review, Archive, and Disposal
Nick van Sinderen
 General
Documents have many uses in the quality management program. They provide the 
structure needed for quality assurance through policies and procedures, ensure qual-
ity control through forms such as pre-printed orders and worksheets, and support 
quality management activities through audit reports, outcome analyses, and training 
records. The quality program needs to identify documents critical to the transplant 
program. The transplant program needs to describe how the critical documents are 
conceived, generated, implemented, distributed, reviewed, and stored. All parts of 
the transplant program require written instructions as to how to undertake key pro-
cesses. Equally, personnel in the facility should use these documents to carry out 
tasks and they need to be sure that the document they are using is the current ver-
sion. Documents (policies, Standard Operating Procedures (SOPs), worksheets, and 
forms) are the foundation of the quality program as they explain how tasks are 
undertaken and facilitate the effective operation of the transplant service. An over-
arching policy encompassing the writing, reviewing, implementation, and control of 
documentation (the “SOP about SOPs”) is a key requirement.
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 Start
Setting up a document management system (DMS) starts with making an inventory 
of what you have and of what you need. What do you think is required and what are 
the JACIE requirements? The standards provide a structure whether you are starting 
from square one or whether you already have a set of transplant-related policies. 
Transplant centers frequently have pre-existing laboratory and, less commonly, 
clinical policies, though, very often, the system is so fragmented that many staff are 
unaware of their existence. From the outset, it is imperative to form a project team 
as the task is huge and needs constant monitoring and steering.
Some key points to consider:
 – Use your in-house expertise
If you make your expertise the starting point, you will make the DMS your own. 
In the development of documents, review the draft contents against the JACIE 
requirements. This will lead to useful discussions which will increase the value 
of your SOPs.
 – Use information available in your own hospital
 – Other departments in your hospital will already have information and policies 
that you can use as a starting point. Refer to them in your own documents and 
this will prevent unnecessary duplication and make yours easier to read, e.g., 
hygiene and safety policies.
 – Don’t go reinventing the wheel in developing new policies about which you 
know little. Ask other hospitals or EBMT quality forum colleagues whether they 
have information or policies that they might be willing to share. Then, modify 
them to suit your own requirements.
 – Refer to other documents rather than continually lengthening your own new poli-
cies and procedures. This will prevent you from falling into the trap of having to 
constantly revise huge, unreadably large documents. Refer to checklists, papers, 
and key supportive information.
 – Make sure that in-document URL hypertext links always relate to the source 
document and that they work. You can use the same link throughout your DMS.
 – Use job titles rather than the names of individuals in your DMS to avoid the need 
for document revisions when people change jobs.
Use the quality manual as your starting point. This is a high-level document, so 
avoid excessive detail and try to keep it short. Refer to SOPs and other relevant 
documents. In your SOPs, refer to checklists and additional information elsewhere 
(see Fig. 3.1). This makes them more readable and accessible.
Example set-up of the quality manual
 1. Organizational profile (facility description)
 2. Definition of the QM program
 3. Impact of the quality management program
 4. Aims of quality assurance
 5. Organizational structure and responsibilities
N. van Sinderen
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 6. Agreements & key relationships
 7. Key personnel – roles & responsibilities
 8. Personnel qualifications, training, and competency
 9. Communication
 10. Documentation
 11. Adverse events
 12. Audits
 13. Outcome
 Workflow
The quality manager has overview of all documents and is usually assisted by docu-
ment managers who are clinicians or scientists with a part-time role in quality (see 
Fig.  3.2). This is a constructive approach in that such individuals have areas of 
expertise which relate to the documents assigned to them. They are therefore best 
positioned to ensure that the relevant policies are fit-for-purpose.
The quality manager is the direct link to transplant program management and is 
responsible for the implementation of the QMS. The quality manager provides a 
quarterly report to the clinical program director and the management team to keep 
them up-to-date regarding new documents and revised versions of existing docu-
ments. These quarterly reports are included in the annual report and the annual 
management review, completing the policy Plan-Do-Check-Act (PDCA) cycle for 
this topic.
Quality
Manual
Policies 
&
Procedu
res &
guideline
s
Work i
nstruc
tions
Record
s, form
s, chec
klist, w
orkshe
ets,
labels
Fig. 3.1 Example document structure
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 – Author
The first author of a document leads in its preparation and writing and should 
have relevant expertise. The goal is to produce an advanced draft ready for wider 
review. This provides an educational opportunity which will be addressed further 
later in this chapter.
 – Reviewer(s)
These are one or more individuals who check the document for factual accuracy 
and clinical relevance. If required, suggested improvements can be incorporated 
into a revised version. This person is often from another department and provides 
different expertise. Such a fresh perspective is often very useful. An example would 
be a pharmacist reviewing medical policies from the point of view of pharmacovigi-
lance. This is a common approach and helpfully ensures that pharmacists are aware 
of all new treatments.
 – Authorization
The clinical program director (CPD) is ultimately responsible for the transplant 
program and the CPD (or his/her designee) therefore authorizes all documents. 
However, the CPD does not necessarily need to review and authorize each docu-
ment. That would take an additional work week. The non-medical documents can 
be delegated to members of the management team or the relevant senior, qualified 
individuals. In such cases, this should be carefully documented in the DMS SOP. If 
necessary, the CPD can review document metadata in order to monitor its develop-
ment. These changes can be summarized in the quarterly and annual reports.
Note: Electronic document management systems generally allow for each step in 
the process to be tracked. This is not the case with paper-based or hybrid systems and 
care is needed in such cases to ensure that the workflow is robust and easy to operate.
 Responsibilities
Involve as many staff as possible when developing new documents. This is crucial. 
It is common at inspections to find that the DMS has deteriorated – missed review 
Quality Manager
Create document Update
Draft
(role and time)
Draft
(role and time)Review
(role and time)
Review
(role and time)Approve
(role and time)
Approve
(role and time)
Reports: numbers created, reviewed, overdue, archived.
Fig. 3.2 Create and review documents
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dates, obsolete policies – as too few people have too many documents to take care 
of. Tasks end up being repeatedly deferred. This can be dangerous for both patients 
and clinical staff as treatment protocols must be kept current and have the latest 
information. It is the job of the quality manager to ensure that newly authorized 
documents are immediately made available for routine use.
Here are some examples of the appropriate staff to be involved in developing 
particular policies:
 – Treatment and medical and supportive care: (senior) nurse, physician-in- training, 
nurse practitioner, physician assistant, oncologist, hematologist, pharmacist, 
counselor
 – Policy: management team, team leaders
 – Data: secretary, data manager, nurse
Medical systems differ and you will need to adopt an approach that best suits 
your local circumstances. However, the key take-home message is to involve as 
many people as possible in order to keep the system going in the long term.
 Duplication of Requirements Between Different 
Quality Systems
Anyone involved in quality is aware of the overlapping requirements between qual-
ity systems such as JCI, JACIE, and ISO. The transplant unit may be a component 
of a wider oncology program; a pharmacy-based QMS might be subject to a differ-
ent regulator; the pediatric unit may be administratively distinct from the adult unit; 
and there are often a number of different information and communication (ICT) 
services networks – whether national, regional, or hospital-based – all available on 
local workstations. Equally, the hematology laboratory may be accredited to ISO 
15189:2012 (medical laboratories – requirements for quality and competence). In 
general, there are few significant differences between these standards. A useful 
approach is to follow the stricter guideline and to try to avoid following separate 
regulations in a given area as it may lead to confusion. For example, if JCI requires 
three-yearly review and JACIE two-yearly, follow the JACIE requirement.
Unfortunately, the different international standards have evolved and diverged 
over time, and it is important to bear in mind when creating DMS policies that they 
meet all of the different regulatory requirements. Inspectors and the EBMT can be 
made aware of these issues.
Each transplant unit has unique circumstances, based on local logistics and 
resources. So it is not possible to be prescriptive. Rather, the key principles to 
remember are that documents need to be kept up-to-date and accessible for every-
one involved. Important underlying concepts include the use of technical solutions, 
cross-referencing between documents to prevent redundancy, and close collabora-
tion with other hospital departments, especially ICT, when setting up and also on an 
ongoing basis to maintain the DMS.
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 ICT Systems and Paper Documents
Recent ICT advances have included hospital-wide electronic patient records (EHRs) 
and remotely accessible document management systems. Some of these allow for 
treatment protocols to be automatically included in patient records, guaranteeing 
the use of the current version. More usually, however, each transplant unit is a 
patchwork of promising innovations and local logistical limitations. The challenge 
might be physical due to lack of space or financial due to inadequate investment. 
Some departments manage to set up their own bespoke IT systems. Although an 
attractive short-term solution, this can pose problems. The hospital ICT department 
will not provide support when something goes wrong and such a system can leave 
the unit dangerously reliant on one motivated individual.
A paper-based DMS offers a reasonable alternative but has some challenges of 
which you need to be aware. These include the revising of policies, filing and 
archiving, and how to keep everyone informed of new versions of documents. This 
is the system where you see frequent handwritten notes. If following Good 
Documentation Practice guidelines, every written update to a document must be 
signed and dated. This is not likely to happen in a hectic hematology department.
Here again, there is no one-size-fits-all solution. However, using a collaborative 
common sense approach, it should be possible to put in place a workable system 
that meets the standards. The basic question you always have to ask yourself is, 
“How do I get the latest version of the document to the people that use it?”
 Education and Document Management
A document management system is a perfect tool for education. Here are some 
examples:
 – New employee: make sure that new employees receive training in the 
DMS. Consider assigning them documents in their field of expertise. Over time, 
they can be assigned first authorship.
 – As mentioned previously, involve pharmacists in the development of treatment 
protocols.
 – Discuss policy changes at quality meetings. Other means of disseminating infor-
mation include newsletters, reading lists, etc. If the change is significant, it could 
be brought to the multi-disciplinary team meeting to ensure that all staff mem-
bers are informed.
 – Secretaries and data analysts use data in patient files on a daily basis. Involve 
them in reviewing documents in their field of expertise.
 – Bring different staff together for collaborative discussions. Taking people out of 
their silos can lead to productive cross-fertilization of ideas: “I never knew you 
could do it that way!”
N. van Sinderen
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These are just a few examples of how you can use document management systems 
for educational purposes. Reflect on how this can be done to benefit your program.
 JACIE on Document Management
The document control policy shall address the points listed in Fig. 3.3
The JACIE document management standards are straightforward. Documents 
should have a standard format and should be revised every two years with clear revi-
sion dates and tracked changes. They must be authorized by the CPD or designee, 
contain accurate references, and information on “who modified what, at what time, 
and why” should be clearly recorded. Methods to ensure safe validation of both 
electronic and printed versions are also required. Finally, and importantly, maintain 
a readily available list of all critical documents.
Documents may require revision for several reasons:
 – If a staff member makes a clear case for revision
 – As a corrective action following an (internal) audit or adverse event
 – Changes in regulations (law)
 – Changes in standards
 – Changes in organization
The DMS SOP should clearly describe these processes. Documents should be 
easily accessible. Finally, maintain open communication with all staff in the 
A standardized format for
critical documents.
Assignment of a numeric
or alphanumeric identifier
and a title
Review of controlled
documents every two (2)
years at a  minimum.
A system for document
change
A system for document
approval, including the
approval date, signature
of approving individual(s),
and the effective date.
A system to protect
controlled documents
from accidental or
unauthorized
modification.
Archival of controlled
documents
A system for the retraction
of obsolete documents to
prevent unintended use.
Fig. 3.3 JACIE and document management
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transplant program and make sure management is aware of all significant 
developments.
Note: Refer to the JACIE/ EBMT manual for the standards and guidance in their 
implementation.
Source for figures
 1. Figures 1 and 2 were created by the author, and Figure 3 is from the EBMT 
Standards quality management presentation.
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Chapter 4
Audits
Olga López-Villar and Julie Dolva
 General Concepts
 Definition and Purpose
An audit can be defined as a documented, systematic evaluation to determine 
whether approved policies or standard operating procedures have been properly 
implemented and are being followed [1, 2].
Audits represent one of the principal activities of the quality management pro-
gram. They are conducted to establish whether the program is operating effectively 
and to identify trends and recurring problems in all aspects of facility operations. Of 
course, an audit can also demonstrate strengths.
A common mistake is to see the audit, particularly external audits, as the goal of 
the quality system. The idea – “I have just passed the JACIE audit so I can relax until 
the next one” – is a misunderstanding of what audits are for.
 Scope
The scope of the audit can range from simple to complete. It can examine a par-
ticular process, the quality system itself (quality audits), or the whole program. 
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The scope must be described in detail in the audit plan. Audits and the audit plan 
are part of the quality management system. Depending on the organization of 
internal audits in a center, the unit can be audited within a single (and comprehen-
sive) internal audit or there can be different audits for different topics.
 Types of Audits
Internal, third party, and external audits [3]:
• Internal audits are performed by an individual who works in the unit but who is 
not solely responsible for the audited activities (see the job requirements of an 
internal auditor later in this chapter).
• Third-party audits of vendors or suppliers may be performed to check that the 
provider has performed the service or provided the product according to the 
agreed criteria. In the accreditation manual [2], it is stated that a remote audit by 
questionnaire (document audit) is an example of how to qualify a vendor.
Another example is that of units being audited by manufacturers of CAR-T cells. 
In this case, the unit (clinical, collection, or processing) does not perform the 
audit; it is analyzed by the company’s auditor.
• External audits are performed by some entity outside the program. There are 
two types:
 – Performed by external certification or accreditation body: JACIE, ISO9001, etc.
 – Inspections by the competent authority
These certification or accreditation entities require internal audits to assess 
the system.
It would be unnecessarily time-consuming if units had to arrange dedicated inter-
nal audits to meet the specific requirements of each accreditation body. It is there-
fore advisable to make sure to include all requirements in the audit procedure.
Deviations detected in third-party and external audits should be managed accord-
ing to the center’s corrective action and preventive action (CAPA) policies in the 
same manner as those detected in internal audits.
Other ways of classifying audits are as follows:
• On-site vs document:
On-site The auditor visits the unit to perform the audit (on-site). The auditor may 
examine documents relating to the scope of the audit or procedures performed on 
the day of the audit, interview personnel, etc.
Document Alternatively, the audit can consist of a review of documents submitted 
by the center. This type of audit is not generally recommended for internal audits 
and is best reserved for interim audits or for audits of remote third-party providers.
O. López-Villar and J. Dolva
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• Audit for accreditation or re-accreditation vs interim audit: more details in 
Chap. 14 (the accreditation process).
The audits for accreditation or re-accreditation are the ones performed to check 
the system and obtain the accreditation.
The interim audit is performed during the accreditation cycle to assess that the 
quality management system is still functioning according to the standards.
 Auditor Requirements
An auditor requires sufficient expertise in the subject manner to be able to identify 
problems and must also be a competent auditor.
Knowledge of the subject being audited is often needed to perform internal 
audits. The organization must be able to demonstrate how they assess auditor com-
petency. Examples could include courses, audits performed, etc.
The auditor can be a transplant program or unit staff member as long as they are 
not solely responsible for the process being audited and did not perform the audited 
activities [2].
 How to Perform Internal Audit: The Steps of an Internal Audit
The program must have a description of precisely how they perform audits, specify-
ing for the particular unit or program all the steps that are summarized in this chapter.
 Audit Calendar
There must be a calendar or schedule of audits (Table  4.1). The auditor can be 
included in this calendar or in another of the documents. The head of the QM pro-
gram should identify areas to be audited and audit frequency [2]. The calendar 
should be shared with key personnel at quality meetings. Depending on the struc-
ture of the transplant program, there may be one overarching program audit sched-
ule or each unit may develop their own calendar.
Examples of audits can include the following:
• Adherence to procedures or policies
• Completion of records
• Completion of training
• Equipment maintenance according to schedule
This chapter is dedicated to internal audits.
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There are mandatory audits required by JACIE or the institution, while other 
audits may be based on local requirements or problems and may be identified by 
risk assessment, for example. There must be regular auditing of critical activities; 
the frequency will depend on the importance of these activities, and, to some extent, 
on the results [2]. There is a list of the minimum requirements in the JACIE stan-
dards. Most of the topics require an annual audit. To make it simple, annual audit for 
all topics is a reasonable approach.
The list of audits might have to be modified or extended during the year, for 
example, to include follow-up audits.
 Audit Plan
Preparation and planning are important parts of a good audit and must be done thor-
oughly. An audit plan is prepared as a specific guideline for the audit and is essential 
to allow the auditor to perform an effective and efficient audit.
Depending on center procedures, auditors can use either a pre-existing checklist 
or a specific checklist prepared by them which includes all the items to be audited. 
The JACIE checklist, or parts of it, could serve this purpose, depending on the 
scope, and other topics can then be included depending on the unit and on the qual-
ity system in use in the unit.
The use of checklists to perform the audit is not mandatory; other tools are 
acceptable if they cover all the topics that are to be audited.
The plan should include the actual date, location, etc.
 Conducting the Audit
Depending on the audit procedure, a formal introduction may not be necessary.
During the audit, the auditor will review the process, the procedures, forms, etc., 
according to the audit plan. The auditor will interview the personnel to assess if 
what they do is performed according to the written procedures of the unit and 
according to the standards [4]. During the audit, the auditor collects evidence to 
assess adherence to standards. For the report, it is important to write down any evi-
dence of a deviation in a particular requirement.
 Closing
Depending on the procedure, a formal closing meeting may not be required. 
However, it may be useful to discuss the audit findings with the individual respon-
sible for the procedure or their designee and with the quality manager.
O. López-Villar and J. Dolva
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 Audit Report
The audit report is an important document and must be prepared by the auditor 
within a pre-defined timeframe.
The use of a template (example in Table 4.2) is recommended to ensure that all 
the necessary details are included. These should include the following: audit title, 
scope, auditor, date, location, plan, copy of the checklist or of the audit findings, 
summary of deviations, and signatures.
Table 4.2 Example template for an audit report form. Adapted from “A practical guide to 
implement quality management in a Stem Cell Transplantation Programme” [5]
Audit report form
Audit title: _________________________________________________________________
Facility: ___________________________________________________________________
Scope: ___________________________________________________________________
Audit type (yearly, key elements, focused, follow-up, etc.): __________________________
Audit purpose (main aim of the audit): __________________________________________ 
Auditor: __________________________________________________________________
Date: ____________________________________________________________________
Location: _________________________________________________________________
Plan of audit: include times, questionnaires, interviews, other staff, or areas involved, etc.
O. López-Villar and J. Dolva
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Auditor findings/copy of completed checklist: 
Summary of deviations: 
Date of the report: __________________________________________________________
Signature of the auditor: _____________________________________________________
Reviews:
Quality Manager: Date, name, and signature ______________________________________
Manager of the audited area: Date, name, and signature ____________________________
________________________________________________________________________
Facility Director: Date, name, and signature ______________________________________
Table 4.2 (continued)
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The audit report should be reviewed and approved by the appropriate personnel, 
such as the quality manager and the facility director. The approved audit report 
should be distributed to the manager of the audited area and should be shared with 
staff, when appropriate [2].
Internal audit reports are always reviewed in external audits (JACIE, ISO, etc.), 
so it is important to make sure that the necessary reports are available for the 
inspector.
 Actions
Audits are performed to recognize problems, trends, and improvement opportu-
nities [1], and any findings should be followed by the necessary actions. The 
center must identify the underlying root cause of the deviation and implement 
corrective and preventive actions (CAPA) (see Chap. 11) or process improve-
ments, as required [2], ideally as soon as possible, and certainly within the 
required timeframe.
The corrective and preventive actions should include a scheduled date for a 
follow- up audit to verify that effective corrective actions have been imple-
mented [2].
The required actions must be documented according to local procedures. The 
findings of the audit can be included within the established system for recording 
deviations, occurrences, etc. (see Chap. 11).
The center can also choose to document the actions in the audit report (Table 4.3). 
The effectiveness of the actions must be reviewed and documented and further 
audits might be necessary.
In subsequent audits, it is important to review stages in the process where devia-
tions have previously been found to occur.
 Communication of the Result of Internal Audits
The results of the audits, as a key component of the quality management system, 
must be shared at quality meetings and included in the annual report.
Audit results, corrective actions, and follow-up actions should be reported at 
least once a year. Review by the Program Director should be documented and there 
should be evidence that audit reports have been shared with the appropriate 
staff [2].
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Table 4.3 Example template for corrective action plans. This table can be added to the audit report 
(Table 4.2) if the center decides to include the actions in the audit report instead of including them 
in the deviation procedure
 Adapted from “A practical guide to implement quality management in a Stem Cell Transplantation 
Programme” [5]
Corrective Action Plan after Audits
Audit title: _________________________________________________________________
Facility: _________________________________________________________________
Scope: ___________________________________________________________________
Audit type (yearly, key elements, focused, follow-up, etc.): __________________________
Audit purpose (main aim of the audit): __________________________________________ 
Date: ____________________________________________________________________
Deviation 1: _______________________________________________________________
Underlying cause: __________________________________________________________
Actions:      Corrective  Preventive  
1st action: Description: ______________________________________________
Responsible: _____________________________________________________
Due date: _______________________________________________________
Follow-up: _______________________________________________________
Due date: _______________________________________________________
Follow-up: _______________________________________________________
2nd action: Description: _____________________________________________
Responsible: _____________________________________________________
4 Audits
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Deviation 2, etc.: ___________________________________________________________
Same structure as in deviation 1
Reviews:
Quality Manager: Date, name, and signature _____________________________________
Manager of the audited area: Date, name, and signature ____________________________
_________________________________________________________________________
Facility Director: Date, name, and signature ______________________________________
Table 4.3 (continued)
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Chapter 5
Qualification and Validation
Renza Monteleone and Dieter Klarmann
Qualified equipment and validated processes ensure satisfactory, safe, and repro-
ducible outcomes and allow personnel to achieve, within the limits of the precision 
of the process, the same output when starting with the same input. Any change of 
equipment, utilities, or process should be formally documented and the impact on 
the validation status or control strategy assessed (change control [Fig. 5.1]).
A process is validated by establishing objective evidence that the process consis-
tently produces an expected endpoint or result that meets predetermined acceptance 
criteria. Process validations can be performed prospectively or concurrently.
The transplant program or facility should have a specific SOP or document (vali-
dation master plan – VMP) related to qualification and validation, detailing which 
validation studies are mandatory, how to perform them, and in what format. The 
design of the validation study should be adequate to determine if the process repro-
ducibly achieves the purpose for which it is intended.
In this SOP/VMP, the following items should be addressed:
 – Scope of validation and critical processes to be validated
 – Activities included in the validation plan, methods, and tools to be used to verify 
the reproducibility of results
 – Activities to perform in the qualification of materials/supplies, facilities, equip-
ment, and verification of personnel training
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 – Collection and analysis of data, tests to be performed, number of samples to be 
tested, range of acceptable results
 – Collection and documentation of results
 – Conclusions and approval of validation study
 – Duration of validation and criteria for revalidation
 – Change control management
The responsibility for the validation SOP/VMP lies with the director of the trans-
plant program. However, responsibility is shared with the quality manager, who has 
the key role of deciding on the methodological tools to be used for qualification and 
validation by the professionals involved in this process. The quality manager is 
responsible for organizing and monitoring training and ensuring the competencies 
of the personnel involved in the validation studies as well as organizing training on 
change control and risk management. Finally, the quality manager verifies the 
implementation of and compliance with the validation SOP/VMP.
The result of each validation study must be reviewed and approved by both the 
quality manager and the transplant program director or facility director (collection, 
processing, or clinical) and/or by the individuals deemed responsible according to 
national pharmaceutical law.
All transplant program personnel should be involved in the validation studies. 
This can be achieved by establishing a dedicated validation team with representa-
tives from across the transplant program. Professionals involved in the qualification 
and validation steps should have specific training in the relevant area and in the 
processes to be validated. They should collaborate with the quality manager and, if 
required, external experts; for example, when qualifying equipment, this may neces-
sitate the involvement of the hospital maintenance office and the manufacturer.
A risk assessment should be performed for each validation study to assess how 
critical the process is and to define the level of risk.
Qualification of the facility, equipment and material, and verification of person-
nel training are included in the validation study (Fig. 5.1).
VALIDATION
STUDY
RISK ASSESSMENT
QUALIFICATION
FACILITY EQUIPMENT MATERIAL
PERSONNEL
Fig. 5.1 Validation study including risk assessment and qualification
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 Validation Process (Fig. 5.2)
Identification of critical processes to be validated JACIE defines some minimal 
mandatory validations, though every transplant program should decide whether 
additional processes are critical to their activities and might therefore merit formal 
RISK
MANAGEMENT 
IDENTIFICATION OF CRITICAL PROCESSES TO BE VALIDATED
Program Director / Quality Manager / Facility Director
RISK ASSESSMENT
Program Director / Quality Manager / Facility Director
VALIDATION
PROGRAM 
VALIDATION PLAN
Program Director / Quality Manager / Facility Director
QUALIFICATION FACILITIES QUALIFICATION
Facility Director / Quality Manager / Personnel 
MATERIALS QUALIFICATION
Facility Director / Quality Manager / Personnel 
EQUIPMENT QUALIFICATION
Facility Director / Quality Manager / Personnel 
VERIFICATION OF PERSONNEL TRAINING & COMPETENCIES 
Facility Director / Quality Manager / Personnel 
VALIDATION TESTS
Facility Director / Quality Manager / Personnel 
TESTS & OUTPUT
VERIFICATION
VALIDATION REVIEW & APPROVAL 
Program Director / Facility Director / Quality Manager
PERIODIC VALIDATION & CHANGE CONTROL
Program Director / Quality Manager / Facility Director
PERIODIC
VALIDATION 
Fig. 5.2 Steps to carry out a validation study and responsibilities
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validation. A process is considered critical if it impacts on the quality and/or safety 
of cellular products.
The minimal Validation studies required by the JACIE Standards are as follows:
• Apheresis collection
• Bone marrow collection
• Processing and cryopreservation
• Labeling
• Storage
• Distribution (included transportation and packaging)
Risk assessment Evaluation of the level of risk and activities that might mitigate 
this risk (see Chap. 18 on Risk Management).
Validation plan For each critical process requiring validation, the facility should 
produce a validation plan that includes the following:
 – Rational for validation: refer to standards, applicable laws, critical nature of pro-
cess, etc.
 – Results of risk analysis: the facility should define the type of validation exercise 
based on the perceived level of risk
 – The expected endpoint or result
 – The different phases of validation, assignment of roles, the output for each phase 
and methodologies to be adopted
 – List of variables to be qualified: facilities, materials, equipment, and personnel
 – Method for qualification of facilities, materials, equipment, and personnel
 – Operating standards (process parameters, SOP, etc.): to guarantee satisfactory 
ongoing supply of the process and to maintain the validation status over time
 – Evidence of validation
 – Validation protocol: method for collection of data and analysis, timeline, 
expected output, presentation of results, deviations management
 – Validation documentation: registration forms, database, etc., to guarantee docu-
mented evidence of the results of the validation process
 – Validation cycle planned for revalidation and requalification of equipment
Qualification: facilities, material, equipment, personnel Each component that 
could influence the results of the process should be qualified. Qualification of facili-
ties, for example, is based on the verification of suitability of the rooms for the 
proposed activities, verification of environmental conditions, access for authorized 
staff, certification, etc. Qualification of materials is based on the verification of the 
manufacturer’s certification, integrity of packaging, expiration date, etc.
Qualification stages for equipment, facilities, utilities, and systems according to 
[1] are listed in Fig. 5.3:
 1. User requirements specification (URS)
 2. Design qualification (DQ)
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 3. Installation qualification (IQ)
 4. Operational qualification (OQ)
 5. Performance qualification (PQ)
 6. Requalification
Competencies The competency of personnel to perform the activities related to the 
process undergoing validation should be verified and, if insufficient, specific train-
ing should be arranged. The validation team should check that there are SOPs for all 
the processes involved in the validation study and, if unavailable, need to generate 
such policies; registration forms need to be available to ensure that every step of the 
process can be clearly traced.
Installation Qualification (IQ)
Operational Qualification (OQ)
Design Qualification (DQ)
The documented verification that the proposed design of the
facilities, systems and equipment is suitable for the intended
purpose  
The documented verification that the facilities, systems, and
equipment, as installed or modified, comply with the
approved design and the manufacturer´s recommendations    
The documented verification that the facilities, systems, and
equipment, as installed or modified, performed as intended
throughout the anticipated operating ranges    
User requirements specification 
The set of owner,user,and engineering requirements
necessary and sufficient to create a feasible design meeting
the intended purpose of the system      
The documented verification that systems and equipment can
perform effectively and reproducibly based on the approved
process method and product specifications   
Performance Qualification (PQ)
Re-Qualification
Equipment, facilities, utilities, and systems should be
evaluated at an appropriate frequency to confirm that they
remain in a state of control    
Fig. 5.3 Qualification stages for equipment, facilities, utilities, and systems
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Validation tests Based on the validation plan, an adequate number of tests should 
be performed. The number of tests required to consider the process validated will 
vary, based on the frequency of the respective activity, level of risk, precision, range 
of acceptable or expected results, etc. The rationale and the established number of 
tests should be documented. The validation study should include the parameters to 
be verified, the expected results, the criteria and acceptance range, and the method 
for verification (test, visual assessment, document-based, etc.)
Validation review and approval Following completion of the validation, all data 
analyzed, the output and results should be included in a final validation report; the 
quality manager and the transplant program director and/or facility director should 
review the report and confirm with their dated signature that the process is validated 
and that it may be used for clinical purposes.
Periodic validation The transplant program or facility shall decide on the length 
of the validation cycle. This decision should be based on various factors, including 
the level of risk, the internal control process, equipment wear, and other compo-
nents. The basis for this decision shall be described and documented.
Change control If a significant change is introduced in the process, it should be 
revalidated. A change control analysis is required before starting the validation 
study to predict the possible impact of the change on the process (Fig. 5.4).
 Example of Documents and Registration Forms for Validation
 Validation Master Plan (VMP)
General SOP or other document that describes how to perform a validation study.
 Validation Study
A specific SOP or document that describes how to perform validation of a specific 
process. It contains the specifications of the process (phases, components to be 
qualified, expected output, prerequisites and performances, type and range of evi-
dence required to confirm that the process is validated).
• Data collection and analysis form
• Qualification form for materials/supplies
• Qualification form for facilities
R. Monteleone and D. Klarmann
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• Qualification form for equipment
• Validation final report
• Change control report
Computerized systems used in the manufacture of medicinal products should 
also be validated according to the requirements of EU-GMP Annex 11; these are not 
included in this chapter, for details see reference [2].
Glossary
Change Control A formal system by which qualified representatives of appropri-
ate disciplines review proposed or actual changes that might affect the validation 
status of facilities, systems, equipment, or processes. The intent is to determine 
the need for action to ensure and document that the system is maintained in a 
validated state.
Process validation The documented evidence that the process, operated within 
established parameters, can be performed effectively and reproducibly to 
CHANGE
CONTROL
SYSTEM  
RISK ASSESSMENT
Program Director / Quality Manager / Facility Director
Does the change
create an adverse
impact on the 
  process/output?   
NO: change
management with
routine SOP  
YES:
RE-VALIDATION OF THE PROCESS 
Program Director / Quality Manager / Facility Director
New tests? Re-qualification? New training?
Program Director / Quality Manager / Facility Director
PROPOSAL FOR PROCESS’S CHANGE
Fig. 5.4 Change control flowchart
5 Qualification and Validation
42
 produce a medicinal product/cellular therapy product meeting its predetermined 
specifications and quality attributes
Qualification The establishment of confidence that equipment, supplies, and 
reagents function consistently within established limits.
Quality assessment The actions, planned and performed, to evaluate all systems 
and elements that influence the quality of the product or service.
Quality assurance The actions, planned and performed, to provide confidence that 
all systems and elements that influence the quality of the product or service are 
working as expected or exceed expectations individually and collectively.
Quality risk management A systematic process for the assessment, control, com-
munication, and review of risks to quality across the lifecycle.
Quality Conformity of a product or process with pre-established specifications or 
standards.
Verification The confirmation of the accuracy of something or that specified 
requirements have been fulfilled. Verification distinguish from validation in that 
validation determines that the process performs as expected whereas one verifies 
that the products of a process meet the required conditions.
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Chapter 6
Outcome Analysis
Anne Emmett
 What Is Outcome Analysis?
Outcome analysis does not directly assess the quality of performance, it only allows 
for interpretation of the quality of the process and structure of care. A set of key 
performance indicators (KPIs) should be established to ‘measure’ against.
Outcome analysis can be a subjective process as good outcomes can come from 
poor care and poor outcomes can come from good care. There are many interplay-
ing factors that need to be considered and a ‘one-size-fits-all’ approach cannot be 
established. It is important to ensure that the intended outcome is consistent with the 
systems and processes put in place by each facility.
Ensure that the intended outcome measure is clearly defined and quantifiable. 
Ways of measurement can be against a scale, by questionnaires, direct observation, 
or retrospective review of data.
Policies and procedures should describe in detail the steps to be taken to perform 
outcome analysis. The process for outcome analysis should follow the PDCA qual-
ity cycle processes of Planning (what is going to be analysed), Doing (undertaking 
the analysis), Check (that what has been done was correct) and Acting (taking action 
to improve based upon the findings).
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 Standards
There are 146 incidences of the word ‘outcome’ or ‘outcomes’ within the seventh 
standards, so it is present in many of the standards, or explanations of standards, or 
evidence required (Fig. 6.1).
As the standards mature, into the eighth, ninth, and tenth standards and beyond, 
it can be expected that the need to present outcome improvements will become more 
prevalent, so the ability to document and review these key performance indicators 
(KPIs) will become more essential.
 Collecting Data
When collecting data, be clear to identify which patient groups/subgroups are being 
included. Data will normally be collated from patient notes/records/care plans.
Outcome analysis, in line with the standards, can be difficult to establish, but the 
fundamental requirements are arguably quite simple:
• The results of what has taken place should regularly be looked at and reviewed, 
at least quarterly and ideally more frequently, depending on patient numbers.
• Analysis that MUST be completed: (Table 6.1) (reference JACIE Standard)
 – 100-day mortality
 – Time to engraftment
 – Recipient outcome after infusion of a product with a positive microbial culture
European Society
for Blood and Marrow
Transplantation
Standard B1.1.1: The Clinical Program shall demonstrate common staff training, protocols, Standard
Operating Procedures, quality management systems, clinical outcome analyses, and regular
interaction among all clinical sites
Definition:
Outcome analysis: The process by which the results of a therapeutic procedure are formally assessed
Evidence: Regular interaction. Regular interaction means meetings and conferences that are regularly
scheduled, multidisciplinary, involve all clinical sites, and are documented in meeting minutes, including
documented attendees. Regular interaction should involve physicians, nurses, coordinators, social
workers, education consultants, processing staff, collection staff, and others.
This should include regularly scheduled conferences for topics such as morbidity and mortality, quality
assessment and improvement, protocol development, journal clubs, patient assessment and
evaluation, patient outcomes, tumour boards, continuing education presentations, interesting case
presentations, etc.
Such topics could also be reported in joint manuscripts or abstracts for national meetings. The inspector
should check attendance to confirm that all sites are represented, and that attendance is documented.
Fig. 6.1 Sample standards from v7
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Have outcome data as a standing item on the quality management/clinical gover-
nance meeting
Quality indicators include CAR-T/IEC and other novel therapies.
• 100-day mortality
• Acute GVHD grade within one hundred (100) days after transplantation
• Chronic GVHD grade within one (1) year after transplantation
• Engraftment data review
• Late engraftment due to complex issues
• KPI for platelets not met
• Auto recovery data (Table 6.2; Fig. 6.2)
• CAR-T metrics (Table 6.4)
• Apheresis data and any cancellations
• Central venous catheter infections
• Complaints
• Incident reports
 – Labs
 – Wards
 – Outpatients
 – Apheresis
 – Pharmacy, etc.
Table 6.2 Sample of data presentation[2]
Patient
Days to 
ANC >0.5
Trust 
Mean
National 
median
Quality 
limit
Lower 
limit
Upper 
limit
Month of 
transplant
Date of 
transplant
Patient 1 10 12 12 21 14 28 Jan-18 01-Jan-18
Patient 2 12 12 12 21 14 28 Jan-18 02-Jan-18
Patient 3 14 12 12 21 14 28 Jan-18 03-Jan-18
Autograft recovery
Days to ANC>0.5 Quality limit lower limit
Trust MeanNational Medianupper limit
0
5
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Fig. 6.2 Sample of data presentation [2]
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Over time a comprehensive tracking system can be established (see Fig. 6.3).
To collect data, consider the following:
 1. Title: ensure this is appropriate and repeatable.
 2. Timeline: decide on appropriate timeline, given issue being measured, and num-
ber of patients/potential occurrences – weekly, monthly, quarterly, annually?
 3. Patients: be clear to identify which patient groups/subgroups you are including 
in the data collection.
 4. Information Source: Specific form extracted from medical records and labora-
tory. Describe personnel and sections of the programme responsible for 
this form.
 5. Measurement: Equipment and analysis used; reporting and recording of 
the data.
Table 6.3 New KPIs [2]
CAR-T metrics TRIAL
ID
FN
Molecular CR % SN
TRM[NRM] % Day 0
DoD
Dsch
Alive at [days] 30
90
365
Remission status at [days] 30
90
365
CD19+ or CD19- If relapse
LOS [days] Post-CART day 0
Date of 1st relapse after day 0
Time from day 0 To first relapse
Incidence of CRS / grade
Incidence of Neurotoxicity/grade
CAR-T cell Persistence
PICU admission Y/N
Grade 3–4 cytopaenias >d30 (Duration/ongoing; not lymphopaenias)
Grade 3–4 infections up to 60 days (duration/ongoing)
B-cell aplasia (Duration/ongoing)
Need for lg replacement from 90 days (Duration/ongoing)
Molecular CR at d30 <70%
TRM >10%
Notes
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 6. Formula: if appropriate, ensure consistent formula is used, e.g. number of 
patients with ANC ≥0.5 × 109/L achieved and sustained for three consecutive 
days without subsequent decline for ≥3 days.
 7. Definitions: ensure any definitions are clearly specified, so there cannot be dif-
ferent interpretations.
 8. Adjustment: make any appropriate adjustments as required, e.g. primary dis-
ease,  stage at transplant, type of transplant, type of donor or period of transplant.
 9. Assessment Criteria: There may be several standards to achieve. Minimum 
acceptable, optimal, or best attainable result.
 10. Related Processes: If measurement results indicate poor outcome, consider 
what problems in the process might have made them happen. Was the process 
done correctly, were there adequate staff in place, did everyone have training?
 11. References Used: EBMT MED-A/B forms, patient registry, national/interna-
tional standards, etc.
 12. Presentation: Report presented and oral presentation at appropriate review 
meeting.
 13. Observations: What were the findings that came out of the analysis and what 
does research suggest might happen to make the results appear as they have – 
e.g. co-morbidities, age or ethnicity implications
Holistic outcome analysis can also be completed; these tend to be more subjec-
tive and completed via questionnaires or interview. Ideally these should have a 
Autograft recovery
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Fig. 6.3 Long-term trending review engraftment [2]
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process for scoring to facilitate analysis, for example using a scale of 1–10 for pain 
and satisfaction with ward facilities.
• Quality of life post-transplant
• Late effects (fertility, etc.)
• Satisfaction with care
Staff-based outcome analysis can be completed by establishing a suitable inter-
nal level of completion and then assessing the following:
• Quality of information in case notes, paper or electronic, and the effect on day- 
to- day care structure
• Annual training, education and competency assessment for all staff groups
• Induction of new staff and their understanding of and participation in the quality 
programme
• Use of drugs and therapeutics against protocols
 Establishing Outcome Analysis for Novel Applications
As each new development comes into implementation in the clinical environment, a 
new set of outcome analysis needs to be developed. One of the more recent of these 
is CAR-T/IEC. In development with the manufacturer, a new set of KPIs was devel-
oped (Table 6.3) and is being monitored as part of ‘business as usual’. Once suffi-
cient data has been gathered, the most indicative KPIs can then be used and the 
remainder used for audit purposes.
 Reviewing Data
Outcome reviews should be completed with a wide range of staff and at regular 
intervals. It is a JACIE standard B/C/D 4.17 (seventh Standards) that the programme 
director, or designee, shall review and report to staff quality management activities, 
at a minimum, quarterly (Table 6.4). This presents a local snapshot of activity.
The director shall annually review the effectiveness (outcomes) of the quality 
management program. An annual report is required by JACIE – so combine the two.
Whilst these are useful, it is critical to look at long-term trending when reviewing 
outcome data. A failure to do this can result in critical trends not being spotted.
This clearly shows outliers that can be investigated.
It could be ‘assumed’ from Fig.  6.4 that treatments should not take place in 
February as two out of 3 years show high pre 100-day mortality. However, a greater 
depth of investigation is required to determine the causes of this.
As with all reviews, a thorough investigation should take place of any outliers.
Reviews can take the form of [1]:
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• Details of the processes you are trying to improve
• Details of the areas where these processes take place, i.e. clinical unit, collection 
facility and processing
• Details of the numbers of staff involved in the processes and who is responsible 
for which part of the process
• Details of any documentation in place to support the current process, i.e. policies 
and standard operating procedures
Pre 100 Day Mortality by Month of transplant
14
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11
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7
6
5
4
3
2
1
0
Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov
Alive
Pre 100 Day Death
Post 100 Day Death
2017 2018 2019
Fig. 6.4 Long-term review mortality [2]
Table 6.4 Sample of quality summary report [2]
BMT and cell therapy lab QM meetings held Oct, Nov, Dec
100-day mortality: Patients reviewed 16
Outliers discussed 2
Engraftment data review: Outliers discussed No outliers
Central venous catheter infection: Line days
Rate per 100 line days YTD (Apl 2017 – Mar 2018)
872
1.2
Documents clinical: Reviewed and reissued
Updated
New
9
24
9
Documents laboratory: Reviewed and reissued
Updated
New
19
4
0
Audits performed: Clinical
Laboratory
3
1
Audits presented: 3
Apheresis: Patients
% target collections reached
10
90
Leucopheresis: Patients
% target collections reached
4
100
CAR T therapy patients reviewed
Outliers discussed
2
0
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• The actions required to improve the process, e.g.:
 – Simple action – development of patient guide and other information as sug-
gested from patient survey
 – More complex – such as revalidation of stem cell machine or discussion with 
supplier re-ongoing breakdown problems
 – Testing of machine against several components
 – Changes to donor clearance forms at registry totally in your control
• Details of who is responsible for the actions
• Dates when actions should be completed
• Details of expected outcomes
• Review of actions and outcomes
• Record it
• Review it
• Record review
• Act on it
• Record actions
References
 1. Donot P, et al. Quality management guide. 2nd edition, 2013, p. 104–113.
 2. Figures and tables modified from standard reporting documents for BMT and Cell Therapy Lab 
QM Meetings held at Great Ormond Street Hospital for Children NHS Foundation Trust.
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Chapter 7
Personnel Requirements Including Job 
Descriptions
Songul Tepebasi and Ilknur Kozanoglu
 Introductıon
Workforce is central to safe and effective delivery of cellular therapy. Staff organisa-
tion and collaboration are essential for successful outcomes [1]. It is important to 
define the roles of key personnel and their support personnel, thus ensuring that 
tasks are uninterrupted. The number of personnel should be determined in accor-
dance with demand, as well as the nature of the respective centre’s activity. Cellular 
therapies are unique, in that they require many personnel with varying qualifications 
and competencies to work as a team. For these therapy centres to achieve their 
goals, employees must work together harmoniously; this requires communication 
and collaboration among employees [2].
To establish mutual understanding and cooperation between components of 
hematopoietic stem cell transplantation (HSCT) programs, it is imperative to estab-
lish a centralised and active communication network. Motivation is another factor 
that ensures effective and efficient employees. Training, organisation, management, 
and development of personnel should all be prioritised within the quality manage-
ment plan, alongside regulations that ensure the occupational safety and health of 
workers for all processes [2–5].
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 Organisational Structure and Organisational Chart
The organisational structure is a coordination system that enables individuals to 
realise their goals by combining their respective efforts, knowledge and abilities 
through collaborating with others, as well as through development and execution of 
a structure considered most suitable to achieve a specific goal. While developing the 
organisational structure in cellular therapy centres, the hierarchy, collaboration and 
communication of all units both within and outside the centre must be easily under-
stood [3–5].
The organisational chart should define, maintain and work with the optimal num-
ber of staff in the quality management system. Each level in the chart should con-
sider the tasks, capabilities, responsibilities, and communication networks shaped 
within the framework of business processes and corporate systems. The scheme 
should reflect quality management, along with clearly defining the roles, authority, 
responsibilities and duties of all employees [3–5].
In centres that provide cellular therapy services, organisational charts should 
never be made for individuals; they should be developed for units as a whole. This 
includes the organisational structure of all units involved, such as clinical units, 
cell processing, peripheral blood or bone marrow collection units, other disci-
plines (e.g., consultants), supporting units (e.g., medical/nutritionist) and admin-
istrative units (e.g., transportation unit and housekeeping), alongside all units 
with a service level agreement. Organisational charts should be developed in 
accordance with targets, systems and processes; staff should be chosen for posi-
tions within the chart, based on their qualifications, competencies and training. 
This is necessary, as the performance of a centre is directly influenced by its 
organisational structure [3–5].
The quality management system should be able to accommodate fluctuations in 
personnel and cover planned and unplanned unavailability to maintain operations 
on a day-to-day basis, e.g. illness, annual leave and departures [1–5]. Succession 
planning for key position should also be considered, e.g. quality manager (1). 
Education, quality and motivation of personnel are the most important factors for 
ensuring well-organised human resources and quality awareness within cellular 
therapy centres.
 Key Personnel
All personnel involved in the planning, management and control of critical activi-
ties, both directly and indirectly, in the field of cellular therapies should be defined 
as key personnel. For example, these personnel would include individuals perform-
ing stem cell collection, processing and freezing procedures. This definition will 
determine in advance when and what individual cellular therapy centres can pro-
vide, along with the personnel available within the centres.
S. Tepebasi and I. Kozanoglu
55
It is necessary to ensure that personnel designated and appointed conform to the 
requirements and qualifications of the job to be undertaken. In addition, the experi-
ence and abilities of individuals should be considered during the selection; those 
selected should be trained in accordance with their duties. Designated key personnel 
should remain unchanged wherever possible; supervisors of key personnel should 
be trained to an equivalent standard, such that where key personnel are not avail-
able, those supervisors may step into the role as necessary [3–6].
 Personnel Competency
Haematopoietic cellular therapies have complex and dynamic treatment pathways. 
All employees working in the field of cellular therapy should therefore be develop-
ing and improving skills and knowledge through continuous training [6]. As such, 
competencies of employees should be measured and recorded regularly within the 
quality management plan (Standards B3, C3, CM3, D3) [5]. The ability of employ-
ees to work effectively provides an indicator of the quality of training, its relevance 
to the requirements of employees in their respective roles and whether the system is 
working correctly with expected results. Various methods can be used to measure 
the adequacy of employees for a given role. A table completed through measure-
ment or observation can be used; electrical monitoring systems can also be used 
(Table 7.1).
 Responsibility and Task Awareness
Once recruited, personnel are given powers and responsibilities required to perform 
in their given roles. Individuals must know and understand their role, to whom and 
to what extent they have authority, and to what extent they can give instructions to 
others who rely on them. To achieve this, job descriptions should include relevant 
duties, necessary qualifications, responsibilities and authority.
 Use of Effective Communication
Cellular therapy centres function as a multidisciplinary unit with other components 
within the same hospital and/or program, as well as with other centres both inside 
and outside of the country. To achieve this objective, interaction, cooperation 
between units and a common language are proven elements for success in the field. 
It is vital for all personnel involved in the process to possess good communication 
skills and be able to use communication resources effectively. Communication 
meetings with all personnel and key personnel involved in the processes should be 
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scheduled regularly. These multi-unit meetings should be recorded and presented 
within annual reports [3–5].
All personnel should undergo annual appraisal of performance and other key 
aspects of their work and relationships with others in the team, with appropriate 
action taken in order to promote team work and good practice and maximise quality 
for product safety and, ultimately, patient and donor benefit [7–8].
 Job Descriptions
The roles of personnel included in the organisational chart of cellular therapy cen-
tres must be clearly defined in advance. Processes within cellular therapy centres are 
complex; as such, any errors that may occur must be minimised. Accordingly, 
European Union Directive 2006/86/EC states that all personnel working in the field 
Table 7.1 Sample personnel performance form
Example of personnel competency evaluation form
Evaluated employee:
Name and surname:
Unit of work:
Start date of work:
Evaluator (director/supervisor)
Name and surname:
Signature:
Date:
Score:
1 Adherence to both written and verbal communication standards of the 
institution (including compliance with working hours and dress code)
2 Knowledge, adoption and implementation of institution’s quality 
policy and objectives
3 Identification of business priorities, including effective use of time 
and resources
4 Communication and collaboration with superiors and other team 
members
5 Adherence to patient, donor, product and occupational safety rules
6 Collaboration with others in tasks requiring teamwork, providing 
support and meeting deadlines
7 Possession of effective communication skills; protection of 
confidentiality for patient donors and medical records
8 Willingness to undergo further training and self-development
9 Attention to detail; timely recognition and resolution of problems
10 Comprehension of working role; ability to perform appropriately; 
leadership potential
Total score (all questions scaled from 1 to 10):
0–20: Very unsuccessful; 21–30: unsuccessful; 31–60: moderately successful; 61–80: 
successful; 81–100: very successful
Employee strengths:
Employee weaknesses:
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of cellular therapies should have clear, documented and up-to-date job descriptions; 
moreover, their duties and responsibilities should be clearly documented and under-
standable [9].
International standards also require that current job descriptions be documented 
within the audits and that employees have received training for their respective job 
descriptions [5]. If employees have been given responsibility for a critical proce-
dure, they must possess sufficient competencies to fulfil this responsibility. In addi-
tion, the level of authority should not be less than or greater than that required for 
the responsibility; the task designation of the employee should be sufficiently 
detailed in the job description. This should detail the positions of employees within 
the organisational chart [3–5].
Job descriptions must be written, understandable, and clear. When employees 
read their job descriptions, they should not have to guess or interpret meanings 
beyond those which are written. Job descriptions should be concise, define the cur-
rent position and possess a dynamic structure. They should not restrict the employ-
ees in their tasks, but should allow the employees’ experience to inform the work 
that each member performs. While creating a job definition, it is necessary to deter-
mine the nature of the proposed task and who will write the task description. The 
author should be competent and knowledgeable regarding the task and how it will 
function. When the definition of the task is initially formed, ideas should be col-
lected from employees by means of interview or survey. It may also be useful to 
examine job descriptions created for similar positions in other institutions [10].
When a job definition is created, it should be properly documented. All job 
descriptions should be reviewed and approved by the relevant centre or unit director. 
The director should convey the final definition of the task to the relevant personnel; 
the relevant personnel should then be trained accordingly. The personnel must be 
confirmed to fully understand the content of the job description. An examination, 
observation or similar method can be used for this confirmation [10].
The structure of the job description may vary among centres; however, all job 
descriptions within an organisation should have a standardised appearance [10].
The following topics should be included:
• Job title – name of the position.
• Salary grade/level/range  – compensation levels, groups or pay ranges, into 
which jobs of the same or similar worth are placed, including minimum and 
maximum pay bands.
• Reports to – title of the position this job reports to.
• Date – date when the job description was written or last reviewed.
• Summary/objective – summary and overall objectives of the job.
• Essential functions – essential functions, including how an individual is to per-
form them and the frequency with which the tasks are performed; the tasks must 
be part of the job function and be required to perform the job.
• Competency – knowledge, skills and abilities.
• Supervisory responsibilities – direct reports, if any, and the level of supervision.
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• Work environment – the work environment; temperature, noise level, inside or 
outside, or other factors that will affect the person’s working conditions while 
performing the job.
• Physical demands – the physical demands of the job, including bending, sitting, 
lifting and driving.
• Position type and expected hours of work – full time or part time, typical work 
hours and shifts, days of week and whether overtime is expected.
• Required education and experience – required education and experience based 
on job-related requirements and consistent with the requirements of the centre.
• Preferred education and experience – preferred education and experience based 
on job-related requirements and consistent with requirements of the centre.
• Additional eligibility qualifications – additional requirements such as certifica-
tions, cellular therapy–specific experience and experience working with specific 
items of equipment.
• Other duties –.
Signature lines Signatures are important in validating the job description. They 
indicate that the job description has been approved and that the employee under-
stands the requirements, essential functions and duties of the position. Signatures 
should include those of the supervisor and of the employee [10].
 Personnel File
Personnel files should be created for uninterrupted monitoring of all key personnel 
in the quality management system. When no longer required, these files should be 
archived in a secure area for the period specified in the quality plan. Personnel files 
are confidential and should therefore be kept with controlled access. These files 
include personal education information, training participation and personnel quali-
fication evaluations. Related documents should be included; when the employee 
leaves the unit, their file should be retained [3–5].
 Conclusion
An important responsibility of directors working in cellular therapy centres is to 
understand and define the roles and responsibilities of employees so that their objec-
tives are best met. This enables directors to better distribute workload to personnel 
appropriately, whilst maintaining safety and efficiency. The collection of personnel 
or staff satisfaction surveys at regular intervals is recommended. The results should 
be evaluated at the quality committee meetings or similar groups with the goal of 
optimising ongoing processes and operations as well as workforce well-being.
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A continuously improving quality management system incorporating the correct 
personnel with clear roles, responsibilities, training, competency and working rela-
tionships will ensure that processes are effective and efficient and maintain safety 
and quality for the programme. Processes are numerous and diverse; personnel 
should have continuous development of skills and qualifications, and key personnel 
should continuously contribute to the training, competency and personal develop-
ment of new and existing personnel. Continuity and robustness of operations should 
be supported by cross-cover arrangements and succession planning. All of these 
aspects are covered by FACT-JACIE standards and the accreditation process, which 
should be used as an opportunity to review personnel and their functions, and, where 
necessary, identify deficiencies or weaknesses, undertake corrective actions or high-
light issues to the accreditation organisation and external inspectors during the 
accreditation process.
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Chapter 8
Third-Party Agreements
Anne Emmett
 Gentlemen’s Agreement
In the past, many issues were resolved following discussion and a handshake 
between two parties (Fig. 8.1). Nothing was written down and progress depended on 
continued verbal agreement. In some cases, the reason for the original agreement is 
lost and things just ‘carry on’. This is NOT acceptable within JACIE, nor any pro-
fessional environment.
 Memoranda of Understanding (MoU) [1]
This is a more formal written arrangement between two, or more, parties. It may 
take the format of a completed form with basic information, or may just be a formal 
letter, but would be signed by both parties.
A MoU (Table 8.1) can be the first step in establishing a process or partnership. 
However, MoUs are not legally binding and so cannot be deemed to be a suitable 
process for maintaining services between parties. They do indicate a degree of seri-
ousness and mutual respect. They imply that a formal written contract, agreement – 
either technical or third party – or a service-level agreement is to follow.
A MoU can be assessed as a ‘first step’ towards a formal agreement. It can be 
terminated without legal consequence in most circumstances.
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Fig. 8.1 Gentleman’s 
Agreement
Table 8.1 Outline of MoU
Name of contracting organisation: Address:
Designated contact person:
Name of third party: Address:
Designated contact person:
Activity/activities MoU covers:
E.g.
    • Procurement
    • Testing
    • Processing
    • Distribution
    • Export
    • Supplies goods or services that affect quality or safety
Reference to protocols and SOPs to be followed to meet the required performance specification 
(attach copies)
Where applicable, reference to control measures or audits to be carried out by the contracting 
organisation and which the third party agrees to support (e.g. on-site audit at specified intervals 
and audit of reports to be provided by third party)
Reference to reporting requirements of the third party to the contracting organisation
Reference to systems for managing adverse events and incidents
Date on which the agreement will be reviewed:
Details of the person with responsibility to review the agreement:
Signed: Contracting organisation Date:
Signed: Third party: Date:
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 Contract/Commercial Agreement (Fig. 8.2)
A contract is the main document governing the deal between you and another organ-
isation. It is the written formal agreement between the two parties. It stipulates each 
party’s legal responsibilities, obligations, governance, contract length, financial 
details and liabilities within the agreement. It will include the commercial agree-
ments and does not go into the purely technical aspects of the manufacturing, sup-
ply or outsourcing of the product or process (Table 8.2). Where possible, sections 
should not be reproduced in multiple documents, as this can lead to contradictions 
and conflicts. Where appropriate, cross references to relevant sections in different 
documents should be made.
As such, it is typically drafted by the legal, financial and management teams of 
the contractual parties.
 Service-Level Agreements (SLAs)
An SLA focuses on measuring performance and quality, as agreed between you and 
another organisation. The SLA should not determine governance arrangements, 
financial arrangements, contract lengths, etc. (see Contract section), though these 
are often incorrectly included in SLAs, making the SLA very long and 
overcomplicated.
Creating an SLA as well as a contract allows you to revise the SLA without 
changing the contract. Though the contract may be for 5 years, the SLA may be 
reviewed and amended as frequently as required and at least every 2 years for JACIE.
The SLA (Table 8.3) should include a description of the services to be provided 
and their expected service levels, metrics or key performance indicators (KPIs) by 
which the services are measured, the duties and responsibilities of each party, the 
remedies or penalties for breach, process for disagreements and a protocol for add-
ing and removing metrics.
Fig. 8.2 Contract
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Table 8.2 Typical contract 
contents
1. Definitions and interpretation
2. Contract period
3. Services
4. Service amendments
5. Contract price
6. Charges and terms of payment
7. Warranties and representations
8. Intellectual property
9. Liability
10. Quality and safety standards
11. Freedom of information
12. Confidentiality
13. Data protection act
14. Information security
15. Force majeure
16. Assignment
17. Contracts (rights of third parties)
18. Complaints
19. Authorised officers
20. Health and safety
21. Publicity
22. Prohibited acts
23. The prevention of fraud
24. Notices
25. Satutory invalidity and severability
26. Audit requirements
27. Law and jurisdiction
Schedule 1 Authorised officers
Schedule 2 Charging structure
Schedule 3 Prices
Table 8.3 Typical SLA 
contents
1. Definitions and interpretation
2. Named contacts and responsibilities
3. Services being provided and key 
performance indicators
4. Service amendments and variations, 
including metrics
5. Quality and safety standards
6. Termination
7. Consequences of termination
8. Dispute resolution
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 Technical Agreement
A technical agreement (Fig. 8.3) (also known as a quality agreement) is a written 
contract that is required whenever you outsource an activity covered by quality 
guidelines – often good manufacturing practice (GMP) guidelines for pharmaceuti-
cal products, but equally JACIE, HTA, FACT and other national and international 
quality standards. It sets out the quality management responsibilities of each of the 
parties, both quality control and quality assurance (Table 8.4).
Even though there is an outsourcing of a process, the organisation contracting the 
process is still accountable for outcomes and is therefore responsible for the activi-
ties of the contracted organization. Make sure there is involvement in change con-
trol, including assurance that any appropriate validation and qualification are carried 
out and documented; that there is involvement in any major or critical investiga-
tions, and in any other critical issues that require both parties’ input; and ensure that 
the level of involvement is detailed in the Technical Agreement. The contracting 
organisation needs to also define how often there will be audits, or audits requested, 
and if it is intended to send in an independent auditor; this too needs to be specified.
Fig. 8.3 Technical 
agreement
Table 8.4 Typical technical 
agreement
1. Definitions and interpretation
2. Named contacts and responsibilities
3. Services being provided
4. Service amendments
5. Accessing service(s)
6. Quality and safety standards 
responsibilities
7. Policies, procedures and documentation 
responsibilities
8. Information security responsibilities
9. Health and safety responsibilities
10. Incident and risks responsibilities
11. Audit requirements and responsibilities
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The technical agreement spells out the technical specifications and responsibili-
ties of the parties required for the technical or outsourcing activities and processes. 
It is to ensure compliance with various QC (quality control) and QA (quality assur-
ance) requirements of the technical process or the outsourcing [2].
It is typically drafted by the technical teams in each organization. It is not usually 
necessary to get legal advice on a technical agreement because a lawyer will not 
usually be able to advise on the actual details of a technical agreement.
 Third-Party Agreement
Third-party contracts are agreements that involve a person who is not a party to the 
contract but is involved with the transaction. This could, for example, be that an 
organisation is contracted to carry out viral analysis in which case the organisation 
will then contract the staff to do the work. The staff completing the viral analysis 
have not directly signed the contract but are involved with the transaction. This can 
get very confusing within the clinical environment if the staff doing the work also 
have honorary, or permanent, contracts with the contracting organisation.
 Quick Checklist [2]
The contract should always refer to the technical agreement for technical matters 
related to quality control and assurance. As such, the technical agreement should 
not contain “legal” or “commercial” terminology.
No duplication of provisions should relate to the same subject matter, so that one 
document simply refers to the relevant provisions in the other document, i.e. instead 
of repeating or restating the same thing. This is to avoid accidental conflicts or 
contradictions.
There should be consistency in nomenclature, definitions, and duration such as 
the same name of the parties in both documents, the same process, the same defini-
tions for terminology and expressions, and the same duration of each agreement.
There should be no “legal” or “commercial” terms in the technical agreement. 
The job of the technical agreement is to set out technical parameters. It is not 
intended to set out the commercial relationship between the parties that should go 
into the contract instead.
That means that the contract is the right place to cover things like patient confi-
dentiality terms, warranties, indemnities, liability limitations, pricing, schedul-
ing, etc.
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 Communication Is Critical [3] (Fig. 8.4)
Define:
• Who
• When
• What
• Where
• Why
Make sure that the contacts are clear to both parties and that their communication 
channels are open.
Ensure there are nominated single points of contact in each organisation for key 
matters, plus ‘local’ contacts as required, e.g. HTA lead, quality manager, service 
manager, accounts. Ensure that, where necessary, there are secure email connec-
tions, or use encryption for any emails containing personal or patient data. Ensure 
this is made clear in all joint documents.
Try to avoid ‘scatter gun’ communications between the organisations when set-
ting up the agreement and then running the process as this can lead to either key 
communications being lost or email overload. When necessary, have face-to-face 
meetings, even if this is by video conference.
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Chapter 9
Performance Measurement
Amal Alseraihy, Waleed Rasheed, and Mahmoud Aljurf
Accountability and performance are vital pillars in healthcare organizations as both 
are key factors on the platform of global initiatives in healthcare and monitored 
through the management of performance measurements. In the context of rising 
healthcare expenditure, performance measurement (PM) is becoming increasingly 
integral to accountability. Healthcare accountability mechanisms have traditionally 
included business planning, annual reporting, and contracting. In recent years, a 
richer sense of accountability has emphasized the achievement of goals effectively 
and efficiently and has stimulated the growth of PM. PM has been described as “the 
use of statistical evidence to determine progress towards specific defined organiza-
tional objectives” (State of California 2003) [1]. The literature includes reports on 
performance measurement initiatives across the healthcare spectrum from primary 
through tertiary health care and public health and the voluntary sector, many driven 
by the backend as a reactive response to demands from governments, consumers, 
other payers, proponents of evidence-based practice, and accreditation organiza-
tions [2]. Substantial resources, by various organizations, have been invested in PM 
system development from policy level to front-line care delivery.
Performance measurement (PM) in its simplest form is the “measurement of 
performance”: the regular and continuous assessment of whether the current pro-
cesses or practices in place are accomplishing the goals and objectives created, 
implemented, and monitored to sustain the organization, company, or program” [3]. 
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Utilizing well defined measures will promote a culture of continuous growth and 
development, both clinically and operationally. Such necessity for PMs is the same 
for a stem cell transplant program – to ascertain and continuously monitor processes 
that function within the program from financial to operational to clinical aspects. 
PM is the process and performance measures are the drivers used to establish the 
level of success or need for improvement (Fig. 9.1).
SCT is a highly specialized and cost-driving service, operating at multiple levels 
of structures and processes, according to each program’s capacity and complexity of 
treated cases. Whether the focus of the program is to achieve excellence or to build 
a quality system or to comply with national or international accreditation, perfor-
mance improvement and management can be challenging for the decision makers 
without objective customized performance measures for such complex medical 
care. The first part of this chapter will provide the reader with a comprehensive 
review of performance measurement definitions, development, and working frame-
work. The second part will focus on performance measurement in SCT program.
 Definitions for Healthcare Performance Measurement
Performance measurement In general terms, it can be defined as the regular mea-
surement of outcomes and results, which generate reliable data on the effectiveness 
and efficiency of various aspects of an organization that keep it afloat.
Input Resources (human resources, employee time, funding) used to conduct 
activities and provide services.
Activity Individual tasks funded by projects or programs.
Output Products and services delivered. Output information does not tell you any-
thing about the actual results achieved or the consequences of the products and 
services delivered. Output information is important to show the scope or size of 
what the inputs and activities produce.
Outcome An outcome represents a specific result a program is intended to achieve. 
An outcome can also be defined as the specific objective of a specific program or 
Performance
Measures
Performance
Measurement
Fig. 9.1 Performance 
measures versus perfor-
mance measurement
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service. An outcome is not what the program produced itself (the output), but the 
consequences of those products, services, or assistance. It is important to distin-
guish between end outcomes (objectives), on one hand, and intermediate outcomes 
(intermediate results), on the other.
End outcomes (objectives) This is the highest-level objective toward which a pro-
gram works. The end outcome is what the program is designed to ultimately achieve: 
which should be the most “ambitious” outcome or result program managers can 
materially affect or influence and for which they are willing to be held responsible.
Intermediate outcomes (intermediate results) An intermediate outcome or inter-
mediate result is a critical outcome or result that must occur in order to reach the 
higher-level, end outcome/objective. As the PM process advances, it is important to 
understand the necessity to obtain and act on the intermediate outcome or result 
before achieving the end outcome/objective.
Indicators An indicator is an instrument that helps you measure change over time. 
It is important to remember that end outcomes and higher-level objectives require 
higher-level indicators. Intermediate outcomes/results require lower-level indica-
tors. Indicators can be quantitative, or qualitative, or a hybrid of the two.
Performance indicator or key performance indicator (KPI) A quantifiable 
measure used to evaluate the success of an organization, employee, etc., in meeting 
objectives for performance.
 Measure Development Life Cycle
Figure 9.2 illustrates the five phases in measure development life cycle. Although 
the life cycle shows each phase as a discrete activity, the measure life cycle is 
dynamic. Some phases may overlap or take place concurrently or result in feedback 
with earlier phases [4].
Conceptualization Develop measure concepts and then narrow down to specific 
measures. The developer conducts an environmental scan and requests input from a 
broad group of stakeholders, including patients.
Specification Identify the population, the recommended practice, the expected 
outcome, and determine how it will be measured.
Testing Assess the suitability of the quality measure’s technical specifications and 
acquire empirical evidence to help assess the strengths and weaknesses of a measure.
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Implementation Identify measures to submit for selection and rollout processes.
Use, continuing evaluation, and maintenance Ensure that the measure continues 
to add value to quality reporting measurement programs and that its construction 
continues to be sound.
The Centers for Medicare & Medicaid Services (CMS) uses the following deci-
sion criteria throughout the measure development cycle to ensure that a measure 
meets the applicable standards before moving to the next phase:
Importance to measure and report including analysis of opportunities for 
improvement such as reducing variability in comparison groups or disparities in 
healthcare related to race, ethnicity, age, or other classifications.
Scientific acceptability including analysis of reliability, validity, and exclusion 
appropriateness.
Feasibility including evaluation of reported costs or perceived burden, frequency 
of missing data, and description of data availability.
Usability including planned analyses to demonstrate that the measure is meaning-
ful and useful to the target.
Measure Lifecycle
Measure
Conceptualization
Measure
Specification
Measure
Testing
Measure
Implementation
Measure Use,
Continuing Evaluation,
and Maintenance
Feasibility Evaluation
Generate a list of
concepts to be
developed
Draft measure
sepcifications and
conduct initial
feasibility testing
Develop and execute
comprehensive
measure
testing plan
Assess how
measure performs
in the field and
conduct measure
maintenance
Support measure
rollout, including,
Federal rulemaking,
business process
definition,
NQF endorsement,
education and
Month 1 Month 5 Month 12 Month 21 Month 27
Fig. 9.2 Example for performance measure life cycle; https://www.cms.gov/Medicare/Quality
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 Measure Development Process
 Bringing It All Together
As previously stated, in this chapter, performance measurements for stem cell trans-
plant programs operate, as they do, in general with all standard healthcare organiza-
tions, ensuring that all indicators and measures directly link to the organizations’ 
strategic objectives, mission, and vision statement – utilizing key performance indi-
cators and the approach of Donabedian’s three domain quality framework of struc-
ture, process, and outcome measures [5]. Such is the case when conceptualizing the 
framework to construct, pilot, implement, and monitor stem cell transplant perfor-
mance measures, ensuring that the critical key performance indicators that are 
essential to your operational strategic plan and also drive your measures.
Before one can create and implement measures or indicators, you should deter-
mine who your key stakeholders and process owners are as this is as important in 
determining your measures/indicators. These are those individuals who will work to 
bring to fruition your desired outcomes after you perform your intense education 
sessions with them and to provide the knowledge and training needed to meet the 
target set for your measures or indicators.
To begin with each measure or indicator is intentionally chosen through the pro-
cess of conducting an RCA (Research, Compare, & Act), which begins with a rigor-
ous internal research to determine specific programmatic needs, performing external 
literature reviews to determine best practice, and applying your finding in research 
to compare your current state with the desired state (Fig. 9.3).
STRUCTURE
PROCESS
OUTCOME
Research to
determine your
need (internal).
Perform literature
reviews
(external).
Enusure evidence-
based.
Compare current state
and desired state.
Design the
measure/KPI
(qualitative/
quantitative).
Determine data
source, collection
frequency.
Create a standardized
data collection tool.
Perform sample data
collection to test and
validate your tool.
Once your tool is valid
to use begin your
formal data collection.
Analyse your data and
Act.
Compare current with
desired state & set
targets.
Develop and schedule
your roll out plan.
Disseminate to
stakeholders/ process
owners.
Educate, train and
shape culture.
Continuosly monitor
to sustain or improve.
Research Compare Act
Fig. 9.3 SCT performance measurement RCA framework
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Once you have accomplished your research, compared your findings, deter-
mined what you need, your team is now ready to agree on the design of the 
selected qualitative and/or quantitative measure/indicator, determine your data 
source and collection frequency, create and validate a standardized data collection 
tool and perform a sample collection to test your tool. If the data tool collects 
what you designed and desired, perform a real data collection session. If not, go 
back to the drawing board, assess your tool, determine the cause, and make the 
revisions, as needed. You will not be able to move forward until your data collec-
tion tool is considered valid and confirmed as effective to collect the data it was 
designed to collect. Once you have collected your data, you are now you ready to 
Act: bring the outcome of your arduous work to action by performing an analysis 
on your data. Once your data has been analyzed and your targets set based on your 
current and desired state, you are now ready to develop your roll-out plan and 
schedule your action. First, disseminate your findings to your stakeholders and 
process owners to get them ready for your upcoming education and training ses-
sions. A well-informed team is a well-equipped team and ready to assist you to 
shape the culture for success. It is now time to perform your educational sessions 
indicating your findings, beginning with the RCA, propose the plan to move for-
ward and ensure to involve your team in continuous monitoring by setting cham-
pions in each area. If you have obtained your goal you will need to sustain the 
gain. If improvement is needed, use your well-informed team champion to per-
form continuous monitoring, education, and training until desired outcome is 
achieved.
As you now have set your data collection schedule, you will need to adhere to 
this to ensure continued success. Create dashboards or scorecards (Tables 9.3 and 
9.4) to maintain intentional active continuous monitoring, allowing you to promptly 
act to any measure or indicator that may fall beyond the set target.
 Performance Score
In most cases, at its basic level, a performance measure is a ratio. The denomi-
nator represents the number of eligible cases, less any exclusions or exceptions, 
and the numerator represents the number of instances the clinical action of 
interest was performed. It is helpful to note that the denominator is often 
derived from, and sometimes equal to, an initial population; this initial popula-
tion is the broadest grouping (e.g., all patients age 14+ with transplanted speci-
fied diagnosis). The initial population can be reduced to a denominator (e.g., all 
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initial population patients that underwent transplant) and then to a denominator 
with exclusions and exceptions removed. Figure 9.4 below visually depicts the 
anatomy of a performance measure from an arithmetic perspective.
 Goals for Measure Development in SCT Program
A critical aim of any stem cell transplant center or program is to ensure that such 
measures are directly aligned with the mission and vision statement of the health-
care organization in which it dwells. In addition, safeguarding the process within 
performance measurement affords one the ability to assess the current state, bench-
mark with competitors, ensure continuous assessment for improvement opportuni-
ties, ensure accrediting governing body’s continuous readiness, and monitor growth 
and development: internal assessment for an external cause corporately and pub-
licly. Some challenges with PM in SCT can be the substantial variations in SCT 
center characteristics; centers have different care models to optimize the use of 
available resources, identifying external benchmarks and utility of comparative 
external benchmarks. However, the primary purpose of quality measurement is to 
identify opportunities to measure and thus improve patient care and other program- 
related outcomes. Table  9.1 summarizes some guiding principles for measure 
development.
Quality measure development remains a focus for quality assurance and value 
staff to continually meet the evolving needs of its members, help its members meet 
national and international accreditation requirements, and to provide members with 
information that informs clinical decision–making.
Performance
Measure Score
Numerator
Denominator - Exclusions/Exceptions
Provider quality score, usually
expressed as a percent. The clinical action
The eligible population; coharts in this
population share some basic characteristic(s).
Patients removed
from the
denominator prior to
numerator
evaluation.
Patients removed from the
denominator after the
numerator has been 
evaluated as “no”.
Fig. 9.4 Anatomy of a performance measure
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 SCT Program Performance Measure
There are several types of performance measures, but structural, process, and out-
come performance measures are the most practical and objective that can be imple-
mented in SCT across its three dimensions: clinical, collection, and processing. 
Table 9.2 outlines some of these performance measures, their definitions, and exam-
ples for their indicators in SCT program.
Structural measure Structure of care is a feature of a healthcare organization or 
clinician related to the capacity to provide high-quality healthcare. Structure mea-
sures are supported by evidence that an association exists between the measure and 
one of the other quality domains.
Process measure A process of care is a healthcare-related activity performed for, 
on behalf of, or by a patient. Process measures are supported by evidence that the 
clinical process, which is the focus of the measure, has led to improved outcomes. 
These measures are calculated using patients eligible for a service in the denomina-
tor and the patients who either do or do not receive the service in the numerator.
Table 9.1 Criteria for performance measures selection [2]
Criterion Description
Evidence based Defines measures that are valid and reliable with operational definitions that 
have already been proven through rigorous research
Strategic The measure directs attention toward the ultimate change desired
Important The measure addresses an important or serious health or health services 
problem (usually defined as health burden or cost) such that there will be 
sufficient impact from collection and service improvement initiatives
Attributable Causal links between the measure, service improvements, and health 
outcomes are known
Actionable Defines a measure that addresses a service area that can benefit from an 
improvement
Feasible Data collection, reporting, and follow-through are cost-effective (potential 
benefits outweigh costs) and there is reasonable technical capacity for 
collection and analysis, including risk adjustment of compared measures
Relevant and 
meaningful
The measure is relevant to most stakeholders, including policy-makers, 
managers, clinicians, and the public
Understandable The measure is understandable to a non-technical audience (often just a 
communication issue)
Balanced The set of measures is balanced across types of treatments, treatment 
settings, major health problems, age groups, special populations, and levels 
of the healthcare system. The set is balanced across short- and long-term 
measures, and balance and appropriateness are considered across process- 
and outcome-type measures
Responsive The measure is sensitive to change over time
Robustness Potential adverse effects of the measure can be mitigated, and vulnerability 
to gaming is minimal
Non-ambiguous The measure is clear in terms of which direction for service change is 
desirable
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Outcome measure An outcome of care is a health state of a patient resulting from 
healthcare. Outcome measures are supported by evidence that the measure has been 
used to detect the impact of one or more clinical interventions. Measures in this 
domain are attributable to antecedent healthcare and should include provisions for 
risk adjustment. The outcome of performance measurement processes should result 
in improved value. Value in the part of health care domains:
Improved patient care
Outcomes (lifestyle and survival)
Improved staff satisfaction
Processes and practices
Improved efficiency
Improved throughput, capacity, and quality of care and decreased cost
Improved competitive edge
Increased marketability and benchmarking
Improved resource utilization
Lowering cost (care and product services)
Table 9.2 Example of performance measures and indicators in SCT
Types of 
measures Clinical indicator Collection indicator Processing indicator
Structural Number of SCT- certified 
physician
Number of SCT- certified nurses
Number of oncology certified 
nurses
Patient volume
Number of publications
Bed capacity
Average length of stay
Supplies and equipment
Access to HCT program
Number of trained 
stem cell collection 
apheresis staff
Number of allogeneic 
products
Number of autologous 
products
Number of trained cell 
processing staff
Number of publications
Process Number of discharges by noon
Number of stem cell infusion 
cancellations
Staff satisfaction
Number of medication errors
HCT clinic wait time
Complications 
during collection 
procedure
Quality of collected 
product (CD34 
quantitation)
SC processing 
turnaround time
Number of acceptable 
HPC viability cells 
post-cryopreservation
Number of available SC 
processing reagents
Outcome Readmission rate
1-Year survival rate
Day 100 mortality
Engraftment outcome
Wrong surgery time
Surgical site infections
Graft failure outcome
Patient satisfaction
Number of HCT patient ED 
visits
Percentage of 
microbial 
contaminations
Number of donor/
patient who are 
eligible for 
apheresis
Percentage of microbial 
contaminations
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 Performance Measurement and KPI
In its simplest form, a key performance indicator (KPI) is a type of performance 
measurement (PM); these are the critical (key) indicators of progress toward an 
intended result. KPIs provide a focus for strategic and operational improvement, 
create an analytical basis for decision-making, and help focus attention on what 
matters most.
Goals of an organization should set the focus of your quality, productivity, and 
financial metrics. The term “metric” means the same as a KPI to some, but to others, 
it means a collection of related measures that when placed together become a met-
ric. Some have used metrics and KPIs for staffing needs, position justifications, 
quality assurance, revenue cycle, and strategic planning in various hematopoietic 
cellular therapy (HCT) programs. Various challenges discovered in implementing a 
PM within HCT programs are due to the substantial variation in the characteristics 
of HCT centers that have different care models to optimize the use of available 
resources, identifying external benchmarks, and the usefulness of comparative 
external benchmarks.
Table 9.3 Sample of annual operational dashboard
KPI FY FY FY FY
Volume (productivity)
Number of transplants
New patient visits
Return patient visits
Admissions
Discharges
Nurse: patient ratio
Quality
Number of adverse occurrence
Medication error
Number of patients admitted to intensive care
100-Day mortality
Readmission 7 days post-discharge
Financial ($)
Revenue per patient
Labor cost per patient
RVU per SCT consultant
Patient satisfaction (%)
Physician
Nurse
Case manager
Clinic wait time
Number of patient’ complaint
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 The Value of Dashboards for Metrics or KPI
Provide a user-friendly, visual summary of operational and clinical information.
• Utilized to track data, improve operational and clinical performance, promote 
transparency, and improve accountability.
• Manage a center’s performance by using key metrics, quality assurance, process 
improvement, clinical outcomes, financial growth strategies, and strategic plan-
ning outcomes.
KPIs can result in great limitations when used without setting in place opera-
tional effectiveness goals; however, goals should drive what you are measuring but 
measures should not drive goals. The question is: what are HCT centers or programs 
trying to assess and analyze? Here are some examples for initiative and strate-
gic goals:
• Evaluate resource utilization.
• Reduce volume variability.
• Use existing capacity more effectively.
• Address staff stress and workflow inefficiencies.
• Measure operational function that has an impact on quality.
• Contrast staffing model with other departments or programs.
 Dashboard Basics for Quality (Table 9.4)
• Determine key objectives or areas for display.
• Develop key performance indicators/measures for areas related to structure, pro-
cess, and outcomes selecting best practice benchmarks externally and/or 
internally.
• Develop your scorecard (Table 9.5), monitor/audit, and over time.
• Use quality management principles to identify areas that require more attention 
whether exceeding or falling below your set benchmark.
Table 9.4 Sample of scorecard metrics
Indicator Benchmark
Engraftment ANC ≥95% of HCT by day +28
Time to engraftment autologous 100% 10–12 days
Time to ANC engraftment – allogeneic- matched related 
(MRD)
100% 14–16 days
Time to ANC engraftment – MUD 100% 14–28 days
Treatment-related mortality Benchmark
100-Day mortality – autologous <5% day
Day 100 allogeneic – MRD <10% day
9 Performance Measurement
80
• Focus on high-risk high-volume indicators.
• Use quality management principles of process mapping and step analysis to 
develop an improvement plan or document acceptable outcome.
 Challenges HCT Programs Can Embrace
• Developing quality management programs that use a variety of key performance 
indicators based on regulatory and accreditation requirements and program needs
• Developing internal quality reporting data systems
• Developing international collaboration to identify core measures for transplant 
programs to capitalize on the opportunity for external benchmarking
 Examples of Quality KPI for Clinical SCT Program 
(Table 9.5)
• Total transplant volumes by type and cell type
• Other cellular therapy – DLI, HPC, volume, and outcomes
• Length of stay by transplant type
• Readmissions within 30 days of discharge
• Bone marrow collections – volume, product cell counts, and recipient outcomes
• Mortality rate at the +30 day, +100 day, and 1 year mark
• Treatment related (non-relapse mortality)
Table 9.5 Sample of template for SCT quality KPI
KPI description 
(title)
Percentage of patients with successful engraftment
Domain Patient centered
Sub-domain Clinical outcome
Definition Percentage of patients with successful engraftment
Calculation Numerator: Number of patients in whom engraftment was successful 
(success defined as neutrophil count >0.5*109 L for three consecutive days 
by day plus 28)
Denominator: Total number of patients transplanted in the first 6 months 
of the previous 7-month reporting period
Reporting 
frequency
Quarterly
Unit measure Percentage
International 
comparison [6]
Specialized services quality dashboards – blood and infection metric 
definitions for 2019/20
Desired direction Higher is better
Data source According to SCT center
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• Engraftment by type of HCT and sourced of stem cells, ANC and platelet count, 
median time to engraftment
• Patient satisfaction (e.g. Press-Ganey-Transplant Survey), case management dis-
charge survey, and donor follow-up reports
• Critical event/quality reviews such as adverse events, intensive care admissions, 
and data audits
• Transfusion medicine service indicators such as collection, processing, 
medication administration, infusion, mobilization, and positive micro-
bial reports
• Known complications – GVHD, ECP for GVHD, and infectious disease markers
• Chemotherapy – verification procedure audits
• Donor and recipient screening and informed consent
• Support service reports and focus compliance audits
 KPI Administrative Focus Areas
• Staffing
• Patient volume
• Capacity planning
• Strategic planning
• Acuity versus procedure-based metrics
• Length of stay
• Mortality
• Readmissions
• Cost and resource utilization
• Managed care/payer reimbursement
• Analysis by type of transplant
• Analyze by disease type
 Conclusion
Performance measurement offers policy-makers in SCT program a major oppor-
tunity for improvement and accountability. Securing improved performance 
measurement often requires active leadership and it should aim to improve the 
quality of decisions made by all actors within the program. It is important to 
emphasize that the presentation of performance measurement data and how this 
influences its interpretation by patients, providers, and the public require more 
attention, as public reporting has many benefits but can lead to adverse out-
comes; mechanisms should be put in place to monitor and counteract these 
adverse outcomes.
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Chapter 10
Tracking and Traceability
Lex Van der Gouw
 Introduction
In the global field of cellular therapy, including stem cell transplantation, traceabil-
ity of the cellular product is of essential importance to be able to ensure the patient’s 
safety [1]. During the process of donation, transportation, processing and infusion, 
storage, or disposal, it is critical that the product can be traced from donor to patient 
and vice versa. Also, in case of any adverse event, such as poor or non-engraftment 
or infection, traceability is paramount.
Unambiguous identification of a cellular product can only be achieved through 
unique donation identifiers and uniform, standardized product description. Stem 
cell products are regularly transported across national borders, thus creating the 
need for international agreement on product descriptions and unique donation 
identification.
Another key element in traceability and identification of cellular products is the 
transfer of product information. To further enhance safety, accuracy and efficiency, 
increasing numbers of facilities use electronic systems. Transfer of information 
between such systems also requires international standardisation of electronic dona-
tion and product information.
In compliance with the JACIE standards, standardisation and encoding of cellu-
lar product descriptions shall be performed according to the ISBT 128 standard 
terminology or the EuroCode standard.
In this chapter, the basic principles and means to standardisation of product 
information will be discussed, using the ISBT128 standard as an example. However, 
these basic principles also apply to the EuroCode standard [2].
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 Information Environment
Several elements are necessary to create an environment in which information is 
standardized and transferable between facilities on a global level [1]. Together these 
elements form the information environment (Fig. 10.1).
The base element is terminology. Without a common international understanding 
of product descriptions, further attempts to standardisation are useless.
Standardisation in terminology is required to be able to make a distinction 
between variations in the following product characteristics:
 1. Cell type and source, for instance the haematopoietic stem cell, can be derived 
from blood (apheresis), bone marrow or umbilical cord blood
 2. Core attributes, such as storage temperature or the type of anticoagulant used
 3. Additional modifications, meaning any manipulation that changes the ‘core’ 
state of the product
Product descriptions vary between facilities, nationally as well as internationally. 
Variations may relate to, for example, storage temperature, the amount of DMSO 
used in cryopreservation or additional additives after processing. Standardisation in 
terminology needs a high level of detail to provide the means to make a distinction 
between different products or track alternations to a product. Once an international 
consensus in terminology is achieved, this information can be used to generate a 
product description, based on the three characteristics as mentioned above.
This information should be managed with great care and be accessible to users 
around the world.
So, with a consensuson terminology, the next layers in the information environ-
ment are the reference tables in which this information is stored. With the provided 
accessibility, facilities around the world are now able to define their products. By 
combining this standardized information, a unique description of the product is 
achieved, which can subsequently be uniquely encoded.
Example 1
An autologous apheresis product which is frozen in 10% DMSO solution, with no 
other additives:
Labeling
Delivery Mechanisms
Reference Tables
Data Structures
Standardized Terminology
Fig. 10.1 Information 
environment [1]
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Source: HPC, apheresis from a mobilized patient
Core conditions:
  Anticoagulant: Citrate
  Storage temperature: ≤ −150 °C
Manipulation: Adding cryoprotectant 10% DMSO
Together this would generate the unique product description:
• HPC, APHERESIS|Citrate/XX/<=−150C|10% DMSO|Cryopreserved|Mobilized
Example 2
An allogeneic bone marrow product enriched for mononuclear cells (MNC) with 
added human serum albumin
Source: HPC, marrow from a non-mobilized donor
Core conditions:
  Anticoagulant: None, removed during processing
  Storage temperature: Refrigerated
Manipulation: MNC enriched
Together this would form the unique product description:
• HPC, MARROW|None/XX/refg|3rd Party Comp:Yes|Mononuclear cell enriched
With the unique product description in place, now one must be able to transfer this 
information electronically. To achieve this, the product description needs to be con-
verted into a unique, electronically readable, product code and a delivery mechanism 
is needed, the next two layers in the information environment. Product codes provide 
the structure and context to be able to decode them to meaningful information. They 
also provide the link to the reference table so that each product code can be traced to 
the corresponding product description. Next to the product description, the product 
code must encode whether or not the product has been divided into separate containers 
(e.g. a cryopreserved autologous product). Only then, each separate product bag can be 
traced regarding storage and infusion.
The most commonly used delivery mechanism to transfer information electronically 
is the linear barcode. As the information that a linear barcode can contain is limited, 
delivery mechanisms with a higher capacity are also available such as 2D (data matrix) 
codes. A single data matrix code can hold the same amount of information as several 
linear barcodes, as shown in Fig. 10.2. The use of a data matrix code is therefore more 
efficient, especially on smaller labels, and will contribute to a safer and more reliable 
transfer of electronic information. By using a universal delivery mechanism, such as a 
barcode, information can now be exchanged between different electronic systems on a 
global scale.
In the last layer, all previous elements come together to generate a label that 
contains all the information, eye-readable and electronic, necessary to identify the 
product and to be able to process that information to maintain traceability. 
Standardizing the label format and layout such that critical information is placed at 
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Donation ID Number
ABO/RhD
Product Code
Expiration Date/Time
Collection Date/Time
Data Matrix Code 128Fig. 10.2 Comparative 
size of information stored 
in linear barcode and a data 
matrix symbol [1]
1 2
3
4 5
AB
RhD POSITIVE
8600
0170222359
FOR AUTOLOGOUS USE ONLY
22 JAN 2027
22 JAN 2017
AUTOLOGOUSS1143100 0270222359
Expiration
Date/Time:
Collection
Date/Time:
A9996 17 876543 00 3
Collection Center or Registry
Address
Anywhere, USA 00700
Do Not Irradiate
Do Not Use Leukoreduction Filters
HPC, APHERESIS
Store at -150 C or colder
Donor/Recipient:
SMITH, MARTHA P
Recipient ID: 123456789
Date of Birth: 14 JUL 1998
Processing Laboratory
2nd Line of Address
Elsewhere, USA 00500
1 Donation Identification Number
2 ABO/RhD
3 Collection Date/Time
4 Product Code
5 Expiration Date/Time
10% DMSO
Cryopreserved
Mobilized
Total Volume       mL containing approx
         mL Citrate
Fig. 10.3 Standardized ISBT128 label format  [3]
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fixed positions, as shown in Fig. 10.3, greatly reduces the risk of errors in the inter-
pretation and (electronic) transfer of information.
 Donation Identification
Product coding alone, however important, is not sufficient in the unique identifica-
tion of a cellular product. Without the ability to uniquely trace the donation of a 
cellular product to the original donor, product coding is meaningless.
Unique identification of a donor is hampered by the sheer number of volunteer donors 
as well as different donor identification strategies used by international centres [4]. To 
further enhance safety and reliability in donor identification, the WMDA (World Marrow 
Donor Association) has developed a global donor identifier (GRID). The GRID com-
prises identifying information about the facility issuing the GRID and a donor identifier.
Next to unique donor identification, the donation itself also needs a unique, uni-
form identification.
Similar to the GRID, the donation information contains a donation sequence num-
ber and identifying information about the facility that issued the donation number, 
e.g. a collection facility or registry. In the ISBT 128 coding standard, the year in 
which the donation took place is also embedded in the donor identification number.
 Combining Donation and Product Information
In April 2017, legislation became effective to apply the Single European Code 
(SEC) on tissue and cell products in compliance with Directive 2004/23/EC of the 
European Parliament. The purpose of the SEC is that donation and product informa-
tion are represented in a consistent, combined manner, further aiding the traceability 
of such products. Basically, the first part of the SEC contains the donation informa-
tion (facility, sequence number) preceded by a country identifier. The second half 
contains the product information including a split number and the expiry date. 
Where the donation identification sequence will not change, the product informa-
tion sequence changes when the core state of the product is altered.
If necessary, products imported from outside the EU for distribution within the 
EU will be assigned a donation and product sequence assigned by the importing 
tissue establishment in order to be able to create an SEC. Records of the original 
donation and product information and the newly assigned SEC should be main-
tained in order to link this information for traceability purposes.
In summary, the key elements to the effective, safe, and reliable traceability of 
cellular products are as follows:
 – Unique global donor identification
 – Unique donation identification
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 – Global standardisation of product description
 – Data structures to enable digital transfer of information
 – Uniform product labelling
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Chapter 11
Adverse Events and Corrective 
and Preventive Actions
Phuong Huynh and Renza Monteleone
A very important part of the quality programme is the development of a robust sys-
tem for reporting, investigating, and resolving errors, accidents, adverse events, bio-
logical product deviations, and complaints. Reporting and reviewing adverse events 
(AE) should not be about “blaming” individuals but about assessing if the process 
which may be at fault can be improved. All personnel should be encouraged to 
report anything which affects transplant safety [1].
Centres often used a hospital-based incident reporting system, but it may not be 
adequate to meet the needs of the HSCT programme. Often, not all AEs were 
reviewed by the programme director and/or a report was issued to the patient’s phy-
sician. Other significant problems included those related to donor selection and test-
ing, labelling and process control [2]. The HSCT programme should have a system 
in place which allows the team to follow the management of any occurrences, to 
propose preventive actions to avoid the occurrences that will happen in the future 
and to assess the efficacy of those actions.
Prevention of errors is one of the most important aspects of safety in transplanta-
tion. Analysis of potential risk factors associated with the entire range of procedures 
should be part of the overall transplant programme development. Every procedure 
should be analysed and potential risk factors identified BEFORE they are imple-
mented. Documentation is important to support the investigation of errors, accidents 
and adverse events, biological product deviations and complaints because these 
investigations are frequently retrospective [1]. Fundamentally, one should know 
where errors occur in the processes, why they occur and how to manage them, e.g. 
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does quality system include a near-miss reporting system (prevention of errors) and 
a corrective actions system when incidents have happened?
 Definitions of What to Report
• Adverse Events/Serious Adverse Events (SAE): any untoward occurrence 
associated with the procurement, testing, processing, storage, distribution 
and application of tissues and cells which might lead to transmission of com-
municable disease, death or life-threatening, disabling or incapacitating con-
ditions for patients or which might result in or prolong hospitalisation or 
morbidity1
• Near Miss: an event which, if not identified in time, would have led to an error, 
accident or adverse reaction or SAE.
• Biological Product Deviation (BPD) [3]: any event associated with the manufac-
turing of a cellular therapy product, including testing, processing, packing, label-
ling, or storage, or with the holding for distribution, of a licensed biological 
product, if that event meets the following criteria:
• Either represents a deviation from current good manufacturing practice (or cur-
rent good tissue practices), applicable regulations, applicable standards or estab-
lished specifications that may affect the safety, purity or potency of that product
• Or represents an unexpected or unforeseeable event that may affect the safety, 
purity or potency of that product:
• Occurs in your facility or another facility under contract with you
• Involves a distributed biological product
• Complaints: many institutions have an institution-wide complaints policy in 
place and the transplant facility will be expected to follow institutional require-
ments. If there is not a policy in place, then one should be developed and imple-
mented. See Example 5 SOP Adverse.
 Investigation, Analysis
While there is no set timeline for investigation, review, and analysis, this should be 
undertaken quickly so that a potential repeat of the issue is avoided. This aspect 
should be included in internal specific SOP.
Investigation and analysis in some centres are done through formal review of the 
entire process to identify where the error has occurred. Collection and processing 
facilities will have quality incident reporting mechanisms in place and these are 
shared with the clinical programme where an incident occurred across the linked 
process, e.g. transportation of the product from collection/processing facility to 
clinical facility: all parties receive the quality incident report analysis and close the 
incident. The investigation itself might involve looking at all documentation, 
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training record, having discussions with staff involved and observing the process as 
it happens.
The forms and reports can be categorised by type, e.g. procedure (e.g. cell rein-
fusion) and equipment used and then evaluated. This evaluation can be done by 
specific groups or as part of one of the regular meetings, e.g. quality group. The 
more frequent events should be prioritised and then resolved (Table 11.1); this can 
be done by amending policies and procedures, implementing revised worksheets or 
retraining staff. By doing this, the quality programme is continuously being 
improved.
 Corrective, Preventive Action
Action taken to eliminate the root causes of an existing discrepancy or other 
undesirable situation to prevent recurrence. As an example, weekly meeting to 
review with relevant director, quality manager, chief nurse and/or medical 
Table 11.1 List of examples templates provided for this section
Number Title
1. Types of incident reported
2. Form to report deviations and near-misses
3. Registration form for recording complaints, adverse events and near misses
4. Example of an allogeneic day case inpatient pro forma
5. SOP adverse event and near-miss reporting
NOTE: This is not a exhaustive list
Example 1 Types of incident reported
Category Details
Medication errors
ABO incompatible blood products
Malfunction/misuse of equipment
Contaminated drugs, devices or products provided by facilities
Labelling of products
Samples missing or delivered to wrong laboratory
Results not provided in adequate time
Signing of drug charts
Verification of cytotoxic drugs
Bag damage during thawing of cellular product
Deviations from policy or procedure if unplanned
Severe reaction during infusion of cellular product
Transport issues
Product found to have positive microbial culture
Failed engraftment
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director and area where incidents occurred. Some centre quality group meetings 
have errors, accidents and adverse events as part of the standing agenda; group 
members should include all related facilities. Some centres have separate risk 
management groups.
The investigation and reporting system is a means of quickly recording near- 
misses as they occur (Table 11.2). All staff are responsible for completing the forms 
which ask three simple questions  – what happened, what immediate action was 
taken and what might be done to prevent recurrence of the problem. Each near-miss 
is categorised, e.g. products, sampling, transport, labelling, infusion, nursing, medi-
cal, drugs, pharmacy, result processing. Every day, reports are collected and on a 
weekly basis, the relevant director, quality manager, head nurse and pharmacy or 
EXAMPLE TEMPLATE 2
FORM TO REPORT DEVIATIONS AND NEAR MISSES
LESSONS FOR IMPROVED CARE SYSTEM
Clinical Area: Category:
Time: Date:
Was there a Deviation from any Policy and/or Standard Operating Procedure : YES/NO 
What is the Title of the Policy and/or Standard Operating Procedure Deviated from :
_________________________________________________________
Job/Role of person completing form:   _____________________________________
What Happened?
What Immediate Action Was Taken?
What Could Be Changed to Prevent Reoccurrence?
Complete on reverse of form or separate sheet if necessary
Was any other type of Incident Form Completed?
Reference No.
Table 11.2 Example form to report deviations and near-misses; adverse events; occurrences
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other services as required review the documents and discuss corrective actions. 
Sometimes, thorough investigation is needed and this will involve observations, 
interviews and complete review of the procedures linked to the near-miss which 
took place. The results and outcomes are reported back to all departments within the 
programme and monthly “Trend” reports are written to establish whether improve-
ments have been made and are working. Whatever corrective action is taken, e.g. 
amending an SOP or re-training staff, must be documented, and assessed whether it 
has achieved the desired impact.
 Biological Product Deviations (BPD)
The most common BPDs encountered by clinical programmes involve products 
with positive microbial cultures or products from ineligible donors. Such products 
are only used by clinical programmes when evaluation shows that the benefits out-
weigh the risk to patient if no alternative is available.
In some cases, the relevant information is not known until after the infusion has 
occurred. Centres are responsible for deciding on whether they will use these prod-
ucts and, if so, under what circumstances. There must be a detailed plan and proce-
dures in place which describe the following:
• Whether a product with positive microbial culture can be used
• In what circumstances its use would be permitted
• How the recipient is protected
• How full record about all aspects of the process is filed
For methods for investigation and review where the BPD was unknown until 
AFTER the cellular product was infused, centres can also follow the processes above.
Investigation and analysis in some centres are done by reviewing the entire pro-
cedure to identify where the contamination might have come from. Collection and 
processing facilities have quality incident reporting mechanisms in place and these 
are shared with the clinical programme where an incident occurred across the 
linked process. All parties receive the quality incident report and meet to analyse 
and close the incident – the investigation itself might involve looking at all docu-
mentation, training records, having discussions with staff involved and observing 
the process as it happens.
Methods for investigation and review where the BPD was known BEFORE cel-
lular product was infused followed the systems described above. As an example, 
we present a case whereby a product from an unrelated donor was potentially 
contaminated due to infection of the donor with a tropical disease. The collection 
centre advised the transplant centre only on the morning of the collection. In the 
meantime, at the transplant centre, the recipient was fully conditioned using full 
intensity conditioning regimens. The reasons behind the potential contamination 
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were fully investigated and revised processes put into place at the collection facil-
ity following close liaison with the clinical facility. The centre had no alternative 
but to use the product as no other donor was available in time. The centre quickly 
liaised with specialists at their own centre and external specialists in tropical dis-
eases, and several different samples were sent to different laboratories and results 
returned within hours prior to cell infusion. All steps were taken to safeguard the 
recipient (prophylaxis), and the recipient was informed prior to, during and after 
infusion. Records of the entire process were documented and filed in patient case 
notes, incident reports, deviations and near-miss reporting with corrective actions 
clearly shown.
The centre where the BPD occurred BEFORE infusion should investigate the 
process of collection and infusion with relevant staff and report to medical director 
of corresponding service, and BPD incidents and reports should be audited regu-
larly. Some centres have separate risk management groups working with all related 
facilities to develop procedures on how products are managed and reported in 
accordance with applicable regulations. Policies are in place which cover criteria 
for release, labelling, notification of recipient, investigation of cause, disposal and 
timely notification of transplant physician and other related facilities involved. 
Procedures are in place for dealing with BPD if unknown until infusion has occurred 
as per JACIE standards [4].
Example 3
Registration form for reporting complaints errors and adverse events
Date reported:
………………………………
Quality manager:
………………………………
Employee
………………………………
Number
………………………………
Informant
Name:
Department/address:
Postcode/place:
Phone number:
Nature of complaint or adverse 
event
Corrective actions
Suggestions
Program director:
Incident closed:  Date:
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Example 4
EXAMPLE TEMPLATE FROM AN ALLOGENEIC INPATIENT DAILY REPORTING PRO-FORMA (PART 
OF)
SHOWING HOW DEVIATIONS MIGHT BE DOCUMENTED
ALLOGENEIC TRANSPLANT DAILY PRO-FORMA 
TO BE COMPLETED IN FULL BY PHYSICIAN ATTENDING AT ALL TIMES OF REVIEW
PATIENT DETAILS
TODAY’S Date :___________________ Days Post-Transplant : _________________
WEIGHT : _______Kg Performance Status :  ____________________
[Good-ECOG 0-1; Poor - ECOG 2-3]  
COMPLETE ON DAY 0 ONLY
Source of Stem Cells : *Bone Marrow / Peripheral Blood / Cord Blood / Other
Ex-Vivo Manipulation : *Yes/No ___________ If “Yes”: *Negative/Positive Selection
Cells actually infused:                        TNC = ×
108/Kg CD34 = × 106⁄Kg 
Adverse Events/Reaction to Infusion of Cells: *Yes/No
If “Yes”, has an IR1 been completed: *Yes/No
Conditioning Regimen Used
Timetable in Notes                                YES NO
***Was there a Deviation from Planned Timetable YES NO ****
If Yes, please give details
_________________________________________________________________________
____________________
WBC x 109/L :- NC x 109/L :- Hb g/dl :- Platelets x 109/L :- 
G-CSF Yes No Date Started:
Platelets Needed 
Today
Yes No
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Example Template 5
ADVERSE EVENT AND NEAR-MISS REPORTING PROCEDURE HEADINGS
STEM CELL TRANSPLANT PROGRAMME
STANDARD OPERATING PROCEDURE
TITLE: ADVERSE INCIDENT AND  NEAR-MISS REPORTING 
Code Issue No: No. Of
Pages:
Copy
No: 
Replaces: Revision :
INDICATIONS FOR PRACTICE
AUTHORISED PERSONNEL/TRAINING REQUIRED (Who is responsible for Reporting
and what level of training is required)
PROCEDURE FOLLOWING INCIDENT/NEAR MISS:
What Actions MUST be taken and how is safety assured following an Incident or Near Miss?
WHEN PRINTED
This SOP is for single use only. Please destroy following use.
Effective
Date:
Review Date: Obsolete 
Date:
STEM CELL TRANSPLANT PROGRAMME
STANDARD OPERATING PROCEDURE  
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Chapter 12
Process Indicators
Olga López-Villar
 Introduction, Definitions, and Example
The organization of work by processes is a strategy well established in quality in 
recent times. It may seem challenging to implement this in the medical field. 
However, working in a process-based organization will help us establish the quality 
system since each process has different personnel, different procedures, different 
risks, controls, indicators, etc. And the interaction between those processes or sub-
processes also requires particular detail.
To start with, clarification of some terms is needed because they may look simi-
lar [1, 2]:
• Process: A goal-directed, interrelated series of actions, events, or steps.
• Process control: The standardization of processes in order to produce predict-
able output.
• Processing: All aspects of manipulation, cryopreservation, packing, and labeling 
of cellular therapy products.
• Product: The easiest way to define it would be “the cells.”
• Standard operating procedure (SOP): A document that describes in detail the 
process or chronological steps taken to accomplish a specific task. It is also 
referred to as working instructions. An SOP is more specific than a policy.
• Policy: A document that defines the scope of an organization, explains how the 
goals of the organization will be achieved, and/or services as means by which 
authority can be delegated.
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• Quality: Conformance of a product or process with pre-established specifications 
or standards.
• Quality control: A component of a quality management program that includes 
the activities and controls used to determine the accuracy and reliability of the 
establishment’s personnel, equipment, reagents, and operations in the manufac-
turing of cellular therapy products, including testing and product release.
• Indicators, also referred to as key indicators or quality indicators: An indicator is 
a measurement done at a critical point that has to be within a defined range. If 
not, an action should be taken.
• Example of a process: The process of “baking bread” is simple and quite visual 
and can serve as an example (Fig. 12.1).
The process has to be validated before opening the bakery (tested to have a cer-
tain result), the equipment has to be controlled, there may be a recipet (SOP), etc.
In the process, there shall be controls to assure that the bread is almost the same 
every time: weight of ingredients, temperature of the oven, etc.
An indicator may be established, depending on the requirements of the clients, 
the controls of the product, the previous occurrences of the bakery, etc. For exam-
ple, more than 95% of breads that are sold at a certain price have to weigh ≥500 g [4].
 Process Definitions
The transplant process is extremely complicated. It can be treated as a single pro-
cess with different sub-processes if all the steps are performed in a single institution, 
or as different processes with a close relationship in case of different entities in the 
same or in different institutions.
For illustrative purposes, the transplant process has been simplified (Fig. 12.2).
When a transplant program is starting in the quality and accreditation process (it 
is also a process) they have to work on many aspects, among them the process 
Baking bread
Described in a general policy and /
or in one or more concreteSOPsStarting
Flour
Yeast
Water
Salt
Personnel
-Professional baker
-Cook
End
Bread
Waste
Equipment and materials
Oven
Fig. 12.1 Example of a process
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definitions. They have to be based on the structure of the program, of the organiza-
tion that hosts the program, responsible staff, etc.
Although it is not mandatory, the division in to at least clinical, collection, and 
processing processes can be a start. Those procedures shall have a clear interaction, 
whether being performed in the same or different institutions.
In the annual review, the indicators of the processes and other issues are included. 
A change to the processes may also be required within time and has to be carefully 
analyzed (risk assessment), planned, and implemented, to be further analyzed again.
 Process Controls
The process controls are described in detail in the current edition of FACT-JACIE 
standards [1, 2].
Transplant
Pre-transplant
process
Personnel
Doctors
Nurses
Personnel
Doctors
Nurses
Personnel
Doctors
Technicians Hood and clean room
Equipment and materials
Equipment and materials
Equipment and materials
Transplant unit
Infusion pumps
End
Patient
follow-up
Donor
follow-up
Waste
Transplanted
patient
End
Collection
Processing
Starting
Donor
Collection
order
Starting
Product
Processing/
infusion
order
Apheresis device
Polices and/ or manySOPs
Polices and/ or manySOPs
Waste
Product
Donor after
collection
End
Waste Cryoprese
rvation or
aliquoted
product
Processed
Product
Clinical
Starting
Patient that
requires a
transplant
Polices and/ or manySOPs
Fig. 12.2 Summary of processes in a transplant program
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CM8 – Marrow collection process controls include procedures, inventory, equip-
ment, blood components, written order for collection, peripheral blood count to 
proceed, suitability prior to collection, anesthesia, mobilization, quality of the prod-
uct, aseptic technique, pediatric donors, packing, filtration, and records.
C8 – Apheresis collection process controls include the ones seen for marrow col-
lection (except for the different requirements for the filtration of bone marrow), plus 
some specific controls regarding central lines.
D8 – Processing process controls include manufacture of the product, written 
request, specific information for allogeneic donors, validated processing proce-
dures, identification of critical control points, aseptic technique, microbial contami-
nation, records, review of processing record, end points not met, more-than-minimal 
manipulation, blood group and antibody screen, cord blood, and sample storage.
Clinical program controls: Through all the chapter of clinical standards, a num-
ber of controls are indicated: control of airborne microbial contamination, document 
control, and outcome analysis (see Chap. 6). In fact, among the principal controls for 
the clinical unit are the ones described in the outcome analysis chapter and also 
performance measurements (see Chap. 9) and benchmarking.
A unit can require further controls, depending on the different procedures 
performed.
 Process Indicators
 Selection, Definition, and Range
How to choose an indicator?
As indicated in the definitions, an indicator is a measurement done in a critical 
point that has to be within a defined range. If not, an action should be taken. They 
are used to monitor the quality of the process [3, 4].
In a visual way, it is like a thermometer. If the measured value is above or below 
a certain level, there are no major issues, and one can continue working the same 
way. But if for instance the value is above that level, it is like having fever, which 
means that there is a problem that has to be studied and treated.
Indicators can be different among transplant programs. They have to be selected 
based on the risky points of the process and procedures, on the occurrences detected 
in the previous months or years, etc.
It is important to remember that if the indicator is not within the range, an action 
should be taken. For example, it is difficult to define the “number of transplants per 
year” as an indicator. It is a measure of the activity. An indicator requires an objec-
tive level. If you select as quality indicator “more than 100 transplants per year,” you 
have to think if there is any action to be performed if a year there are 90 transplants 
(probably not).
A way of starting would be taking into account the process controls that have 
been briefly reviewed before. Transplant programs do have data on those 
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parameters, some of them with associated occurrences or that have been shown in 
audits or in the risk assessment to be “difficult” or “critical.”
The parameters included in the outcome analysis are often used as indicators, for 
example, neutrophil above 500/μL at day X in ≥90% of transplants and/or graft 
failure in ≤5%. The accepted level or the accepted range has to be defined according 
to the center experience, the literature, etc. An individual delay in engraftment in a 
certain patient may be studied as an occurrence and a graft failure as an adverse 
event. But those are the studies on individual patients. But if those cases become 
more and more frequent in the transplant program, a detailed review of the system 
and a corrective action should be implemented. In these cases, the study should 
include not only clinical aspects (data of the patient, lines of chemotherapy, time to 
recover, conditioning, etc.) but also aspects of collection and processing, for exam-
ple, number of cells and potential issues affecting viability. After reviewing the 
potential causes, an action should be taken and analyzed at a later step.
Regarding indicators of collection, a typical example would be collections fin-
ished with the number of cells ≥X% or efficiency of collection above a certain level 
in a percentage of procedures. Regarding the procedure itself, depending on the 
program, other useful indicators would be percentage of side effects, etc.
In processing, the indicators are focused on the product: products with positive 
culture below a certain percentage, viability over a certain percentage, etc.
The definition of the indicator has to be clear: what are we going to measure and 
how [5]? The definition, the range, etc., have to be included in quality documents. 
The way to obtain details to do the measure can be by reviewing the patient’s clini-
cal data or the collection or processing procedures, etc.
 Persons Responsible for the Measure and Timing
Depending on the indicator and on the organization, indicators can be measured by 
a person directly related to the process (e.g., nurse of collection) or indirectly by the 
quality manager.
How often are indicators measured?
It depends on the point to measure and the urgency to take measures if the indica-
tor deviates. They can be monitored monthly, quarterly, or, in some particular indi-
cators, on a yearly basis.
 Indicator’s Table
After defining what and how to measure, by whom, and when, it can be useful to 
have a summary in a table (Table 12.1). This table would be filled with the results 
and the actions taken. And in a quick view, you can see the evolution of the measure 
within time.
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The table may be split in clinical, collection, and processing if those units are 
independent. But results have to be shared with the entire program.
 Actions
If the indicator falls above or below the target level, a corrective action shall be 
done. If an indicator is about to reach the level, a preventive action should be carried 
out in order to avoid reaching the dangerous level. For the development of correc-
tive and preventive actions, see Chap. 11.
The action can be registered in the indicators panel (Table 12.1) or in the forms 
for occurrences. The deviation in the indicator, study of the cause, actions, etc., have 
to be opened and reviewed as other occurrences of the unit. The effectiveness of the 
actions has to be reviewed and will be seen in the following measures of the 
indicator.
 Other Indicators
Besides the indicators seen, other key indicators may be required to monitor other 
aspects of the program. Indicators of the quality system itself may be required in 
other systems to review and keep under control particular points (e.g., corrective 
actions reviewed on time).
Table 12.1 Example of indicator’s table
T trimester
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When selecting the process indicators, take into account that they have to be use-
ful. It is not about having a long list, or indicators difficult to measure, but they have 
to be a practical tool to measure and improve the quality system.
 Indicators Within Time
Indicators are a dynamic tool. If one gets better and better results in the point of 
measurement, a more demanding objective can be set.
If occurrences start to happen in a certain part of the system, or if a new issue 
appears on the risk assessment, a new indicator can be opened to measure it more 
frequently and keep it under control.
In the same way, if a previously not-controlled issue gets to be fully compliant in 
each patient, year after year, having an indicator may not be as useful as before. It 
could be considered to be closed. If occurrences in that issue are seen again, it can 
be started again.
 Communication
The measure of the indicators is a fundamental part of the quality management sys-
tem. They have to be shared in the regular quality meetings.
They have to be included also in the annual review of the system [2]. To assess if 
an improvement is seen, a comparison with the indicators of the previous years is 
also advisable.
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Chapter 13
Writing a Quality Management Plan
Mara Magri
 Introduction
Quality management systems (QMS) are central to FACT-JACIE accreditation stan-
dards [1]. As the first edition of the JACIE standards has been published, every 
haematopoietic cell transplant (HCT) programme must decide on how to develop 
and implement its QM programme via a written quality management plan (QMP). 
The QMP should be “just right” for the type and size of an HCT programme. It 
should be a top-level overview of how the organization operates, aimed at imple-
menting quality improvement whilst being realistic and deliverable. The QM plan 
(QMP) is usually collected in a single document, often and interchangeably referred 
to as the ‘quality manual’, that outlines how the QMS is implemented and managed.
Although JACIE standards require that the HCT programme has a QMP/quality 
manual, the style and structure are not specified. There is considerable flexibility in 
how to prepare it, and an HCT programme can construct the QMP so that it is most 
useful and suited to the needs of the organization and ultimately patient care.
When writing a QMP, it is good practice to create a working group. The QMP 
needs to be tailored to the specific needs of the HCT programme, so each facility 
should carefully consider how to best involve those who are needed. Also, the devel-
opment of a comprehensive QMS is often the most challenging and time-consuming 
exercise that a clinical programme encounters when preparing for JACIE 
accreditation.
As HCT programs are almost always part of a broader healthcare organization, 
they can apply policies and procedures of the existing institutional QMS, for exam-
ple, ISO certified, or they can have a standalone QMS. An integrated HCT pro-
gramme may, but is not required to, have one QMP that addresses all aspects of the 
M. Magri (*) 
Hematology & BM Transplant Unit, ASST Papa Giovanni XXIII, Bergamo, Italy
e-mail: mmagri@asst-pg23.it
108
clinical, collection, and processing facilities. If managed across organizational 
boundaries, there must be clear evidence of relationships among the QM pro-
grammes, usually associated with service-level agreements (SLA) detailing roles 
and responsibilities.
A generic, too broad, or poorly written QMP may be an indication that the QMS 
is not deemed an integral and important component of the HCT programme.
The key points to remember about the QMP are as follows:
• There is only one official version.
• It should be a working document. It is never finished – it is always being improved.
• It should be read, understood, and accepted by everyone.
• It should be written in clear, easily understood language.
• It should be dated and signed by the leadership (HCT programme director or 
designee).
• It should describe the system as it is operated and not a description of an 
ideal world.
 QMP Structure
The QM plan must detail all key elements that affect the quality of recipient and 
donor care and cellular therapy products as described in the FACT-JACIE standards 
and manual. The specific SOPs to be followed for each of these elements does not 
have to be fully repeated in the QMP, but must be briefly summarized and refer-
enced within the QMP and linked to the appropriate document where the details are 
described. Quality is the responsibility of all personnel involved in the HCT 
programme.
Although there is considerable flexibility in how to prepare a QMP, the content 
and structure should address the elements listed below.
 – Organization – roles and responsibilities
 – Personnel – qualification, training, and competency
 – Document control
 – Outsourced activities management (contractual arrangements)
 – Quality control – key performance data and outcome analysis
 – Self-assessment and internal and external audit
 – Investigation and reporting of deviations, adverse events, reactions, and 
complaints
 – Traceability
 – Disaster and contingency planning
 – Qualification and validation
 – Quality risk management
 – Tools for continuous quality improvement
 – Operational environment
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 – Premises and infrastructures
 – Equipment and materials supply
If there are no organizational boundaries, it could follow the index of FACT- 
JACIE standards and manual, to be sure of having addressed all requested quality 
elements.
 HCT Programme Description
The QMP should begin with an introduction that contains an overview or descrip-
tion of HCT programme, its history, where it is located, how many beds/staff, basin 
of reference, type of procedures performed, i.e. autologous and/or allogeneic trans-
plantation, paediatric and/or adult setting, clinical unit only, collection only, etc. It 
gives basic but important information about the HCT programme organization, 
interaction and activities; it is helpful for users and new staff and shows how changes 
occur over time. In case of an integrated HCT programme, the collection/processing 
profile would also be documented under this heading even if they have their 
own QMP.
 Organizational Structure – Roles and Responsibilities
The QMP shall include or summarize and reference an organizational chart of key 
positions and functions within the HCT Programme, including clinical, collection 
and processing with a clear description of how key positions interact to implement 
the QMS in the HCT programme [2].
The overall organizational chart should include the titles of key positions and the 
reporting structure of the HCT programme. The chart should also outline the rela-
tionship among the different sections of the HCT programme (clinical, collection 
and processing at a minimum) even if supporting functions are performed by con-
tract with other facilities or organizations. Lines of responsibility must be clearly 
defined in a way that is understood by all involved. It would be useful, but not man-
datory, outlining the names of the key positions and verifying its applicability and 
correctness (Fig. 13.1).
Keeping clear and active communication within the HCT programme and 
between the HCT programme and any other departments and health care profes-
sionals is fundamental for the quality of processes performed.
PLEASE NOTE: The basis for all audits and assessments of the QMS, includ-
ing JACIE inspection, will be based on the contents of the QMP and the docu-
ments to which it refers.
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For example, JACIE standards require guidelines for communication with both 
the collection facility and the registry in the event of collection-related complica-
tions. Moreover, if responsibilities in donor selection, evaluation and management 
are shared, documented communication between teams is required.
It is clear then the HCT programme should address all these aspects in the QMP or 
in any other policy or procedure, detailing the methods of communication used such 
meetings, mails, reports and oral communication. The HCT programme should also 
describe when using one method instead of another. (i.e. written report for sharing of 
quality data among key individuals within participating facilities in the HCT programme).
 Key Personnel – Qualifications, Training, and Competency
The QMP should address policies and procedures (normally kept separate from the 
quality manual itself) summarizing personnel requirements for each key position in 
the HCT programme.
 These should include at least:  a job description, initial qualifications, new 
employee orientation, initial training, competency, and retraining when appropriate, 
continued competency assessed annually and continuing education.
All persons working in the HCT programme must have an accurate and clearly 
defined job description. Documentation of training for everyone must include all 
procedural skills routinely practiced. These requirements are detailed in FACT- 
JACIE standards and manual.
Organizational Chart of a Transplant Program “Colors”
Hematology unit Blood transfusion center
Clinical Trial Office
Transplant search CoordinatorProgram Quality Manager
BM Collection Facility Processing Laboratory Clinical Unit PB Collection facility
HPC donor evaluation Center
Transplant Center
Sibling Donor evaluation Center
Post-transplant follow-up & care
outpatient area
HPC Transplant Program
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Head Dr. White
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Director Dr. White
Dr. PurpleDr. Green
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Director Dr. Grey Director Dr. Red
Medical Director Dr. Blue
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Resp. Dr. Plum
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Head Nurse Mrs. Gold
Staff & Quality Manager
Head Dr. Red
Fig. 13.1 The organizational chart of the “Colours” HCT programme
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 Document Control
The QMP shall include or summarize and reference a system for document control 
with the identification of the types of documents that are considered critical for the 
HCT programme and with the description of how they are controlled (Fig. 13.2). A 
critical document refers to a document that is directly related to and could impact 
patient care or cellular therapy product integrity.
The hierarchy and number of documents or extent of documentation is depen-
dent on the processes, the size and the complexity of the HCT programme and will 
differ from one organization to another.
There are many different types of documents such as policies, SOPs, operative 
instructions, guidelines, protocols, providing description of activities and processes 
performed by the HCT programme. Other types of documents such as worksheets, 
checklists, records or forms are essential tools to provide quality control and evi-
dence of conformity to FACT-JACIE standards (provision of evidence that what was 
planned has actually been done).
If the HCT programme participates in an existing QM programme in its 
Institution, it can or has to use portions of the hospital’s QM programme, in 
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Programme)
Quality 
Manager
Quality 
Manager
Staff
Instruction I + Facility + Area + XX
Annex A + Document code + XX
Table Tbl + Document code + XX
Flyer, 
Leaflet, 
booklet
Inf + Facility + Area + XX Staff
Director (HCT
Programme )
Director (HCT 
Programme) Quality 
Manager
Staff stakeholders
Executive board
Checklist / 
Form / 
worksheet
C/L / F/Ws + Document 
code + XX
Staff Quality Manager
Director (HCT 
Programme)
Facility / 
Program
me staff
Quality 
Manager
Staff
Agreement
Registration XX
Responsible 
of Parties 
involved
Director (HCT
Programme )
Director (HCT
Programme )
Director 
(Facility / 
Program
me)
Executive 
board of 
Parties
Staff
Executive board of 
Parties
Parties 
involved
Laws & 
Regulation
/ / /
Quality 
Manager
Quality 
Manager
Staff
Fig. 13.2 Document control table of the “Colours” HCT Programme
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particular for the document control system. In this case, the quality manual can 
summarize and reference institutional policies or procedures for document control 
with due regard to any differences with FACT-JACIE standards (i.e. storage period 
of obsolete documents).
The system for document control should describe policies for the following:
• Document development and implementation, using a standardized format for 
critical documents, and assign a numeric or alphanumeric identifier, a title and a 
version.
• Document approval, including the approval date, signature of approving 
individual(s), the effective date and distribution.
• Document review and revision or change control that includes a description of 
the change, version number, the signature of approving individual(s), approval 
date(s), communication or training on the change as applicable, effective date 
and archival date.
• Document protection from accidental or unauthorized modification.
• Document archival, the inclusive dates of use, and their historical sequence for a 
minimum of 10 years from archival or according to governmental or institutional 
policy, whichever is longer.
• Retract obsolete documents to prevent unintended use.
• Establish and maintain written agreements with external parties providing criti-
cal services that could affect the quality and safety of the cellular therapy product 
or health and safety of the donor or recipient.
The quality manual can summarize and reference institutional policies and pro-
cedures also for agreements preparation, outlining the roles and responsibilities of 
each party for the performance of critical tasks to maintain accreditations and to 
comply with applicable laws and JACIE standards. Agreements shall be dated, 
reviewed, revised on a regular basis as defined by the HCT programme, and at least 
every 2 years, and approved by both parties and by legal representative of the parties.
The term agreements includes the contingency plans with an external facility 
such as service-level agreements, contracts and preventive maintenance arrange-
ments, and written agreements with donor registries and external laboratories per-
forming testing of donors, recipients or cellular therapy products.
Moreover, the QMS shall ensure that essential services for patients are not inter-
rupted. Each facility of the HCT programme – from collection to processing and 
administration of cellular therapy products – should have a continuity plan in place 
that details how services will be maintained if activities must temporarily be sus-
pended or permanently ceased. Usually this plan will include a mutual agreement (a 
service-level agreement or contract) with another organization for the transfer of 
product, documentation and services in these circumstances.
For the emergency and disaster plan, the HCT programme may use institutional 
policies for the general responses; however, specific SOPs and agreements with 
external facilities to address the safety of recipients and donors and of stored cellu-
lar therapy products are needed to augment the institutional policies.
An HCT programme within a single institution is not required to have written 
agreements for the collection and processing facilities.
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 Key Performance Data and Outcome Analysis
The quality manual shall include or summarize and reference policies and proce-
dures for the  collection and analysis  of the selected  key performance  indicators 
(from clinical, collection, and processing facilities) and their review by the Program 
Director at least once a year. The outcome analysis of clinical data and the other 
quality measures, described in the paragraph “Tools for continuous quality improve-
ment”, are usually part of the annual report and they provide clues on areas for 
improvement and documented evidence of the effectiveness of the QM Program (Fig. 
13.3). All monitoring, measuring and evaluation outputs shall be documented, ana-
lysed and reported to staff and the HCT programme will choose how to aggregate 
data based upon its size and complexity.
The parameters to be monitored or reviewed in a regular fashion should be iden-
tified in the quality manual and they should address all key elements of the HCT 
programme such as the safety and efficacy of the cellular therapy product, and the 
clinical outcome and adverse events related to the recipient, donor or product. These 
data shall be provided in a timely manner to facilities involved in HCT programme 
activities.
The HCT programme is also encouraged to define internal benchmarks and com-
pare them to national or international data.
Clinical Unit 
indicators
Transplant activity indicators Collection facility Processing Facility
N° of inpatients/year
N° of transplants /year (allogeneic and/or 
autologous)
N° of potential donors 
evaluated / year
N° of cryopreserved 
procedures / year
Mean length of stay
N° of follow up examination for 
allotransplanted patients/year
Time from donor starting 
evaluation to final selection
N° of cryopreserved bags / 
year
Index of bed 
occupation
Time from donor search activation to 
final selection of an HSC donor
N° of donors collected / year N° of clonogenic assays / year
Index of turnover
Time from donor search activation to 
transplant
N° of collection per patient 
% of viability after thawing 
(mean)
Index of bed rotation
N° of withdrawn donor workups / N° of 
activated donor workup per year
cell yield per collection
CD34+ cell recovery (post 
processing vs post thawing)
N° of new 
diagnoses/year
Waiting list for transplant duration of each collection
N° of validation procedures
/ year
N° of follow-up  
visits/year
Engraftment (time to recovery of neutrophils > 0.5 x 108/L and platelets > 20 x 108/L)
N° of falls/year N° of no engraftment/year
Clinical trials 
indicators
overall and treatment-related morbidity 
and mortality (at 30 -100 days and 1  
year after transplantation
% of products with positive microbial culture results
N° of Phase I clinical 
trials with active 
enrolment
aGvHD grade within 100 days and cGvHD 
grade within 1 year after allogeneic 
transplantation
N° of non-compliant products / year
N° of internal audits/year
N° of Nonconformities (product, process, service)/year 
N° of adverse events (product infusion, chemotherapy treatments) / year
N° of complaints / year
N° of staff training and education activity
N° of peer review publications
N° of SOPs reviewed / N° of SOPs to be reviewed
Fig. 13.3 Key performance data of HCT Programme “Colours”
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Even the frequency for data collection and analysis should be established in the 
QMP. Some indicators may be reported with each occurrence, while others may be 
prospectively analysed and reported at defined intervals (i.e. during the QM meeting 
or the annual HCT programme review) to determine causes of issues and make 
improvement. There should be documentation of measurement results, analysis, 
improvement activities, and follow-up measurement.
FACT-JACIE standards state which data for each type of cellular therapy product 
and recipient type shall be evaluated. Some of them are as follows:
 – Time to engraftment following cellular therapy product administration (HPC 
products)
 – An endpoint of clinical function for immune effector cells
 – Overall and treatment-related morbidity and mortality at 30 days, 100 days and 
1 year after cellular therapy product administration
 – Acute GVHD grade within 100 days after allogeneic transplantation
 – Chronic GVHD grade within 1 year after allogeneic transplantation
 Audits
The QMP shall include or summarize and reference policies and procedures for 
planning and conducting audits of the HCT programme’s activities to verify com-
pliance with QM documents, applicable laws, or regulations, and JACIE standards.
If the HCT programme participates in an existing QMS in its institution, it can or 
has to use institutional policies or procedures for audit process. In this case, the 
quality manual can simply summarize the audit process and reference institutional 
procedures with due regard to any differences with JACIE standards (see “the com-
pulsory audits” in FACT-JACIE standards and manual).
Alternatively, the audit process can be detailed in the QMP or in a dedicated 
procedure of the HCT programme describing the following:
 – Different kinds of audit available for different purposes (self-assessment, inter-
nal and/or external audits)
 – Competences and the expertise of auditors
 – Audit annual planning
 – Preparation of an audit programme
 – Management of the results of audits
 The Management of Products with Positive Microbial 
Culture Results
The QMP shall include or summarize and reference policies and procedures for the 
management of cellular therapy products with positive microbial culture results.
This quality element can be merged with the next one paragraph addressing 
problems and errors management or it can be treated in a dedicated procedure. In all 
cases, the QMP shall describe at a minimum the following aspects:
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 – Criteria for the administration of cellular therapy products with positive micro-
bial culture results
 – Notification of the recipient (who, how, informed documentation)
 – Recipient follow-up and outcome analysis
 – Follow-up of the donor if relevant
 – Investigation of cause (as described in the next paragraph)
 – Reporting to regulatory agencies if appropriate
For each aspect, the HCT programme should detail what action is to be taken, 
who is responsible to take the action and the expected timeframe of the actions.
An over-arching document for the management of cellular therapy products with 
positive cultures is recommended because it could involve the clinical unit, the pro-
cessing and/or the collection facility.
 The Management of Occurrences
The QMP shall include or summarize and reference policies and procedures for occur-
rences. This term (which could be understood as non-conformity) refers to errors, acci-
dents, deviations, adverse events, adverse reactions and complaints. As described in 
paragraph “Audits”, if the HCT programme participates in an existing QM programme 
in its institution, it can or has to use institutional policies or procedures for the manage-
ment of occurrences. In this case, the quality manual can simply summarize the process 
and reference institutional procedures with due regard to any differences with FACT-
JACIE standards. Nevertheless, the HCT programme should define errors, accidents, 
deviations, adverse events, adverse reactions and complaints and describe when, how, 
by whom and to whom each is reported. The HCT programme should define when 
events need CAPA plans along with their plan to audit the effectiveness of the changes.
Alternatively, the management of occurrences can be detailed in the quality man-
ual or in a dedicated procedure of the programme describing the following activities:
 – Detection
 – Investigation
 – Documentation
 – Reporting
 – Corrective and preventive action
 Traceability
Traceability describes the ability to verify the origin, location, or application of an 
item by means of documented recorded identification.
In JACIE standards, traceability means the ability to locate and identify the cel-
lular therapy product, the donor and the recipient during any step from procurement, 
through processing, testing and storage, to distribution for transplant to the recipient 
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or disposal. Traceability also applies to the facilities and personnel involved in the 
above mentioned activities so it implies the ability to identify the collection facility, 
the tissue establishment and the Clinical Unit in each step of the process 
(Fig. 13.4). [3].
Given the premises, the quality manual shall include or summarize and reference 
policies and procedures for cellular therapy product tracking and tracing that allow 
full traceability of donations from donor to recipient, all materials, reagents and 
equipment that come into contact with cellular therapy products and tracing from 
the recipient or final disposition to the donor.
A policy for the traceability of all patients and their clinical and medications data 
(including blood transfusions) is also mandatory to guarantee patient safety.
If the HCT programme participates in an existing QMS in its institution, it can or 
has to use institutional policies or procedures for traceability (i.e. medical records 
management, inventory management, drug prescription and administration). In this 
case, the quality manual can simply summarize the process and reference institu-
tional procedures with due regard to any differences with FACT-JACIE standards.
 Business Continuity Policy
The HCT programme should be prepared for situations that may interrupt opera-
tions so that such interruptions do not adversely affect recipients, donors, or cellular 
therapy products. While a policy or procedure is required that addresses emergen-
cies and disasters as describe before (see paragraph “Document control”), the HCT 
programme must also have a plan for the management of temporary interruptions 
(actions to take, who needs to be contacted, how to prioritize cases, key personnel 
to be involved and notification of staff).
Fig. 13.4 Traceability of unrelated haematopoietic progenitor cells donor and recipient data
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The QMP shall include or summarize and reference policies and procedures for 
actions to take in the event the HCT programme’s operations are interrupted.
For computerized systems of critical processes (e.g. electronic health record, 
computerized drug prescription), provision (e.g. business contingency plan) should 
be made to ensure continuity of support for those processes in the event of a system 
breakdown (e.g. a manual or alternative system).
Generally, the institutional information technology department ensures that soft-
wares in use are validated for their function and that there is a regular schedule of 
back-up to allow for retrieval of information when necessary. In this case the quality 
manual can simply summarize the process and reference institutional procedures 
with due regard to any differences with FACT-JACIE standards.
 Qualification and Validation
 General Principles
Validation is the part of the QMP concerned with proving that all critical aspects of 
the HCT programme operations are sufficiently under control to provide continual 
assurance that product/service will remain safe for patients and fit for purpose.
Validation is usually split into two components: qualification and process or test- 
method validation.
The term qualification is applied to each part of the process including facilities, 
equipment, computer systems, materials and operators. Each item should be quali-
fied separately to demonstrate consistent performance. Process validation should 
only be performed once all the items used have been qualified.
The quality manual shall include or summarize and reference policies and proce-
dures for qualification and for validation or verification of critical procedures.
Sometimes a procedure regarding qualification and validation called validation 
master plan (VMP) could be in place for the processing facility. In this case, the 
QMP can simply summarize the processes and reference this VMP, applying it even 
to bone marrow and peripheral blood collection facilities.
Alternatively, the qualification and validation process can be detailed in the QMP 
or in a dedicated procedure of the HCT describing the following:
 – Key elements of the process to be qualified (i.e. critical manufacturers, vendors, 
equipment, supplies, facilities, operators and services)
 – Critical procedures to be validated
 – Preparation steps of the qualification plan
 – Preparation steps of a validation plan
 – Management of the results
 – Approval of the qualification and validation plans, results and reports by the 
quality manager and HCT programme director or designee
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 Quality Risk Management
Evaluation of risk is a process to assess and document the risks involved in a change 
in a process, procedure or environment that has the potential to affect a critical pro-
cedure (patient care safety, product integrity, sterility, viability and/or recovery).
The QMP shall include or summarize and reference policies and procedures for 
the evaluation of risk before introducing a new activity and changes to a process to 
confirm that the changes do not create an adverse impact or inherent risk elsewhere 
in the operation. Risk assessment is not a once-only process but a cyclical one 
(Fig. 13.5) considering a continuous re-evaluation of residual risk.
Since the risk assessment represents a basic step to go through in the validation 
process and it is one of the key elements also for ISO standards, the HCT pro-
gramme could have a dedicated procedure for it. In this case, the quality manual can 
simply summarize the processes and reference to the existing document.
Alternatively, the risk assessment process can be detailed in the QMP or in a 
dedicated procedure of the HCT programme describing the following elements:
• Approach to risk assessment used (i.e. brainstorming, Hazard Analysis and 
Critical Control Points (HACCP), Failure Mode and Effects Analysis (FMEA) 
and Failure Mode, Effects and Criticality Analysis (FMECA)).
Risk analysis:
Identify hazards
Identify harm
Assign severity
Assign probability
Evaluate frequency
Risk of evaluation:
Is the risk
acceptable?
Risk control:
Analyze options for
risk reduction in
relation to cost &
benefit evaluation
Risk reduction:
Implement
measures if
appropriate
Re-assess residual
risk
Fig. 13.5 Cycle of risk assessment of HCT programme “Colours”
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• Policy regarding risk acceptance
• Mitigation planning (target, task, responsible person, deadlines)
• Evaluation of residual risk (monitoring and re-assessment)
 Obtaining Feedback
The quality manual shall include or summarize and reference policies and proce-
dures for obtaining feedback from associated collection and processing facilities 
and from donors and recipients or legally authorized representatives. It may be 
obtained directly by the HCT programme; however, it is also acceptable to use a 
hospital-wide system, such as patient satisfaction surveys.
 Tools for Continuous Quality Improvement
Products, services or processes of the HCT programme should be constantly evalu-
ated and improved for efficiencies, effectiveness and compliance (Fig. 13.6). If the 
HCT programme participates in an existing QMS in its institution, it can or has to 
use institutional policies or procedures for continuous quality improvement system. 
In this case, the QMP can simply summarize the process and reference institutional 
procedures with due regard to any differences with JACIE standards. Alternatively, 
the continuous quality improvement system can be detailed in the QMP or in a dedi-
cated procedure of the HCT programme describing the structured planning approach 
to evaluate the current practice processes and improve systems and processes to 
achieve the desired outcome.
Input to management reviews shall include at a minimum the following:
 – Key performance data and outcome analysis
 – Quality objectives (i.e. document control management with SOPs introduced or 
revised)
 – Quarterly reports of the quality management activities
Continuous Quality improvement process
Program structure Processes Outputs
Outcome
clinical outcomes &
quality measures
- organization
- premises
- personnel
- equipment
- policies
- cellular therapy
product
- donors
- patients
- audits
- validation
- occurrences
- complaints
- patient satisfaction
Fig. 13.6 Continuous quality improvement process of the “Colours” HCT programme
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 – Qualification and validation results
 – Non-conformity and CAPA
 – Customer complaints and feedback
 – Inputs from employees, suppliers and other interested parties
 – Results of internal and external audits
 – Personnel education and training reports (continuing medical education, compe-
tence evaluation)
 – Assessment of the adequacy of the resources available (personnel, premises, 
equipment)
As described in the paragraph “Key performance data & outcome analysis”, the 
QMP should describe the frequency for data collection and analysis. The represen-
tative in key positions involved in the quality management review should be defined, 
as well as the means of communication to the HCT programme staff of Key perfor-
mance data and review findings (at a minimum on an annual basis), and the type of 
documented information to be retained (i.e. the minutes and attendance lists).
 Other Aspects
The QMP can also provide information on other key elements of the quality man-
agement system of the HCT programme such as the following:
• Operational environment
• Premises and infrastructures
• Equipment and materials supply
If the HCT programme participates in an existing QMP in its institution, it can or 
may even have to use institutional policies or procedures. In this case, the QMP can 
simply summarize the abovementioned elements and reference institutional proce-
dures with due regard to any differences with FACT-JACIE standards. Alternatively, 
some aspects like operational environment equipment and supply management can 
be detailed in the QMP or in dedicated procedures of the HCT programme.
Typically, the QMP of the processing facility might include a map of the labora-
tory premises, showing all space that the laboratory uses and restricted points of 
access. The reagent section might address order procedures, storage requirements, 
preparation and quality control of reagents.
Also, requirements for instrument/equipment management should be addressed 
in the QMP or in dedicated procedures of the HCT programme, including the 
following:
• Instrument logbooks management
• Written procedures for use and preventive maintenance
• Procedures for instrument replacement and disposal
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Chapter 14
The Accreditation Process
Mara Magri and Raquel Espada Martín
The complexity of haematopoietic cell transplantation (HCT) as a medical technol-
ogy and the frequent need for close interaction and interdependence between differ-
ent services, teams and external providers (donor registries, typing laboratories, 
etc.) distinguish it from many other medical fields [3]. At around the turn of the 
millennium, recognition of these challenges led to efforts by the HCT community to 
standardize processes based on consensus to better manage quality, including the 
inherent risks of HCT [2]. Ever since, HCT has continued to be a pioneer in setting 
agreed clinical quality standards [5, 8] and subsequent external inspection and cer-
tification via the process of accreditation (via JACIE). An accredited programme 
can therefore demonstrate that it is performing at a required level of practice in 
accordance with agreed standards of excellence, including operating an effective 
quality management system (QMS). Such a hallmark of quality provides reassur-
ance to healthcare professionals, health service payers and, most importantly, 
patients and their families.
The accreditation process is divided into three phases. The first phase is a pre- 
inspection phase where the applicant submits the relevant documentation and the 
inspectors review it in advance of the inspection. The second phase is an inspection 
phase, where the inspectors assess on-site if the documentation from the pre- 
inspection phase meets the reality of the day-to-day work in the centre through 
interviews with key personnel, tour of the facilities and review of additional docu-
mentation. Inspectors document findings and observations in the inspection report 
which is reviewed by the accreditation committee which decides on the next steps 
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for the centre to achieve the accreditation. The third phase is a post-inspection 
phase, where the applicant submits evidence of corrections for the deficiencies iden-
tified in the report. The programme achieves compliance once the inspectors assess 
the evidence of corrections, the standards are compliant and the accreditation com-
mittee gives the approval. After achieving the accreditation, the main challenge for 
the programme is to maintain all the aspects, including the QMS, making it more 
robust and adhering to the new editions of the FACT-JACIE standards and manual.
 Why Seek Accreditation?
Accreditation is the means by which a centre can demonstrate that it is performing 
a required level of practice in accordance with agreed standards of excellence and 
certify that it operates an effective QMS.
A quality management system is a mechanism to ensure that procedures are 
being carried out in line with agreed standards with full participation by all staff 
members. In an HCT programme, this ensures that the clinical, collection and labo-
ratory units are all working together to archive excellent communication, effective 
common work practices and reassurance for patients. It is a means of rapidly iden-
tifying errors or accidents and resolving them so that the possibility of repetition of 
the problem is minimized. It assists in training and clearly identifies the roles and 
the responsibilities of all the staff.
Once the required level of quality has been achieved through modifications to 
practice, the remaining challenge is to maintain this standard of practice. With a 
working quality management system in place and adequate resources, the funda-
mental elements necessary to sustain the programme are continued staff commit-
ment and vigilance.
Initial evidence of a positive relationship between the implementation of a QMS 
and an outcome of HCT in Europe was published in 2011 [6]. In this paper, patients’ 
outcomes were systematically better when the HCT centre was at a more advanced 
phase of JACIE accreditation and independent of year of transplantation and other 
risk factors. Another analysis [7] was performed on a large cohort of patients who 
received either an allogeneic or an autologous HCT between 1996 and 2006 and 
reported to the EBMT database. The authors showed that the decrease of overall 
mortality in allogeneic HCT procedures over the 14-year observation period was 
significantly faster in JACIE-accredited centres, thus resulting in a higher relapse- 
free survival and overall survival at 72 months from transplant. Such improvement 
was not shown in autologous transplantation. Similar results published in an 
American study [10] showed that centres accredited by both FACT and Clinical 
Trial Network (CTN) demonstrated significantly better results for more complex 
HSCT such as HLA-mismatched transplants. These data reinforce the concept that 
clinical improvement is driven by the implementation of a quality management sys-
tem embedded in external accreditation standards, especially in the context of more 
complex procedures. This process also results in a wider standardization of 
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procedures across different countries and geographic areas, thereby contributing to 
providing patients with similar treatment expectations even when accessing differ-
ent health management systems. A comprehensive review summarized these devel-
opments [13]. Other studies have assessed the impact of accreditation on quality and 
organizational aspects of transplantation programmes [1, 4, 11].
 Where to Start?
Before starting with accreditation process, the HCT programme needs to be for-
mally recognized by the institutional authorities and by competent authorities if 
needed. This is an important step to be entitled to assign duties and responsibilities 
to the key persons of the HCT programme.
The accreditation process starts with a centre’s aspiration to achieve certification 
and subsequent plan (see Fig. 14.1).
Planning The first step is preparing a timetable (see Table 14.1) triggered on the 
goal to reach JACIE accreditation. The introduction of JACIE standards is embed-
ded in an accompanying quality management system, the type of which is at the 
discretion of the single HCT programme [14].
Implementation of an action plan and its monitoring The second step is the 
preparation of an action plan detailing all the operative activities, their timeframe, 
the key persons, and responsibilities involved and the final objectives to be reached. 
Where there is a QMS already implemented by the hosting institution, the  preparation 
of the plan of action for achieving accreditation should be organized in close col-
laboration with the quality office of the institution.
DECIDE
IMPLEMENT
SEEK
Documentation
DocumentationIndicators
QM Team Audits
A Quality Management System:
To work according to the Standards
Accreditation under an Accreditation Organitzation
Fig. 14.1 Aspects to consider prior to starting the accreditation process
14 The Accreditation Process
126
The analysis of the HCT programme processes and activities and the organiza-
tion of the QMS documentation already available are the starting points to prepare 
a good action plan. The analytical comparison between the documentation already 
present and requirements of the FACT-JACIE standards enables evaluation of how 
much commitment must be expected in terms of personnel and working time to 
complete the preparation of documentation required by FACT-JACIE standards.
The action plan must also include education on FACT-JACIE standards of HCT 
programme staff, possibly before starting with document preparation, to enable per-
sonnel to work on documentation and on the accreditation process (awareness and 
competence).
Table 14.1 Timetable
Time Activity Responsibility Indicators
Before starting 
accreditation 
process
Formalization of the 
transplant programme
HCT programme 
director(s)
Hospital 
Management
Formal institution of the 
HCT programme and 
leadership assignment
1–2 months Preparation of the 
action plan
HCT programme 
director(s)
Quality officers
Working groups
Analysis of activities and 
processes in the light of 
JACIE requirements
Meeting minutes of the 
working groups (clinical, 
collection and processing 
facilities)
Finalized action plan for 
JACIE accreditation
12–18 months Implementation of the 
action plan and its 
monitoring
Quality officers
Working groups
Meeting minutes of the 
working groups
Writing of the quality system 
documentation
Staff education
Audits for monitoring action 
plan implementation
Action plan adjustments if 
needed
1–2 months JACIE application Hospital director
HCT programme 
directors
Quality officers
Upload of checklist, 
application form and 
requested documentation
3–5 months JACIE inspection & 
report
HCT programme 
team and hospital 
key persons
JACIE inspectors
JACIE report and checklist 
post inspection
3–9 months CAPA plan 
post-inspection
Quality officers
Working groups
Analysis of JACIE report and 
inspectors’ checklist post 
inspection
CAPA implementation
Upload of checklist with 
CAPA evidences
1 month JACIE accreditation JACIE accreditation 
committee
HCT programme 
accreditation award
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The action plan must be monitored during its application so that it can be cor-
rected and amended if necessary (action plan adjustments). The monitoring can be 
carried out through regular and routine meetings of people responsible of the differ-
ent working groups and/or through focussed audits (on quality system documenta-
tion or on processes).
 Phases of the Accreditation Process
Accreditation is the means by which a centre can demonstrate that it is performing 
a required level of practice in accordance with agreed standards of excellence and 
certify that it operates an effective QMS. According to the International Society for 
Quality in Healthcare, accreditation is a process “in which trained external peer 
reviewers evaluate a health care organization’s compliance with pre-established 
performance standards ... Unlike licensure, accreditation focuses on continuous 
improvement strategies and achievement of optimal quality standards, rather than 
adherence to minimal standards intended to assure public safety” [12].
Programmes interested in achieving accreditation for hematopoietic cellular 
therapy product collection, processing and administration can contact relevant 
accreditation organizations, including the following:
• JACIE: www.ebmt.org/jacie-accreditation
• FACT: http://www.factwebsite.org/
• AABB: www.aabb.org
Although each accreditation organization has its own accreditation process and 
specifications, the following sections provide a general description of the different 
phases that the applicants are subject to. The accreditation process is divided into 
three main phases: pre-inspection, inspection and post-inspection.
 Pre-inspection Phase
HCT programmes seeking accreditation are encouraged to start the accreditation 
process with the accreditation organization of their choice once their QMS has been 
in place at least for a year and there is sufficient evidence to prove compliance with 
the FACT-JACIE standards.
Out of the three phases of the accreditation process, the pre-inspection phase is a 
phase that often requires more efforts for all the involved parties: applicant and 
inspectors. The pre-inspection process starts when applicant submits the corre-
sponding documentation to the accreditation organization for review and approval.
Following are the documents that are to be provided during the pre- 
inspection phase.
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 Application Form
Key information about the HCT programme seeking accreditation should be pro-
vided, including the following:
• General information: Name of the programme, contact details and invoicing 
information.
• Scope: Standards cover the entire HCT process, starting from the selection of the 
donor/patient to collection, processing, storage, and subsequent infusion and 
follow-up. Thus, programmes are encouraged to apply for the accreditation as a 
full programme, which includes the clinical unit (adult and/or paediatric), the 
administration of immune effector cells (IEC), the bone marrow and/or apheresis 
collection unit and the processing unit. However, stand-alone applications are 
accepted for processing units, for clinical units that work with accredited collec-
tion and processing units or for collection units that work with accredited pro-
cessing units.
• Structure of the programme: Key personnel of each unit, organization of the 
HCT programme and distance among the units.
• Activity: Standards establish minimum activity numbers for the clinical and col-
lection units.
The information provided by the HCT programme in the application form 
enables the accreditation organization to determine the eligibility for the accredita-
tion process.
 Self-Assessment Standards Checklist
Applicants need to self-assess their compliance with every one of the standards 
indicating if they comply or not with it and referencing supporting documentation 
as a proof of compliance. The information provided by the programme in the self- 
assessment checklist enables the applicant, the accreditation organization and the 
inspectors to determine the readiness of the centre for the accreditation process.
Once the application form and self-assessment checklist are reviewed and 
approved by the accreditation organization, the applicant provides an established set 
of pre-inspection documents.
 Pre-inspection Documentation
This consists of selection of documents that the applicant needs to submit prior to 
the on-site inspection. This documentation allows the inspectors to understand the 
centre’s activity, organization and to check compliance with some of the standards 
before the on-site visit. Depending on the accreditation organization (and subject to 
the language capabilities of the inspectors), the documentation can be submitted in 
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the language of the centre or only in English. Following are examples of the key 
documentation requested:
• Selection of key SOPs
• Evidence of staff training and qualifications records of key personnel
• Facility licences and authorizations
• Quality management plan (QMP), interchangeably referred to as the Quality 
Manual or Quality Handbook
• Documented evidence that the QMS is functioning
• Consent forms and related information
• Sample labels
• Plans or maps of the centre
• Sample agreements with third-party service providers
Examples of pre-audit documentation can be found at https://www.ebmt.org/
jacie-document-quicklist.
Support prior to submitting the forms is available from the accreditation organi-
zation, i.e. the JACIE office. Once the application is submitted to the accreditation 
organization, each HCT programme is assigned to an accreditation coordinator to 
help and guide through the process. Also, the accreditation organizations have sup-
porting guides to accompany centres during the process.
Completing the application form, self-assessment checklist and pre-audit docu-
mentation thoroughly and accurately leads to a more efficient on-site inspection.
During the pre-inspection phase, applicants will be requested to sign an accredi-
tation agreement with the accreditation organization and will be invoiced with the 
corresponding accreditation fees.
Once all the pre-inspection information is submitted, the accreditation organiza-
tion starts to assemble the inspection team for the on-site inspection. Each accredi-
tation organization has their own pool of inspectors who are volunteers and experts 
in one or more of the areas covered by the FACT-JACIE standards. Inspection teams 
consist of at least one inspector per area to be inspected: clinical, collection and 
processing, one of whom is also a team leader. For example, if the applicant applies 
for adult clinical, collection (bone marrow and apheresis) and processing accredita-
tion, the inspection team will consist of the following: a clinical inspector, an apher-
esis inspector and a processing inspector. Each inspector is responsible for assessing 
the standards under their area of expertise and it is the clinical inspector who is 
usually responsible for the marrow collection facilities. Some accreditation organi-
zations also include a quality manager specialized inspector. When a quality man-
ager inspector is included, they are responsible for assessing the QMS in relation to 
the quality-related standards in the HCT programme. During this process, both 
applicant and inspectors need to communicate to the accreditation organization any 
conflict of interest to exclude those inspectors from the inspection team. Furthermore, 
one of the inspectors also has the additional role of being the team leader. The 
responsibilities of the team leader include to provide a general overview of the inter-
actions between the units of the programme and to become the main point of contact 
(among the inspectors, with the applicant and with the accreditation organization).
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As soon as the inspection team is confirmed:
• Inspectors receive all the pre-audit information of the programme so that they 
can review and assess it prior to the inspection. During the review time, inspec-
tors can ask for additional information and have a pre-inspection team meeting 
to share their preliminary assessment.
• Both applicants and inspectors start working on the inspection’s agenda and the 
logistics of the inspection, which mainly revolves around the travel/accommoda-
tion arrangements.
 Inspection Phase
The inspection phase is the most visible part of the accreditation process. Inspectors 
will travel to the HCT programme to verify that the information provided during the 
pre-inspection phase corresponds to the way they work and that it meets the require-
ments of the FACT-JACIE standards. The inspection is a thorough peer-reviewed 
examination of the aspects of the HCT programme and/or its component parts.
Inspections are conducted in the language of the centre or in English depending 
on the accreditation organization.
The on-site inspection consists of 1 or 2 days of inspection and comprises the 
following items:
• Opening meeting: This meeting is the opportunity for the applicant to present 
their programme and for the inspectors to introduce themselves, explain the pur-
pose of the inspection and set a collaborative atmosphere for the inspection. It is 
attended by the personnel of the HCT programme.
• Review of documentation: Even though inspectors review documents from the 
HCT programme during the pre-inspection phase, at the time of the inspection, 
they dedicate a necessary amount of time to this task, looking for evidence of 
compliance with FACT-JACIE standards.
• Tour of the different units seeking accreditation: It allows inspectors not only to 
see the facilities but also to interact with the personnel working to better under-
stand how they work on a day-to-day basis.
• Observation of a clinical/collection/processing procedure or a mock procedure: 
Specific observations of the procedures help inspectors to understand the process 
and traceability of the product.
• Interview with key personnel: It allows both applicant and inspectors to exchange 
key information for the accreditation. The purpose of the interview is not to 
assess the performance of the personnel, but it is to assess the compliance of the 
HCT programme with the FACT-JACIE standards.
• Closing meeting with the programme director followed by a meeting with all the 
programmes to highlight the observations and findings of the inspection: The 
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inspection team and the programme director will discuss any sensitive issues 
identified. Afterwards, the inspection team meets with all the personnel involved 
in the on-site inspection to explain the main findings and observations from each 
of the units inspected. The team leader takes the opportunity to explain the next 
steps in the process and highlights that inspectors write the report based on their 
observations, but it is the accreditation committee that makes a judgement on the 
compliance of the centre with the standards. This closing meeting helps appli-
cants to manage the expectations about the inspection report.
After the on-site inspection, inspectors write the inspection report (see Fig. 14.2) 
identifying which standards are compliant and which ones need further adjustments. 
The inspection report is provided by the inspectors to the accreditation organization 
for review and it is presented to the accreditation committee (see Fig. 17.5) to decide 
the next steps for the HCT programme to achieve the accreditation. Once the report 
is finalized with the observations from the inspectors and the committee, it is pro-
vided to the applicant so that they can continue working towards achieving the cer-
tification for accreditation. The report is a fundamental part of the accreditation 
process.
The possible results of the accreditation report are as follows:
• All standards are compliant – In the rare case that a centre applying for accredita-
tion complies with all the standards at the time of the inspection, the applicant 
will receive the accreditation without going through the post-inspection phase.
• Some standards are not compliant – The great majority of the reports reveal defi-
ciencies and the centre needs to continue working to achieve compliance with all 
the standards during the post-inspection phase.
Accreditation
Committee
Accreditation
Committee
Inspectors
Accreditation
Organitzation
Applicant
Inspectors
Fig. 14.2 Report pathway
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 Post-inspection Phase
Once the applicant receives the inspection report, they can start working correcting 
the deficiencies, implementing the corrective actions, and generating the supporting 
evidence. The degree of deficiencies identified will vary in seriousness. In most 
cases, it will be sufficient to provide documentary-based evidence, while in other 
cases, for example when the QMS is immature or facility structures are not ade-
quate, a focussed reinspection will be necessary. Whether the centre submits docu-
mentary evidences or is subject to a focussed inspection, the same inspection team 
that participated in the inspection phase will assess the adequacy of the corrections. 
When those are assessed as compliant by the inspectors and are approved by the 
accreditation committee, the applicant is awarded with accreditation.
Some accreditation organizations are assessing how to offer a stepwise accredi-
tation programme for programmes in low-to-middle income countries (LMICs). 
The main concept is to help centres to achieve full accreditation in different stages, 
which makes the accreditation goal more reachable. Programmes subject to the 
stepwise process must achieve the same level of compliance as programmes going 
through the full accreditation process, but they can do it more gradually over a lon-
ger period. This stepwise programme would allow LMIC to connect with an inter-
national network focussed on quality in HSCT and could also serve to stimulate 
local authorities to support accreditation in the interest of patients and donors.
 Plan the Post-accreditation Period
Maintaining JACIE accreditation is probably as challenging as being awarded it first 
time. JACIE standards are not something that should be forgotten about until getting 
ready for the next accreditation cycle. The effort in the post-accreditation period is 
to maintain an up-to-date QMS, making the FACT-JACIE standards a part of the 
everyday life of the HCT programme.
Any system, without maintenance, is destined to deteriorate, including adher-
ence to key aspects such as the QMS that depend on the possibility of changes in 
many aspects in the internal institutional and external health care systems. The con-
tinuous improvement of the QMS is not a simple update of the documented infor-
mation over time but also means maintaining all elements and ensuring 
implementation on everyday working practices.
• Documentation including SOPs should continue to be updated and developed.
• Audits should continue to be planned and carried out.
• Information about JACIE developments should continue to circulate among 
the team.
• Regular meetings on the run up to the next inspection should continue.
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• Continuous education of HCT programme staff should be planned and guaran-
teed to maintain competent personnel over time who are able to operate on pro-
gramme processes.
• Monitoring the HCT programme activities and processes through suitable and 
relevant indicators (key performance data and outcome analysis) should be 
planned and performed at least annually.
Prompt and accurate collection of occurrences (this term refers to errors, acci-
dents, deviations, adverse events, adverse reactions and complaints deviations) 
should be maintained and the need for CAPA plan should be investigated.
If you do not continue to develop and maintain JACIE, most of the hard work in 
achieving accreditation will become redundant and you will find yourself back at 
the beginning when applying for reaccreditation.
 Key Agents
This peer-reviewed accreditation process is possible, thanks to volunteer profes-
sionals in the field of HSCT, who devote their valuable time and expertise to con-
tribute, promote and implement quality in the transplant community: inspectors, 
accreditation committee members and cellular therapy standards committee.
Inspectors
Inspectors are involved in the three phases of the accreditation process (see 
Fig. 14.3); thus, they dedicate their efforts and knowledge to learn about the appli-
cant and visit their programme to assess their compliance with the standards. As 
Application
Form
Checklist
Pre-inspection
Documents
Applicant Inspectors Inspectors Accreditation
Committee
Report
Applicant Inspectors
Evidence of corrections
Accreditation
Committee
Applicant
Fig. 14.3 Accreditation process flow, documentation and key agents
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previously mentioned, they are the eyes and ears of the accreditation committee and 
include all their findings in the inspection report. Inspectors are also involved in the 
review of the evidence of corrections during the post-inspection process, and thus 
they follow the progress of the programme from the application until they achieve 
certification of accreditation.
The entire process is usually performed in a collegial and positive atmosphere 
and is often a learning and rewarding experience for both inspectors and applicants. 
In addition, inspectors benefit from meeting and collaborating with colleagues 
while helping to implement and promote quality in the transplant community [9]. 
Accreditation organizations might offer specific benefits to their volunteer inspec-
tors, such as discount in the application fees of the inspector’s centre or educa-
tional events.
Professionals from HCT field interested in becoming inspectors should contact 
the accreditation organization to learn more about the requirements. Inspector 
requirements are based on professional experience, completion of an inspector 
training course and associated exam. Before becoming an inspector, candidates 
must participate in the observation of an inspection.
Accreditation Committee Members
Accreditation committee members are the main source of expert opinion and peer 
review. Membership is formed by experienced inspectors from all the areas, clini-
cal, collection and processing, and some accreditation organizations also include 
quality managers members. The accreditation committee members meet regularly 
to discuss the inspection reports, determine the next steps for the centres to achieve 
compliance and decide on the accreditation of the centres.
Cellular Therapy Standards Committee Members
Members of the cellular therapy standards committee oversee establishing, main-
taining and reviewing the standards. Members are usually experienced inspectors 
and members of the accreditation committee.
Standards are reviewed periodically and are subject to a public consultation pro-
cess before the publication of the final version.
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Chapter 15
Data Management
Fazal Hussain, Riad El Fakih, and Mahmoud Aljurf
 Data Management
Hematopoietic stem cell transplantation (HSCT) is a multidisciplinary and defini-
tive treatment modality for myriads of life-threatening conditions. HSCT has wit-
nessed tremendous development and evolution since its inception and has emerged 
as an area of high priority. Traditionally, HSCT has been used and continues to 
expand as a definitive treatment for multitudes of malignancies, inherited disorders, 
and bone marrow failures [1–3]. This growth has been witnessed not only in the 
developed countries but also in low- and middle-income countries (L&MIC). 
Cellular therapies have emerged as the most promising treatment modalities in 
HCT, and this trend is expected to continue.
HSCT databases are the backbone of any quality transplant program to achieve 
desired end states as per the institutional lines of efforts. These registries are orga-
nized systems to collate uniform data using observational study methodology to 
determine trends, patterns, and treatment outcomes in HSCT. The source documents 
for these outcome registries are mostly the patient’s medical record. Transplant 
database encompassing complete, accurate, and reliable transplant data is geared 
toward capturing evolving trends, best practices, and resource allocation/utilization 
and streamlining multidimensional quality indicators for continuous quality 
improvement (CQI) and optimal outcomes. Data management is crucial for deter-
mining trends, developing quality observational studies, and answering the 
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questions that can’t be answered otherwise to improve HSCT knowledge globally. 
Observational registries provide state of current knowledge and gaps in evidence to 
form the basis for prevention/intervention programs, delivery, and effectiveness. 
They can help in designing the optimal schema for prospective and retrospective 
studies and for comparative analyses of diverse HSCT strategies for HSCT vs. non- 
HSCT therapies. Registries are particularly useful in situations where a comprehen-
sive and flexible research design is needed or when the purpose is to discover how 
a product works in a wide variety of sub-groups, including ethnicity and socioeco-
nomic status. A hybrid approach registry collects data retrospectively and prospec-
tively. If data collection is sufficiently comprehensive, outcomes findings from 
patient registries can be widely generalizable. Rapidly evolving HSCT technology 
and widely varied outcomes among diverse patient populations need to be balanced 
with data management support.
Transplant databases are aimed at monitoring the natural history of the disease, 
demographics, therapeutic interventions, toxicity/safety, treatment effectiveness, 
quality assessment, and sustainability of this high-stake tertiary care service in a 
systematic approach. Short- and long-term complications of HSCT require long-
term follow-up of patients. Databases and the consent formats need to be approved 
by the Institutional Review Boards (IRBs) as per the local rules and regulations and 
the Standard Operating Procedures (SOPs). Data managers (DMs) play a significant 
role in capturing contemporary knowledge about the indications, stem cell utiliza-
tion, benchmarking data quality, and assessing outcomes for better resource plan-
ning/allocation/utilization [4]. Minimal essential data on each transplant recipient 
and donor can be captured using EBMT and CIBMTR minimum essential forms 
(MED-A), and Transplant Registry Unified Management Program (TRUMP) by the 
APBMT, the survey form of the EMBMT, and other organizations. The HSCT data-
base is pivotal in conducting innovative observational registry studies, providing a 
platform for clinical trials, and enhancing transplant outcomes. Qualified, trained, 
and experienced personnel are essential to initiate and maintain such registries [5]. 
Data managers are required for quality data management and their continuing edu-
cation and training, and interdisciplinary teamwork is critical for the optimum use 
and outcomes of the HSCT databases [6]. Precision, communication, collaboration, 
and close coordination are crucial for achieving the desired end states. High-quality 
transplant program data management encompasses advanced methodology, opera-
tional excellence, enhanced validity, and discernable outcomes (Table  15.1). 
Changing trends and patterns in personalized medicine have underscored the impor-
tance of data management to ensure that all cellular products are being processed as 
per protocol, safety standards, and guidelines to optimize disease outcomes. Data 
management is a dynamic process with myriads of dimensions, applications, and 
deliverables as the backbone of quality HSCT program, leading to evidence-based 
medicine. If designed and executed correctly, it can yield huge dividends to fill in 
the knowledge gaps and support the center’s lines of effort (Table 15.2).
Data management is pivotal for a high-quality HSCT program to identify chal-
lenges, find solutions, and overcome potential barriers to maximize clinical and 
patient-reported outcome measurements (PROMs). Following guidelines and 
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Table 15.1  
Fundamentals  
of data  
management
Qualified personnel
  Trained and qualified personnel
  Familiarity with staging, grading, toxicity criteria
  Teamwork/effective communication/collaboration/
multidisciplinary approach
  Cross-training of research coordinators/data managers
  Workload, proportionality, and time management
Regulations
  SOPS/IPPs/by-laws, data/material transfer agreements
  Accreditation for standardization (JACIE/FACT/etc.)
  Ethical committee/IRB regulations
  Informed consent issues
  Central Institution Review Board (CIRB)
  Privacy and confidentiality
Data processing
  Documentation: accuracy and integrity
  Source documents: case report forms (CRFs)
  Harmonized forms (uniform use of standardized data elements/
definitions)
  Linking data sources for efficiency
  Data quality/comparability/standardization
  Data monitoring safety board/committee (DMSB)
  Quality assurance and performance improvement (QA/PI)/audits
  Electronic data capturing (EDC): long-term follow-up data
Medical record
  Electronic (EMR)
  Paper-based (charts)
  Hybrid
  Training and in-service
Standardized data management software
  Uniformity, standardization
  Globally acceptable/compatible
Communication and cultural issues
  Language barriers
  Cultural, social, and economical heterogeneity
  Cultural sensitivities/QOL instruments
Quality management
  Homogeneity and uniformity of the databases
  Accreditation standards: JACIE/FACT
  Variation in labs/toxicity criteria/performance status (PS)
  Annual review of database: new variables, biomarkers, staging/
grading
(continued)
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Table 15.2  
Dynamics of data 
management  
in research
Benefits of effective data management
  Identifying population
  Fulfilling gaps in knowledge
  Monitoring transplant trends/outcomes
  Resource allocation – priority setting
  Advocating for improved health care
  Serving as a distribution mechanism
  Facilitating establishment of communication network
  Synchronization
  Ensuring streamlined global data
Principles of data collection
  Accuracy
  Reliability
  Validity
  Simplicity
  Completeness
Minimum requirements
  Data collection/source documentation
  Attributable, legible, contemporaneous, original, and accurate
  Personnel
  Regulations
  Communication
  Quality assurance
  Funding
  Data utilization/sharing/publications
Quality assurance
  Standardization/accreditation
  Uniform QM standards
  Audits/site visits (internal and external)
  Implications/outcomes of data quality
Courtesy of Hussain et al. [11]
Data utilization and publications
  Overlapping registries/databases
  Integration/interfacing/interoperability
  Access to data
  Authorship guidelines
Funding
  Sustainable funding sources for long-term follow-up
  Quality data generates new funding sources
Courtesy of Hussain et al. [11]
Table 15.1 (continued)
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recommendations from the CIBMTR, EBMT, WMDA, and Worldwide Network of 
Blood and Marrow Transplantation could be an effective way of streamlining data 
management issues for the HCT programs. However, following the data standards 
set forth by the HSCT accreditation bodies in the USA (Foundation for Accreditation 
of Cellular Therapy [FACT]) [7]and in Europe (Joint Accreditation Committee of 
the International Society for Cellular Therapy and the European Group for Blood 
and Marrow Transplantation [JACIE]) [8] is the ideal way to promote improvement 
in data quality of the HSCT program from harvesting to grafting. Regional trans-
plant registries can promote HSCT in a specific region and identify locoregional 
trends and practices, standards and interventions, and benchmarking outcomes. 
National registries can be used to benchmark transplant outcomes using the large 
multinational outcomes registry (EBMT, CIBMTR, EMBMT, APBMT, etc). As a 
reference. CIBMTR carries out an annual assessment of one-year survival post- 
allogeneic HSCTs in each transplant center in the USA and provides it to participat-
ing centers and the public. The globalization of patient and donor registration for 
HSCT is a realistic goal and can contribute to the improvement of patient care, 
outcomes, and donor safety. Registry data have provided valuable insights into 
international differences in indications for HSCT and access to HSCT. Accuracy, 
reliability, and validity in data management are pivotal for quality improvement, the 
efficiency of care, and donor/recipient outcomes. Therapeutic outcomes of HSCT 
are optimized by utilizing myriads of clinical indicators encompassing transpar-
ency, close coordination, teamwork, and effective communication in a multidisci-
plinary approach (Table 15.3). Studies have shown a significant improvement in the 
donor and recipient care in the accredited centers by adhering to international 
Table 15.3 Strengths of HSCT databases
Excellent source of demographic and activity data – dynamic measure of patterns of care
Useful for planning intervention trials – hypothesis generation and calculating effect size and 
potential recruitment
“Real-world” therapeutic effectiveness and safety data (as opposed to efficacy) – compare 
disease management by program, region, country
Heterogeneity of standard practice across participating sites facilitates research into “best 
practices”
Heterogeneity among study subjects
Detection of rare consequences is satisfied by large numbers of patients followed for long 
periods of time – a unique advantage
Low risk to participating subjects (observational rather than interventional) can promote broad 
participation
Flexibility: serves as a platform for extending observation or intervention to particular groups of 
subjects; sub-studies
Relatively low cost to develop and maintain on a per-patient basis
Useful as a comparative arm in comparative effectiveness research
Provide meaningful data for decision-making where a clinical trial is not feasible or practical
Approximation of treatment impacts is more realistic
Courtesy of Hussain et al. [11]
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standards for optimal clinical, laboratory, and auxiliary practices in HSCT [9]. The 
databases’ value is enhanced by following the universally acceptable ethical and 
quality standards for the design, collection, analysis, reporting, monitoring, and 
auditing of the data. Scientific rigor and transparency of the registry can be strength-
ened by following good registry practices. Easy access of registry data to the inves-
tigators and ensuring safeguards for credible, accurate, and reliable data are cardinal 
elements of a quality registry. Registries must provide assurance for the privacy, 
confidentiality, and integrity of data.
Quality management is crucial in the operational domain of a high-quality HSCT 
program for optimizing patient outcomes as per the existing SOPs and playbooks 
for efficient, quality, and sound therapeutic yields. The minimum essential elements 
of data management are as follows:
SOPs/IPPS/Playbook SOPs and control measures for HSCT data management 
ensure the integrity, confidentiality, and authenticity of transplant data. 
Documentation is crucial in setting up and maintaining a quality HSCT program as 
per the written SOPs or Internal policy and procedures (IPPs) to ensure that each 
team member is aware of its roles and responsibilities at the operational, strategic, 
and tactical levels. The playbook is pivotal for the continuity of quality data man-
agement by underscoring techniques, tactics, and procedure of data collection, qual-
ity assurance and outcomes to optimize operations planning and execution. It 
highlights the importance of what, when, where, who, why, and how to optimize the 
process flow in a multidisciplinary approach. The playbook provides a standardized 
and centralized guidance to conduct HSCT data management, record data into the 
appropriate data management system repository, and utilize the existing outputs to 
analyze, plan, and forecast future requirements and best practices. It also provides 
instructions for accessing the data management systems and generating reports and 
specific instructions for data capture support.
Trained/Qualified Personnel Qualified and trained personnel with adequate 
HSCT experience and process knowledge are pivotal to design, conduct, and man-
age the registries (processing, multidisciplinary coordination, and managing regula-
tory issues). Collaborative efforts of DMs can help facilitate registry activities from 
data acquisition to data processing and publications. The data management staff are 
responsible for the smooth flow of pre-transplant, transplant, and post-transplant 
care, documentation, validation, discrepancy management, adverse events report-
ing, and safety as per the local and international standards.
Data Processing The scope and quality of the data collected determine the value 
of an outcome registry. It’s critical throughout the entire life cycle of HSCT by 
assessing donor/recipient eligibility, screening, workup, informed consent process, 
HLA matching, follow-up, protocol-specific procedure, data entry, regulatory com-
pliance, pharmacy coordination, quality assurance, risk communication, document 
submission, and data management of transplant patients per treatment protocols. 
The purpose and objectives outline the scope of the outcome registry and are 
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affected by a myriad of factors. Size of the registry, complexity of the data elements 
and outcomes collected, number of observations, and duration are essential consid-
erations to achieve registry objectives. A core dataset of crucial variables and patient 
outcomes are defined by the registry to accomplish its objectives. An internationally 
accepted core dataset has been developed by the major outcome registries (CIBMTR, 
EBMT) and is recognized internationally as a model for HSCT registries endorsed 
by the WBMT. Case report forms (CRFs) need to be revised periodically to ensure 
capturing of most current data (novel biomarkers, interventions, etc.). The reliabil-
ity, accuracy, and validity of data are critical elements of a quality outcome data-
base. Data comparability is crucial for interpretation and depends on the 
standardization of methodology and the diagnostic criteria utilized. Robust quality 
control can be achieved by regular internal and external audits, monitoring, and 
evaluation. Good quality, user friendly, cost-effective, reliable, validated, and com-
patible health information systems are essential for maintaining good quality out-
come databases and registries [10]. Next-generation and web-based data entry 
applications, with efficient data validation tools, are required to streamline observa-
tional databases. Enhanced electronic data capturing efforts with built-in auditing 
and quality assurance tools can be very helpful in performance improvement, 
research, and publications.
Cultural Sensitivities/Communication There is significant cultural, social, and 
economic heterogeneity globally. Such cultural sensitivities and language barriers 
among diverse countries in a regional/international database/trial need to be 
addressed. Cultural sensitivities must be considered when collecting patient- 
reported information, like quality of life (QOL) data. Sometimes, certain QOL tools 
cannot be used for sociocultural reasons. Therefore, QOL forms should be cultur-
ally sensitive and validated.
Regulatory Compliance This is pivotal for yielding high-quality outcomes of 
transplant data and is monitored by internal and external regulatory authorities 
(IRB, Sponsor, FDA, etc.). Safeguarding patient safety, privacy, and confidentiality, 
with dignity and respect, while on research protocol is paramount. Developing and 
implementing SOPs/IPPs, administrative and regulatory support, surveillance, and 
monitoring are critical quality indicators of the participant’s privacy and confidenti-
ality protection during collection, storage, and utilization of data. Supporting inter-
nal and external quality assurance site visits/audits, clinical review committees, 
Data and Safety Monitoring Boards (DSMB), morbidity and mortality (M & M) 
meetings, and QA committees are required elements of a quality data management 
program. Outcome registries and databases are often considered “low risk” in terms 
of the potential of harm to human subjects for being observational. Privacy concerns 
with regard to identifiable patient information can be addressed by registries by col-
lection of de-identified data and collection of identifiable data for “internal use” 
with linked identifiers. A significant proportion of the annual HSCT performed 
globally use allogeneic donors acquired through a donor registry or a cord blood 
bank. Since most of the donor registries and cord blood banks are required to report 
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outcomes of products used for transplants, patient outcomes can be linked with the 
donor products with justification for identifiable information gathering. WHO has 
recommended that data collection and data analysis should be considered a manda-
tory part of transplantation programs following full ethical, legal, and privacy 
guidelines.
Pharmacovigilance Adverse drug reaction reporting, risk management, and 
patient safety are paramount for a transplant program and are managed by continu-
ous surveillance, effective communication, and robust teamwork. During transplant, 
patient safety monitoring is a critical component throughout the transplant by pre-
cise coordination and communication among all the stakeholders.
Intellectual Property Rights, Data Utilization, and Publications Integration, 
interoperability, full access to each center’s own data, and clearly defined authorship 
guidelines (based upon the number of transplants, contribution, and the center par-
ticipation, etc.) are the pivotal success elements. Transplant data can be used to plan 
prospective HSCT trials in areas not well studied (role of geographical variations, 
genetic pre-disposition, genotypic and phenotypic variations, and biology of dis-
ease) by utilizing preliminary registry data. It can also be utilized to estimate out-
comes and accrual patterns, sample size calculations, and implementation plans. 
Information about the most commonly used supportive care measures can be used 
to adapt protocols to standard practices and, thus, increase their acceptability in the 
transplant community. Comparison of clinical trial outcomes with observational 
outcomes can give an insight about generalizability and patient selection practices. 
The source of stem cells is highly influenced by chance for each patient, and in 
many occasions, it will not be possible to apply prospective randomization to answer 
some of the important clinical questions.
Funding and sustainability Collection of complete, accurate, and high-quality 
data is resource-intense and spans over a long period. To be sustainable over the 
protracted time frame, long-term financial support is required. Consideration of the 
intended uses of the transplant database and those sponsors who can derive value 
from registry information (government/non-governmental agencies, scientific orga-
nizations, research collaborators, biopharmaceuticals, accreditation bodies, philan-
thropic organizations, etc.) could provide additional funding support. In the context 
of the contract for the US Stem Cell Therapeutic Outcomes Database, the CIBMTR 
derives substantial funding from the Department of Health and Human Services to 
support its outcomes registry operations. As an outcomes registry develops robust 
information, it can be a rich source of data for research, and grant funding to support 
research represents an excellent opportunity. Biopharmaceuticals or device manu-
facturers may have an interest in registry data to better understand utilization of 
their products, and short-term projects or long-term reporting may represent a fund-
ing source. Outcome databases should remain vigilant for the innovative and col-
laborative research opportunities to utilize or expand the database to secure new 
funding opportunities.
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Quality Assurance and CQI These concepts are fundamental for generating high-
quality, accurate, and reliable outcomes. Quality Assurance (QA) is the best way to 
determine process deviations and non-compliance. Quality transplant data has mini-
mal unknowns or missing variables and acceptable levels of procedural deviations 
per regulatory requirements specified for transplant program. Periodic QA site vis-
its and audits conducted by the regulatory authorities and accreditation bodies 
ensure compliance, safety, and optimal outcomes. The accreditation bodies for 
HSCT in the USA and Europe (FACT, JACIE, etc.) mandate that transplant centers 
collect and utilize standard core dataset defined by the field to analyze and under-
stand their program quality. The built-in internal and external audit process for con-
tinuous quality improvement (QQI) is one of the best practices [11]. Quality 
maintenance of an HSCT center warrants added  personnel, IT support, strategic, 
and risk communication. Quality management in HSCT can optimize survival out-
comes by improving transplant practices.
 Conclusion
HSCT has emerged as a definitive treatment for a myriad of inherited and acquired 
hematological malignancies and solid tumors. Data management is a core compe-
tency and one of the crucial components of the HSCT program that encompasses 
initiating and maintaining an institutional transplant database to augment data col-
lection, analysis, and spearheading the research. There is a growing need to adopt the 
best data management practices for high-quality transplant data infrastructure to 
determine trends for QI and the most advanced therapeutic option to optimize health 
outcomes (engrafting, toxicity, and survival outcome) and benchmarking. Accredited 
and standardized databases can provide highly valuable information and research 
data that cannot be obtained by other research methodologies. Existing international 
models are an excellent resource for adopting best practices in maintaining data 
management with advanced standards and capabilities. The standardization of data 
quality is critical to ascertain the scientific credibility and function of outcome regis-
tries. The World Health Organization (WHO) recommendation to mandate data col-
lection on guiding principles on cell, tissue, and organ transplantation has been a 
significant new development. The data collection and analysis would be an integral 
part of therapy and an obligation rather than a choice for transplant centers and will 
be a requirement for HSCT program accreditation. The program data standardization 
is vital to ascertain the scientific credibility and reliability of a transplant program.
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Chapter 16
Maintaining the Quality Management 
Program
Nick van Sinderen
 General
In this chapter, we will take a closer look with a global view on the design of a qual-
ity management system. Many standards originated a long time ago, including the 
FACT-JACIE standards. The FACT-JACIE standards were created to satisfy an 
unmet need, viz., to standardize the quality of care for patients and donors in a field 
of medical intervention that had high mortality and morbidity rates and operated 
across international boundaries. We have now arrived in a time when quality man-
agement has become commonplace and many things have become much more regu-
lar. We even have to watch out that the various quality management systems not to 
overlap leading to unnecessary duplication. But do we? If you compare three well- 
known standards such as
JCI, ISO15189, and JACIE, you already see in the general topics that there is 
overlap. Every single QM system has requirements on documents, education, 
adverse events, changes. And of course the new CAR-T treatments where JACIE is 
already very advanced but has to deal with regulations coming from pharmaceutical 
companies that are GxP based (Good Scientific Practices, where “x” stands for any 
of the following: M, manufacturing; L, laboratory; T, tissue; D, distribution; C, 
clinical; PV, pharmacovigilance). Altogether, this puts considerable pressure on 
hospitals and their staff. So we are no longer setting up a QM system from scratch 
but trying to find a way in existing QM systems where we need to combine all of 
them in order to protect our departments from duplication of the same rules and 
regulations from different standards that are often mandatory by law. Maintaining a 
QMS is about to become an art. It would be good that the organizations would come 
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together to discuss the topics and make sure they are complementary so that valu-
able time can be saved which in the end is beneficial for the patient.
Establishing and maintaining a quality management system is easier said than 
done. It requires a lot of time, energy, and full commitment of everyone involved, 
starting with the (top) management. The time involved may be several years, 
depending on the scope (part B, C, D of the FACT-JACIE standards; see Fig. 16.1) 
and the clinical activity (autologous and/or allogeneic transplantation in adults and/
or pediatric, cellular therapy) of your system and the starting point. The most impor-
tant pool of knowledge, however, is the education, training, and experience within 
the team(s). All standards are initially created by colleagues in the field and, at least 
for FACT-JACIE, also further developed in the 3-year review cycle.
It all starts with the organization wanting to implement a QMS.  Firstly, this 
ambition cannot have any result without the full support of the top management and 
the (medical) staff and all supporting staff including all other operational managers. 
Secondly, it sounds obvious, but your starting point is the knowledge and experi-
ence of your employees. A quality management system is there to help you organize 
it. Compare your own point of view with the standards and you will see that mostly 
you think the same. That shouldn’t be that much of a surprise because the standards 
have been set up and developed by colleagues in the field. Starting from your own 
professional point of view keeps you alert and will eventually increase the level of 
the standard. Blindly following the standards will not.
When team members are assigned tasks in the maintenance of the system, it 
always goes alongside their primary work. One of the statements a department can 
make in the policy is that everyone is responsible for the QMS and gets smaller or 
bigger tasks assigned alongside of the quality manager, next to their primary tasks. 
This could be a responsibility for a specific document, participating in audits or 
maybe implementing an improvement if it is the field of expertise. There are so 
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Fig. 16.1 FACT-JACIE standards, their parts, and QMS. (With permission from EBMT)
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many examples in organizations, which you will recognize, where there is no time 
for these extra tasks. One of the reasons for that is that the number of colleagues 
involved are too limited and QM tasks are many times last on the list. You can pre-
vent this by making the number of colleagues involved bigger so that they only have 
one internal audit per year or have to update just a few documents instead of 20 per 
year. A secretary can be involved in checking transplant data because he or she pro-
vides a lot of the input during their daily work, for example by creating and main-
taining files. The advantage of this approach is that you reduce the pressure on your 
department, the medical team, and, therefore, also the patient. If you go one step 
further, you can use your QMS for education. Team up experienced with less- 
experienced colleagues in every topic and you will see in the long term that many 
can perform the same tasks. You will create continuity and less dependence on just 
a few key staff.
 The Setup of the Quality Manual
Here you describe your organization, policy, scope, communication, collaborations, 
the treatments you offer, education, and so on. Furthermore, you address the topics 
in a general way linked to documents that go further into detail. Fortunately, the 
times when the quality manual was hefty tome, that included many or sometimes 
even all SOPs, are almost gone. The organizational chart (both of the department 
and the HSCT), shows you how the communication is setup between the facilities. 
Also, the position of the quality manager relative to the program can be identified 
here. You see everywhere in the standards that the clinical program director (CPD) 
is ultimately responsible for everything and must have oversight at all times. But 
how can this be done in practical terms? By making sure the CPD gets this informa-
tion in the monthly, quarterly, and annual reports, by discussing with them regularly, 
including minutes of meeting, and by generating an end-of-year report that is 
approved by the CPD, you can cover this. It is impossible to have the CPD view 
every single item but it is possible to give a general overview with the ability to dig 
deeper when necessary. Make this visible in general in your quality manual and 
refer to the underlying SOP.
 Work Area
The locations of parts of your scope define a large part of your logistics. This has an 
influence regarding your equipment, transport of cells, communication, and so on. 
It is not uncommon that parts of the HSCT chain are also a part of another depart-
ment (for example, oncology or the HSCT lab is part of a bigger lab). Experience 
also tells us that in a small site, communication is likely to be good because the 
colleagues are used to really short lines and usually know each other very well. 
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However, you may see this closeness and familiarity reflected in an out-of-date 
documentation, and in external audits, it may appear that your document manage-
ment is poor, even though everyone knows exactly what to do. What is missing is 
the engrained habit of documenting what you do.
 Material and Supplies
It is good to see more and more that hospitals have a general way of buying goods 
and equipment that are validated by the manufacturer and/or during a first (test) use. 
Does the equipment perform like we want to? Reports and contracts are kept in a 
general system. Maintenance is often done internally but sometimes also by special-
ized companies. For these critical items, it is important to clearly describe how you 
deal with urgent situations regarding backup and response time agreements with the 
supplier.
 Hygiene
In an environment where HSCT is performed, normal cleaning is not enough. Extra 
hygienic measures require specialized cleaning methods. This can vary between 
hospitals and includes the patient rooms with air and water filtering. Analyze what 
information your hospital already has on cleaning methodologies and routines and 
add what you as a department find necessary with the help of the JACIE standards. 
By involving the hospital-wide responsible person, you will achieve a good and 
natural flow in the way you work and learn from each other. The result will be an 
extra paragraph in the hospital-wide protocol or an additional hematology protocol 
with a reference. It can be expected that collaboration will build up shared knowl-
edge. Make sure to train your staff on how it is arranged.
 Education
You need the right people to do the work. Their education and experience are the 
basics. Educational sessions (meetings, on the job training, courses, reeducation 
after longer leave, congresses, participation in the development of documentation) 
ensure that continuous education is secured. Describe what is addressed in the ini-
tial training program, also termed “introduction,” for new employees. A good edu-
cational policy where colleagues see that their annual improvement is facilitated is 
very motivating. Encourage them also to write down and implement their plans and 
maybe even send it as an abstract to congresses such as EBMT. It is a great way to 
recognize their work.
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 Documentation
All the information mentioned is kept in the famous standard operating procedures 
(SOP). We have lots of them. The key trick is to make sure that SOPs are relevant 
and don’t overlap with other internal SOPs or maybe general ones that are used in 
other departments or even across the hospital. Another challenge is also who to 
assign to be an author, reviewer, or authorizer. More on that topic is discussed in 
Chap. 3 on documentation.
 Changes
Changes are a consequence of the analysis of outcome, adverse events, audits, 
trends, and daily experience. How to implement changes can differ per case. A stan-
dard analysis of influence and impact  – even a small one  – is recommended. A 
process that records and documents any changes using a change control approach 
is strongly recommended, incorporating where necessary a risk assessment of the 
proposed change (see Chap. 18 on risk management).
 Validation
The FACT-JACIE standards define validation as, “Confirmation by examination and 
provision of objective evidence that particular requirements can consistently be ful-
filled. A process is validated by establishing, by objective evidence, that the process 
consistently produces a cellular therapy product meeting its predetermined specifi-
cations.” In order to achieve the aims of validation, you need to know how your 
processes and methods perform in order to improve and be specific in what to 
improve. Validation is a tool that helps. You can divide this for example in validation 
of your equipment. For instance, does the apheresis machine perform within the 
operational parameters provided by the manufacturer? What objective measures can 
be used to confirm conformation to the anticipated operational parameters? For 
example, for an apheresis device, the harvested cell dose based on pre-harvest pre-
dictors could be a target. This is comparing expectations against real performance. 
How do you validate your process? That is more difficult because you need to trace 
the patient from the first visit until discharged from hospital. Nevertheless, if you 
combine your documents (electronic), patient file, and all related topics, it is possi-
ble to achieve the aim. This is teamwork! By tracing the completed patient pathway, 
every aspect of your process should be covered. As a suggestion, take five differ-
ently diagnosed patients per year and trace their routes and you will uncover any 
gaps that might be there. You could call this a process audit or a prospective risk 
inventory (“what if?”). The validation of your methods would be, for example, how 
you handle your protocols or audit cycle.
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 Information and Communications Technology (ICT)
The ICT process is usually covered by the hospital systems in general, and therefore 
it is always a challenge to get a good grip on this area. It is not uncommon that more 
systems are in use even sometimes in the same department. And because the HSCT 
chain can cover more departments, you can run into this problem. Together with the 
other departments and the ICT department, you need to find a way for good commu-
nication and fine-tuning. For instance, there may be more than one document man-
agement system, different processes in adverse events, different colleagues 
responsible, and so on. Solutions for deficiencies on this topic mostly start with the 
upper management in deciding how the process is changed. Due to the many respon-
sibilities and complicated multiple systems managed by the ICT department, you 
really need to make a solid case on why implementing changes are necessary. Finally, 
a contingency plan in case of a general ICT system shutdown is an absolute must-have.
 Meetings
Meetings and evaluations shows your daily, weekly, monthly, and annual lines of 
communication. Make sure you describe the individual meetings well and who or 
per specialty, is attending. There is a never-ending discussion if you need attendance 
lists or not; however, a list does help a JACIE inspector quickly to determine whether 
important meetings such as transplant operational planning meetings, QM meet-
ings, and morbidity and mortality meetings are attended by sufficient representation 
of the department. In particular, to demonstrate that the CPD has oversight, a list 
provides this evidence. Anything that helps during the JACIE inspection will 
improve the efficiency of the inspection. Where electronic patient files are in place, 
you can also be able to see when a treatment/patient was discussed and by whom 
[not a good way to have oversight]. The best thing to do is describe this in your 
meeting overview or the protocol related. You need to fine-tune it to your own situ-
ation and improve by your experiences.
 Outcome
Analysis of treatment outcomes are done on different levels – on a daily basis and 
over the long term. It varies from discussing a single patient to aggregate outcome 
results. Together with any benchmarking schemes in your country and or via the 
EBMT registry, you will get a good insight into how well the program is performing.
Outcome analysis, a summary of important outcomes and review, will teach the 
transplant team a great deal by spotting trends and helping to indicate where to 
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make changes. A strong advice would be to categorize generally which sounds obvi-
ous but make sure you categorize the same as your adverse events, complaints, audit 
findings, and so on. If you do this for your whole department, you will be even more 
capable of making global as well as detailed analysis. For further details, see the 
chapter on outcome in this book.
 Risk Assessments
Risk assessment is a crucial tool that must be a core component of any transplant 
and cell therapy program. Risk assessment is essential in managing change as part 
of change control and when introducing a new process, procedure, or therapeutic 
intervention into the program. The challenge is to keep the risk assessment process 
simple. You easily drown in too many risk assessments. Define what is important 
and how you want to do it. A risk assessment is also the result of a discussion about 
a change in treatment from which the why and how you will put in the (electronic) 
patient file, without saying it is a risk assessment, so partly what you do on a 
daily basis.
A Practical Example
In JCI, you are required to use the RSVP (reason, story, vital signs, plan) method for 
verbal and written communication. While implementing this in a facility, the team 
realized that they already did this through the electronic patient file, not realizing it 
was a method. The facility saw this as common sense to do so.
Again, it is important to restate that you always need to check what is already in 
place before implementing a “new” change. What the exact best way is you will 
learn during implementing and evaluating and can differ per facility.
 Audits
There are many audits described in the JACIE standards (see Fig. 16.2) and they will 
need fine-tuning depending on the scope of your activities. Do not hesitate to com-
bine audits when possible. They are a great tool for learning and should form part of 
the educational program for staff. One approach for well-funded departments is to 
set up a team of auditors with members of every discipline. Make teams with a focus 
to learn from each other. An alternative strategy is to have a small group of individu-
als with audit training who help less senior staff members such as trainee doctors 
and nurses who are given individual audit topics to prepare and present to the 
department. Audit experience is a mandatory requirement in many countries for 
trainee medical staff and provides good opportunities to gain experience not only in 
the audit cycle but also in presentation of the completed audit. Good audits can be 
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submitted as abstracts to meetings such as the annual EBMT meeting. The impact 
that this can have on awareness of processes, who is doing what and implementing 
changes, is underestimated. Here are some examples of audits that must be per-
formed regularly.
Some take aways:
 – Your professional knowledge is your starting point.
 – The FACT-JACIE standards are a really good helpful tool when used with the 
FACT-JACIE manual.
 – Involve as many of the staff within the transplant program as possible in small 
and larger tasks, make it “their” system.
 – Make teams for audits and documentation review with the aim to learn and grow.
 – Appoint colleagues with a special field of their attention and give them regular 
opportunities during the year to present and discuss issues.
 – Check what is already there, which can be used as a starting point for implemen-
tation of new things.
 – Ask for input from colleagues in other hospitals who are more experienced on 
topics that you are not familiar with.
 – Have every new colleague meet the quality manager in their initial training pro-
gram so that new colleagues are familiarized with QM from the very beginning.
Interim donor
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Fig. 16.2 Critical processes that must be audited. (With permission from EBMT)
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Chapter 17
Training Programme
Ilknur Kozanoglu and Songul Tepebasi
Cell therapy guidelines and standards, for staff training and quality control, are 
outlined in the European Union (EU) Directives and by other international agencies 
[1–5]. In addition to staff qualifications and training, the directives also require doc-
umented evidence of the qualifications of the trainers [4].
Educational activities aimed at developing staff knowledge and skills [6] are 
fundamental for safe and effective cell therapy. Such educational activities can facil-
itate the manufacturing of a cost-effective product while improving overall process 
and improve management. Appropriately trained staff have more self-confidence, a 
greater sense of accomplishment and ability to fulfil personal goals, and better com-
munication and leadership skills [7]. High-quality and motivated cell therapy staff 
are indispensable regarding developing and maintaining an effective QM system. 
Therefore, it is advantageous for cell therapy staff to have continuous training and 
receive competency evaluations at regular intervals.
 Types of Education
FACT-JACIE has established international standards for cell therapy, including the 
following training and education requirements for personnel.
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 Orientation Training
This includes activities to introduce new employees to their colleagues and the 
treatment centre. The aim, history, philosophy, rules and procedures of the centre 
should be reviewed with all new staff. Information about human resources policies 
to include business hours, staff support services, payroll procedures, overtime 
requirements and benefits are provided, together with information on the physical 
capacity of the organisation. Specific orientation training for staff working in cell 
therapy should cover general therapeutic principles for each area involved in cellu-
lar therapy as well as the functionality of the cellular therapy clinical units within 
the centre. All training should be clearly defined in the standard operating proce-
dures. To facilitate orientation, a handbook could be provided to all personnel to 
ensure compliance (Table 17.1).
 Initial Training
After attending a general facility orientation, initial hands-on training of new per-
sonnel should begin. It is especially important that personnel, who will be perform-
ing critical procedures, clearly understand the work that they will be undertaking. 
Table 17.1 Example orientation training programme for new personnel in a cell therapy unit
Days Topic Trainer
First day Meet colleagues
Roles and responsibilities
Payroll and human resource requirements policy
Benefits package
Dress code regulations
Organisation, mission and vision
Unit director
Technician
Personnel manager
Second 
day
Bone marrow centre/vision, mission, values
Quality management system
Organisation chart
Working hours
Training courses/certification
Procedures/bonuses/policy violations
Standard operating procedure and other forms and 
booklets
Promotion of the hospital
Transportation/housing/services
Patient rights/satisfaction
Unit director
Technician
Quality control 
manager
Personnel manager
Third day General operating principles of the unit
Employee, donor, patient, and product safety
Workflow processes
Unit director
Technician
I. Kozanoglu and S. Tepebasi
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Initial training should focus on relevant scientific and technical material, organisa-
tional structure, the QM system, health, and safety rules, and ethical, legal, and 
regulatory policies [4].
Moreover, the initial training should allow sufficient time to grasp the concept 
and application of the treatment processes at various interval of patient care. For 
processes where minimising error is critical, training should be repeated, at specific 
intervals with assigned knowledge and skills sign-offs, to ensure that personnel 
fully comprehend the content.
 Continuous Education
Continuous staff training, both personally and professionally, is essential to ensure 
that both staff and the department keep abreast of the latest developments in cellular 
therapy [4]. Centers can develop and apply their own continuous education pro-
grams or use methods based on international standards. New developments in cell 
therapy occur constantly, and training will facilitate the adoption of new methods 
and processes by personnel. Continuous training is a dynamic process that ensures 
that the centre itself is committed to continuous growth and development.
According to FACT-JACIE, key personnel should participate in a minimum of 
10 hours of educational activities related to cell therapy annually, and continuing 
education should include, but not be limited to, activities related to hematopoi-
etic stem cell therapy. Appropriate continuing education activities [4] include 
the following:
• Annual meetings of professional societies presenting information which is 
directly related to cell therapy
• Presentation of papers at scientific meetings
• Participation in webinars and online tutorials
 Training Methods
 Theoretical Education
All cell therapy centres should provide theoretical training with a predetermined 
purpose, method, and content (Table 17.2).
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 Practical Training
Mistakes made during cell therapy can be fatal to patients and may also lead to 
product loss. Thus, practical training should be provided to personnel involved in all 
relevant procedures but especially those considered critical.
 Rotation Training
Rotation of personnel between departments and roles will enhance experience, 
skills, and knowledge. The aim is to familiarise employees with the functions, rules 
and procedures of all departments included in the rotation cycle. Rotation training 
constitutes a holistic approach to the training of new personnel, who will engage in 
activities involving a variety of disciplines.
 Conferences
Given the rapid advances in cell therapy treatments and methods, information 
exchange at the international level is essential to remain up to date. This can be 
accomplished through attendance at relevant courses and conferences.
 Case Training
Case training requires personnel to analyse cases, identify problems and discuss 
possible solutions with their colleagues; this process allows personnel to readily 
apply their knowledge and skills.
 Online Training
The information and technologies available through the internet have become indis-
pensable tools for modern education. Online training has increased dramatically 
due to ease of access and the possibility of training many people in a single session. 
In addition, participants can provide feedback and their proficiency can be assessed 
automatically [8].
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 Standard Operating Procedure (SOP) Training
Cell therapy personnel should be familiar with the SOPs in a QM system. Personnel 
should be trained in the use of these documents so that they can be effectively 
applied, when needed.
 Unplanned Training
Unplanned training may be required to address repeated errors, following an inspec-
tion by an auditor, or in response to events occurring on a particular day. The loca-
tion and timing of unplanned training are inherently undefined but should be 
recorded by the QM system, as required.
 Trainer Qualifications
The most important factor in the effectiveness of training is the trainer. International 
standards for cell therapy do not specify the qualifications required by a trainer. 
However, he or she should have sufficient skills, experience and knowledge of the 
topic to be taught and should be able to demonstrate specific competencies on 
request by auditors. Centres should not only employ qualified educators but also 
define their own training methods according to their QM plans. The effectiveness of 
the trainer should be assessed using a survey of training participants.
 Determination of Training Needs
The training of personnel starts by determining their needs. The required training 
should then be delivered in accordance with legal and institutional requirements. 
The training required for maintenance of unit activities (e.g. SOP training) should 
consider not only what is needed to perform the tasks required by that unit but also 
the necessity to develop new skills [1–4].
The types of training needed by employees can be assessed by means of surveys, 
interviews, observation and performance tests. Ideally, a training commission 
should be created by each centre to determine training parameters including dura-
tion, location, method and certification (Table 17.2).
After training needs have been determined, a training programme should be 
planned and discussed with trainers. Decisions should then be made regarding who 
should participate in the training, and its format, delivery date/time and location. 
I. Kozanoglu and S. Tepebasi
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Training programmes should be run once or twice a year, although this will depend 
on the identified needs and capacity to deliver training. All training should be opera-
tionally and clinical focused on the cellular therapy programme.
 Documentation of Training
As discussed above, training should be conducted in accordance with the training 
programme. If a training session does not take place in accordance with the plan, the 
reason for this should be documented; postponing the session until the next training 
period should also be considered.
All training activities should be documented in accordance with the QM system. 
Every stage of the training procedure should be recorded and archived, according to 
the regulations and standards of the individual centre.
 Training Evaluation
Evaluation of the quality and outcomes of training are essential to assess how much 
information has been imparted to personnel. Clear and quantitative assessments 
facilitate determination of the effectiveness of the training.
The criteria used in training evaluations should be defined in the training plan. 
Significant work aimed at quantifying the learning that occurs during training has 
been carried out by Kirkpatrick, who assessed four different areas: (i) participants’ 
responses to education, (ii) learning efficacy, (iii) participants’ behaviour after train-
ing and (iv) training outcomes [9].
The optimal methods for evaluating training outcomes for key therapy personnel 
should be determined to ensure patient/donor/product safety. Indirect evaluation 
methods, including product effectiveness and patient outcomes, can also be used.
In addition, training sessions should be recorded to allow subsequent evaluations 
thereof, whether by testing or observing the participants.
 Conclusion
Training is a critical part of any QM system and can contribute to continued prog-
ress in the field of cell therapy. International standards have defined the training 
required for key cell therapy personnel. Within this framework, all centres should 
establish their own procedures for conducting and evaluating training. The proce-
dures should be dynamic and meet the needs of the individual unit.
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Chapter 18
Risk Management
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ICH International Conference on Harmonization
ISCT International Society for Cell and Gene Therapy
ISO International Organization for Standardization
JACIE Joint Accreditation Committee of the ISCT-Europe & EBMT
MSC  Multipotent Mesenchymal Stromal Cells
PHA  Preliminary Hazard Analysis
QbD Quality by Design
QC Quality Control
QoL Quality of Life
RD Related Donor
RRF  Risk Ranking and Filtering
SOP Standard Operating Procedures
UD Unrelated Donor
US  United States
 Defining Risk in Cell Therapy
A risk is defined as a combination of the probability of occurrence of harm and the 
severity of that harm [1]. It is recognised that complex processes are involved in cell 
therapy embracing a life cycle that encompasses people, facilities and equipment, 
reagents and materials, documents, and procedures. The risk of altering any critical 
quality factors related to safety (that is, for any of the stakeholders involved) and 
efficacy of the cell-based product administered to patients need to be taken into 
consideration in order to improve established workflows and pursue better thera-
pies. In our context, major risks to be considered are those affecting the health of 
donors and patients, so all efforts should focus on the identification of risks that may 
critically impact on their health and the cost of cell processing to make improved 
therapies affordable. Fortunately, existing pharmaceutical standards, such as GxP 
(Good Scientific Practices, where “x” stands for the following: M, manufacturing; 
L, laboratory; T, tissue; D, distribution; C, clinical; PV, pharmacovigilance), already 
developed tools for risk management that can cover not only the critical quality 
attributes (CQA) of the cellular products but all the activities involved in the entire 
process, from the procurement of starting material from donors to the administra-
tion in patients and their follow-up, that is “from vein (of donor) to vein (of 
patient)” [2–4].
The advent of a new generation of cell-based medicines, in which cells are sub-
stantially manipulated, even genetically (e.g. MSC, CAR-T cells, iPSC), poses 
major risks and therefore robust methods need to be established and validated to 
ensure safety consistently [2, 5–7].
The Foundation for the Accreditation of Cellular Therapy (FACT) and Joint 
Accreditation Committee of the International Society for Cell and Gene Therapy 
(ISCT)-Europe & European Society for Blood and Marrow transplantation (EBMT) 
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(JACIE) have published guidelines that incorporate risk-based assessment as a key 
element to consider in every critical decision [8]. However, it is important to note 
that the acknowledgement of risks does not make an unsafe or a low-quality product 
into a safer one. In other words, risk assessment is useless unless a proactive attitude 
and willingness to make a (positive) difference exist. This means that risk manage-
ment is not adding an additional documentation burden but a critical quality tool 
that holds the potential to assist us to better understand the weakest points of pro-
cesses involved in the life cycle of cell therapy treatments. Then, improvements can 
be implemented upon accurate documentation of processes, analysis of risks, and 
definition of suitable actions for mitigation. Several other factors must be taken into 
consideration, ranging from the design of facilities and the manufacturing process 
to adequate personnel training and efficient documentation system, to name a few 
[3]. The main goal of following a risk-based approach is to improve decision- 
making and lead to a more effective and efficient management and oversight frame-
work, as well as optimal use of institutional resources.
Quality risk management (QRM) is a tool recognised and incorporated in man-
datory and voluntary accreditation schemes, GMP being the strictest standard in this 
regard [8]. GMP is of mandatory application in drug manufacturing and, therefore, 
they are also applied to substantially manipulated cell-based products, which are 
considered medicines by most regulatory authorities [6, 9]. QRM is in fact the adap-
tation of the topic Q9 from the guidelines issued by the International Conference on 
Harmonization (ICH) of Technical Requirements for Registration of Pharmaceuticals 
for Human Use. This is the major guideline providing principles and examples of 
tools for QRM that can be applied to different aspects of pharmaceutical quality. 
Importantly, ICH Q9 provides advice on the use of QRM considering that the level 
of effort and formality must be in accordance with the level of risk [1].
Guideline ICH Q10 (on the pharmaceutical quality system) establishes the struc-
ture to build an effective pharmaceutical quality system to support pharmaceutical 
development and manufacturing across the product life cycle incorporating QRM as 
a facilitator agent. Here it is important to note that the earlier we start considering 
risks, the better the management of processes could be expected in the future and, 
subsequently, this would lead to safer treatments. Likewise, voluntary accreditation 
schemes (e.g. FACT-JACIE, ISO9001) incorporate QRM, thereby showing some 
similarities and/or equivalences between standards [8].
 The Quality Risk Management Process
In cell therapy, QRM can be defined as the systematic process for risk assessment, 
risk control, risk review, and communication of the quality risks in the processes 
involved during the entire life cycle of the treatment. A standardised and robust 
system is needed to identify risks, determine their potential hazards, and reduce or 
eliminate those that are unacceptable.
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According to current FACT-JACIE guidelines, the identification of a risk can be 
made by providing a description and establishing the context or scope, so all the 
possible risks are identified and the possible ramifications or impact in all areas are 
analysed thoroughly [10]. Once the context or scope has been established success-
fully, the next step is identification and evaluation of potential risks by either source 
or effect. During source analysis, the source of risks is analysed and appropriate 
mitigation measures are put in place. This risk source could be either internal or 
external to the system. During problem analysis, the effect rather than the cause of 
the risk is analysed. Once the risk has been identified, it must be assessed on its 
potential criticality or on their likelihood of occurrence and the potential impact by 
either quantitative or qualitative evaluation, as shown in Table  18.1 and further 
described in this section.
There are many different approaches to calculating risk, and there are tools that 
can help assist in defining the probability of the effect occurring, the root cause, 
effects, and magnitude of risk under different scenarios. Risk Evaluation and 
Mitigation Strategies (REMS, in the USA) or Risk Management Plan (RMP, in the 
EU) may include (but are not limited to) detailed procedures for providing educa-
tion and instructions to personnel involved (including donor and patients), monitor-
ing patients, managing adverse events, and reporting outcomes to manufacturers. 
Once the risk assessment is established, an RMP can be developed and imple-
mented. It comprises the effective controls for mitigation of risk. Risk management 
involves the justification and rationale for accepting risks and how to manage their 
impact if applicable. This can often be established in a simple one-page document 
for change with low impact and risk.
The QRM must be integrated into the pharmaceutical quality system to be prop-
erly documented and become a consistent tool for improvement. Risk management 
must be proactive rather than reactive, and it must be incorporated into the culture 
of prevention of the organisation. One could say that the process of QRM takes the 
steps depicted in Fig.  18.1, which are taken from current GMP [11] and further 
discussed next.
 Risk Assessment
Risk assessment consists of the identification of hazards and the analysis and evalu-
ation of risks associated with exposure to those hazards. Quality risk assessment 
begins with a well-defined problem description or risk question. In doing an effec-
tive risk assessment, the robustness of the data set is important because it deter-
mines the quality of the output. The document reflecting the risk assessment can be 
completed by following three successive steps, as described next.
Step 1: Risk identification The purpose of this phase is to recognize and record the 
risks of the situation being evaluated, identifying the origin of the risks and their 
causes. It aims to answer the question: What could go wrong? Risk identification 
J. Vives and J. Amposta
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Table 18.1 Methods commonly used for identification of risks
Method Objectives Pros Cons
FMEA FMEA identifies, analyses, 
and prevents potential 
failures, as well as their 
effects and causes
Method widely used in different 
sectors
If used prospectively, it may 
highlight shortcomings that had 
not been previously contemplated
It is more objective than other 
tools if severity, probability, and 
detectability are categorised 
precisely
Not useful for very 
complex processes. If 
this were the case, 
specific steps should be 
selected
FMECA FMECA takes FMEA process 
one step further. Each failure 
mode is assigned a severity 
level
The FMECA team will not only 
identify but also investigate 
potential failure modes and their 
causes being able to prioritise 
their importance
Not useful for very 
complex processes. If 
this were the case, 
specific steps should be 
selected
FTA FTA identifies the possible 
root causes of a failure or 
unwanted consequences, to 
prevent recurrence
The results of the analysis are 
represented pictographically in 
the form of a fault mode tree 
using symbols and standards
Visual method
Useful for complex systems
If applied in the design phase, it 
provides an overview of the risks 
that can help to create 
requirements, before starting the 
process
Limited approach as it 
only evaluates one 
unwanted event for each 
tree
HACCP HACCP is a preventive safety 
system in which every step in 
the manufacture, storage, and 
distribution of a food product 
is scientifically analysed for 
microbiological, physical, and 
chemical hazards
Determines critical control points 
in the process
Allows continuous improvement 
and better knowledge of the 
processes
So far it is a tool mainly 
used in the food sector 
with great potential for 
application in cell 
therapy.
It should be reviewed 
frequently to introduce 
all the changes being 
made in the process
HAZOP HAZOP is a technique for 
identifying risks that occur as 
a result of a deviation of the 
process variables, with 
respect to the operating 
parameters of the system
Helps to identify potential 
deviations from normal use or 
design intentions
The output analysis is a list of 
critical operations for risk 
management
Qualitative tool
PHA PHA is based on applying 
prior experience or 
knowledge of a hazard or 
failure to identify future 
hazards that might cause harm 
and to estimate their 
probability of occurrence
It is most used early in the 
development of a project when 
there is little information on 
design details or operating 
procedures
Simple method, easy to 
implement
It is only a preliminary 
estimate of the risks of 
the system.
Hazards identified will 
require further 
assessment with other 
risk management tools
RRF RRF is a tool for comparing 
and ranking risks
It is particularly helpful in 
situations in which the possible 
risks and the consequences to be 
managed are diverse
Good justification of 
filtering must be made 
to ensure its relevance
FMEA failure mode effects analysis, FMECA failure mode, effects and criticality analysis, FTA 
fault tree analysis, HACCP hazard analysis and critical control points, HAZOP hazard operability 
analysis, PHA preliminary hazard analysis, RRF risk ranking and filtering
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methods that may be used include reviewing of historical data, brainstorming, ele-
mentary cause, and assign consequences (e.g. fishbone Ishikawa, diagram, failure 
mode/effect table), fault tree analysis, process map, flow charts, just to name a few.
Step 2: Risk analysis Estimation of the risk associated with the identified hazards 
can be either a qualitative or quantitative process of linking the likelihood of occur-
rence and severity of harms. In some risk management tools, the ability to detect the 
harm (aka. detectability) also contributes to the ability to estimate risk. Risk analy-
sis aims to answer the following questions: What are the chances (probability) of 
happening? What would be the consequences?
There are several methods suitable for the management of risks. From these, the 
next seven recognised tools are considered relevant in the cell therapy field (further 
described in Table 18.1).
• Failure Mode Effects Analysis (FMEA)
• Failure Mode, Effects and Criticality Analysis (FMECA)
• Fault Tree Analysis (FTA)
• Hazard Analysis and Critical Control Points (HACCP)
• Hazard Operability Analysis (HAZOP)
• Preliminary Hazard Analysis (PHA)
• Risk Ranking and Filtering (RRF)
Depending on the particular situation to be evaluated, one method or the other 
will be chosen. When the risk is expressed quantitatively, a numerical probability is 
used. Alternatively, risk can be expressed using qualitative descriptors, such as 
“high”, “medium”, or “low”, which should be defined in as much detail as possible. 
The application of statistical tools (e.g. Pareto charts, histograms, Process Capability 
Index – CpK, dispersion graphs) together with these risk management tools helps to 
obtain additional information.
Step 3: Risk evaluation The purpose of this final step is to compare the identified 
and analysed risk(s) against given risk criteria.
 Risk Control
Risk control involves the decision-making of either (A) reducing the risk or (B) 
accepting and managing the residual risk. Ideally, identified risks will be reduced to 
acceptable levels, always remembering the premise that the effort and resources 
applied must be proportional to the risk. It aims to answer the following questions: 
Is the risk beyond the acceptance level? What can I do to eliminate or reduce the 
risk? What is the appropriate balance among benefits, risks, and resources? Are 
there any new risks introduced because of the actions taken to control a risk?
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Step 1: Risk reduction Here we must focus on actions to decrease severity and the 
likelihood of any harm occurring when it exceeds a specified (acceptable) level 
(Fig.  18.1). This step may imply a redesignation of the process (e.g. inadequate 
controls, lack of robustness of the process).
Step 2: Risk acceptance Risk acceptance is a decision to accept risk after the eval-
uation of severity, likelihood, and the detectability of hazards. Risk acceptance can 
be a formal decision to accept the residual risk (risks well specified) or it can be a 
passive decision in which residual risks are not specified (risks are part of the natu-
ral variability of the process). For some types of harms, even the best-quality risk 
management practices may not help to eliminate the risk completely, but only 
reduce it partially. This (specified) acceptable level may depend on many parame-
ters and should be decided on a case-by-case basis. The rationale behind such a 
strategy should be documented, residual risk described, and appropriate manage-
ment strategies put in place.
 Risk Review
It is very important to carry out continuous monitoring and verification of risk man-
agement to identify changes in the assessed situation. This could generate new risks 
or affect the effectiveness of the initial risk management plan. We must be aware 
that the probability of risk and the risks themselves will change when the conditions 
change. Risk review serves as a verification and is key to promote the concept of 
continuous improvement. Risk review is easier to perform if there is someone in 
charge of monitoring the progress of the implementation of the action plan . 
Importantly, this step adds value to the risk analysis management.
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Fig. 18.1 Overview of quality risk management along the life cycle of cell therapies
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 Risk Communication
Risk communication is the act of sharing information on risk and risk management 
between the decision makers and stakeholders involved in critical steps of the cell 
therapy process (as discussed in section “Stakeholders Involved in Risk 
Management”), thus ensuring an effective information flow. Parties can communi-
cate at any stage of the risk management process (dashed arrows in Fig. 18.1). The 
output of the quality risk management process should be appropriately communi-
cated and documented (solid arrows in Fig. 18.1). The included information might 
relate to the existence, nature, form, probability, severity, acceptability, control, 
treatment, detectability, or other aspects of risks to quality. Communication need 
not be carried out for every risk acceptance. Risks which are subject to frequent 
changes by trend need to be reported more frequently than constant risks.
 Stakeholders Involved in Risk Management
Activities involved in risk management of cell therapy processes should be carried out 
by multidisciplinary teams, including experts in the different areas (e.g. quality assur-
ance, process and quality control, medical management, pharmacy) and a risk man-
agement coordinator. It is very important to establish well-defined, up-to-date standard 
operating procedures (SOP) and having the necessary resources. This team should 
meet on a regular basis to keep the risk analysis in a living state, which is updated with 
the latest data available (e.g. incidences, non-conformities, bio-vigilance).
 Illustrative Examples of Specific Applications
Risks in cell therapy are diverse due to the complexity of the whole process and may 
impact on any critical step along the life cycle. A good understanding of the six Ws 
(summarised in Box 18.1) is key to realise the potential of risk management. Some 
explanatory examples are described next to illustrate the applicability of QRM and 
its potential to support continual improvement.
Box 18.1 The Six W of Risk Management in Cell Therapy
• Why? Improve safety of donors; improve survival and QoL of patients
• What? Identify hazards and the risk of impacting in critical steps along the 
life cycle of cell therapies
• Who? Multidisciplinary team involving quality assurance, process and 
quality control, medical management
• Where? Hospitals and processing units
• When? Always, being part of a continual improvement process
• How? Following the risk management process
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 Related vs. Unrelated Donors
Donation of HSC from related donors (RD) is associated with higher occurrence of 
adverse events (including death) than in unrelated donors (UD) [12]. Circumstances 
particularly applicable to RD are complex and contribute to increased risk. Risks 
include the lack of regulatory guidance, logistical and financial barriers, lack of the 
benefit of anonymity, close relationship with the transplant recipient, and the conse-
quent pressure to donate. RD tend to be older than UD and therefore more likely to 
have morbidities. The impact of quality management in driving change was con-
firmed by Anthias and collaborators, who reported that improvements observed in 
donor care were successfully achieved in areas where recent FACT-JACIE standards 
were introduced [12]. Continual improvement can be further achieved by gradual 
understanding of risks, particularly present in each individual institution.
 Processing of Cell Therapy Products
Cell-based therapies are rapidly evolving from traditional HSCT to current geneti-
cally engineered immune cells and mesenchymal stem cells [13, 14]. Therapeutic 
activity of cell-based products is susceptible to intrinsic biological variability, as 
opposed to traditional pharmaceutical drugs, such as small molecules or biologi-
cals. In this context, it is crucial to deeply understand the cell’s critical quality 
attributes (CQA) (directly impacting on the product’s safety profile and clinical 
efficacy) and how these are affected by any disturbance in the process [15]. 
Moreover, cell manufacturing is a poorly automated process, prone to operator- 
introduced variations, and affected by heterogeneity of the processed organs and 
tissues and batch-dependent variability of reagent efficiency [16]. In a recent study, 
we reported the impact of risks associated with main failure groups (that is pro-
cess, equipment, personnel, documentation, environment, reagents, and materials) 
on the specifications of a mesenchymal cell-based product with multiple applica-
tions including the management of acute graft-versus-host disease (GvHD) [17]. 
From all risks that were identified, those associated to cell processing and appara-
tus were high in the initial steps of product manufacturing but replaced by risks 
associated to operator errors at later stages of production. In this study, the risk 
analysis was performed following FMEA/FMECA and actions were prioritised 
using a simple Pareto chart, proving to be a powerful method within a clinical cell 
therapy manufacturing context, as well as an ideal vector for prompting alternative 
and proactive improvement processes [18, 19]. Moreover, the intrinsic flexibility 
of the method makes it ideal for critical risk assessment in all processes related to 
the entire life cycle of the cell-based product, thus allowing to properly identify 
risk priorities and corresponding control activities, supports the identification of 
necessary actions for quality improvement, and provides a specific model for guid-
ance of cell transplantation centres and cell processing facilities approaching risk 
management for the first time, especially if lacking personnel with specific risk 
analysis expertise [16, 18, 19].
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 Patients
From EBMT registry data, Snowden and collaborators confirmed the correlation of 
occurrence of new centre accreditation with improvements in patient survival and 
reduction of procedural mortality, demonstrating the clinical benefits of adoption of 
quality standards [20]. Consistently, transplant centres in advanced phases of FACT- 
JACIE accreditation are linked to significantly higher survival rates, independent of year 
of transplantation or other risk factors [21]. Therefore, the implementation of FACT-
JACIE standards contribute to improved processes and mitigate existing (maybe hid-
den) risks. In addition to general QRM, specific tools have been created as is the case of 
the EBMT risk score, providing a simple way to assess benefits and risks of HSCT for 
an individual patient pre-transplant, by assessing only five factors (namely, age of the 
patient, stage of the disease, time interval from diagnosis to transplant, HLA matching, 
and gender of donor and recipient). Higher risks are observed for an individual patient 
with increasing score from 0 (best) to 7 (worst) in an additive way [22]. Integration of 
the EBMT risk profile into the risk assessment should guide in the decision process, 
ultimately leading to a better decision in the selection of transplant patients.
 Final Remarks
Remarkable improvements can be achieved by following simple risk assessment 
tools. Growing evidence shows that the systematic and comprehensive evaluation of 
risks impacting on safety and efficacy of cell therapy contributes to proper manage-
ment of risk affecting donors and patients. Institutions already accredited for stan-
dards incorporating QRM are best positioned to drive change in cell therapy by a 
systematic risk-based approach. Rather than following each of the different quality 
guidelines and standards separately, we encourage institutions to customise their 
own methodology of QRM to fit them into the unique characteristics and needs of 
their institutions. Importantly, quality management systems need to be flexible 
enough for continuous evolution from traditional HSCT and stay open to the future 
trends in cell and gene therapy.
It should be noted that Lean Six Sigma strategies are fully compatible with 
QRM. In fact, some hospitals and blood and tissue banks are already using these 
tools and we expect this to become the trend if they both are dynamic and facilitate 
continual improvement in the life cycle of the treatment.
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